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SUMMARY 
Clostridium difficile, a Gram-positive spore forming bacteria, is the leading cause of 
healthcare-associated diarrhoea in the UK and represents a major healthcare challenge.  The 
vegetative form of the bacterium colonises the gut mucosa and produces two exotoxins, 
which are responsible for the pathology associated with the bacterium.  We thus sort to 
characterise the host immune response directed against the surface of the bacterium and 
toxins A and B. 
 
Our studies revealed that the vegetative form of the pathogen is capable of altering its 
physiology in vitro to produce two distinct colony morphotypes.  The differences observed 
in the cell surface, autolytic activity and bile salt sensitivity; suggest that the M2 morphotype 
may be better equipped to survive in the hostile conditions encountered in the gut.  The 
mechanisms by which these changes are mediated are as yet unclear; however given the 
characteristics of the morphotypes it may involve one or more phase variable proteins.  The 
identification of immunogenic proteins, including pyruvate-flavodoxin oxidoreductase, an 
anaerobic metabolism enzyme associated with oxidative stress warrants further investigation.  
To be effective, a future immuno-therapeutic should target the form of bacteria which is 
most often encountered during infection. 
 
Toxins A and B remain the primary virulence factors of C. difficile, with toxin neutralising 
antibodies targeting the receptor binding domains conferring protection and reducing 
recurrent infection.  To characterise the antibody response directed against toxins A and B, 
the cell binding and translocation domains of each toxin were expressed in Escherichia coli.  
To identify immunogenic regions, the native, recombinant and toxoided proteins were 
subjected to enzymatic digestion with clostripain and probed with toxin neutralising animal 
sera and sera from C. difficile infected patients.  The immune sera consistently identified two 
fragments of 40 and 60 kDa within both toxins A and toxin B, which may contain toxin 
neutralising epitopes and thus warrant further investigation.  
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1.1 Introduction 
Clostridium difficile is an anaerobic, Gram-positive, motile rod with sub-terminal 
spores, responsible for C. difficile-associated diarrhoea (CDAD) in humans and 
animals.  Pathogenesis is attributed to the production of two biologically and 
immunologically distinct toxins; the enterotoxin (toxin A) and the cytotoxin 
(toxin B) (Voth and Ballard, 2005; Jank et al., 2007; Jank and Aktories, 2008).  This 
introductory chapter provides an overview of C. difficile, focusing primarily on the 
toxins and reviewing the existing and future therapeutic options for C. difficile 
infection (CDI). 
 
1.1.1 The Clostridia 
It is estimated that clostridia emerged approximately 2.3 billion years ago, before the 
‘great oxidation event’ (Sheridan et al., 2003; Battistuzzi et al., 2004), with 
Clostridium difficile evolving within the last 1.1–85 million years (He et al., 2010).  
The genus Clostridium, encompasses a wide range of metabolically diverse, obligate 
anaerobic, spore-forming bacteria (Cato and Stackebrandt, 1989), with genetically 
diverse genomes, ranging between 22-50% in G+C content (Cato et al., 1986; 
Lawson et al., 1993).  Members of the genus are ubiquitously found inhabiting a 
wide range of anoxic environments, including the intestinal tracts of insects, humans 
and animals (Cato et al., 1986).  The genus includes fifteen known human and/or 
animal pathogens (Clostridium botulinum, C. difficile, Clostridium novyi, 
Clostridium perfringens, Clostridium sordellii and Clostridium tetani) (Popoff and 
Bouvet, 2013).  The organisms themselves are non-pathogenic but are able to exhibit 
pathogenicity via toxin production. 
 
1.1.2 Clostridium difficile Characterisation and History  
C. difficile produces irregular, flat to slightly raised colonies ranging between 
2-9 mm in diameter with a lobate margin and smooth glossy, greyish-white 
appearance on blood agar (Hall and O'Toole, 1935; Hafiz and Oakley, 1976).  The 
organism is generally Gram-positive, although older colonies may exhibit Gram stain 
variability (Brazier and Borriello, 2000).  C. difficile cells are large, ‘drumstick’-like, 
3 
 
with a length of 2-8 μm and width of 0.5 μm (George et al., 1979).  The majority of 
cells are motile with peritrichous flagellae and multiple fimbriae (Hafiz and Oakley, 
1976; Borriello et al., 1988).  Sub-terminal elongated spores that are slightly wider 
than the body of the cell are produced under unfavourable growth conditions (Hall 
and O'Toole, 1935).   
 
CDI presents an array of symptoms, ranging from asymptomatic carriage to 
pseudomembranous colitis and toxic megacolon (Kelly and LaMont, 1998).  
Although C. difficile was first isolated in 1935 (Hall and O'Toole), the symptoms of 
pseudomembranous colitis (PMC) were described as early as 1893 (Finney, 1893), 
thus the bacterium and disease were identified separately, before they were linked 
together.  The antibiotic era saw a rise in the number of reported cases of PMC and 
in 1952, PMC was recognised as a complication of antimicrobial therapy (Reiner et 
al., 1952).  As it was a major nosocomial pathogen of the time, 
Staphylococcus aureus was initially suspected as the organism responsible for PMC 
(Altemeier et al., 1963; Hummel et al., 1965), with oral vancomycin quickly 
becoming the standard treatment of choice (Khan and Hall, 1966).  The aetiological 
role of S. aureus in antibiotic-associated diarrhoea (AAD) was not seriously 
questioned until 1974 (Tedesco et al., 1974), with investigations reporting a high 
incidence of AAD amongst patients receiving clindamycin treatment.   
 
The presence of a cytotoxin in the faecal exudate of patients was implicated as the 
causative agent (Larson et al., 1977; Rifkin et al., 1977).  As the toxin was 
neutralised by C. sordellii antitoxin, the toxin was believed to be derived from 
C. sordellii, however this organism was rarely isolated from patients with PMC.  The 
1970s marked the start of the C. difficile era resulting in the successful isolation of 
C. difficile from the stools of PMC patients (George et al., 1978; Larson et al., 1980).  
Whilst investigating antibiotic-associated caecitis in hamsters, in a series of studies 
Bartlett et al. (Bartlett et al., 1977a; Bartlett et al., 1977b; Bartlett et al., 1978; 
Bartlett et al., 1979) identified vancomycin prolonged survival, this coupled with the 
earlier work of Khan and Hall (1966) resulted in vancomycin being established as an 
effective antibiotic of CDI.  The latter half of the 1980s, saw C. difficile fade into 
obscurity, as it became perceived as a nuisance disease, manageable by increasingly 
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effective diagnostics and therapeutics (Bartlett, 1988).   However, the turn of the 
century saw the re-emergence of C. difficile, with the prevalence of highly virulent, 
epidemic strains, associated with increased morbidity, mortality and environmental 
dissemination.   
 
1.1.3 Clostridium difficile Typing and Epidemiology  
Early typing methods were initially based on phenotypic characteristics 
(antibiotic susceptibility, bacteriophage and bacteriocin) which have since been 
superseded by molecular typing techniques.  The most commonly used typing 
schemes are summarised in Table 1.1. 
 
Table 1.1: Molecular typing methods for C. difficile 
Method Summary 
Restriction Endonuclease 
Analysis (REA) 
Enzyme restriction (HindIII) of total genomic DNA 
Toxinotyping Sequence data of toxin A and toxin B 
PCR-Ribotyping (PCR RT) Amplification of intergenic region between 16S and 
23S ribosomal DNA 
Multilocus Sequence Typing 
(MLST) 
Sequence analysis of seven housekeeping genes 
(aroE, ddl, dutA, tpi, recA, gmk, and sodA) 
Multilocus Variable-Number 
Tandem Repeat (MLVA) 
Number of repeats in a set of VNTR loci is assessed 
by PCR  
Pulsed-Field Gel 
Electrophoresis (PFGE) 
Enzyme restriction of total genomic DNA with rare 
cutting restriction endonucleases (SmaI, KspI, SacII) 
Surface Layer Protein A Gene 
Sequence Typing (slpAST) 
Sequencing of variable region of the surface layer 
protein A gene (slpA) 
Amplified Fragment Length 
Polymorphism (AFLP) 
Combination of enzyme restriction and PCR 
Table adapted from (Killgore et al., 2008; Cairns et al., 2012) 
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All of the above methods have been found to be comparable (Killgore et al., 2008), 
in Europe PCR RT is widely used with over 427 PCR ribotypes identified, to date 
(Cairns et al., 2012).  MLST studies have indicated that C. difficile has evolved into 
six distinct lineages which can be broadly divided by the most important PCR 
ribotypes (017, 023, 027 and 078) (Knetsch et al., 2013), as summarised in Table 1.2. 
 
Table 1.2: Correlation between sequence type (ST) and PCR ribotype (RT) 
Lineage 1 ST-3 (PCR RT001), ST-54 (PCR RT012) and ST-2, ST-14 and ST-49 (all PCR 
RT014) 
Lineage 2 19 STs (PCR RT016, PCR RT036 and PCR RT176, ST-120 (PCR RT006) 
ST-1 (PCR RT027) 
Lineage 3 ST-5 (PCR RT023) 
ST-22, ST-25 and ST-96 (PCR RT058) 
Lineage 4 16 STs  
ST-37 (PCR RT017) 
Lineage 5 ST-11 (PCR RT078, 033, 045, 066, 126 and 193), ST-147 and ST-148 
Lineage 6 ST-122 (PCR RT131) 
Adapted from (Knetsch et al., 2012) 
 
Voluntary surveillance of C. difficile was introduced in 1990 in England and Wales 
and made mandatory in 2004, for all reported CDI in patients aged 65 and over (CDI 
is now reported in all patients aged 2 and over).  In England and Wales the number 
of deaths involving C. difficile has begun to decrease (Figure 1.1).  This is partly 
attributed to an increase in awareness of CDI, resulting in prompt diagnosis, 
increased antimicrobial stewardship and improved infection control practices 
(hand hygiene and hospital cleaning).   
 
Figure 1.1: Number of deaths involving C. difficile in England and Wales.   
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Data from the Office for National Statistics (2013). 
The decline in the three most prevalent PCR ribotypes (027, 106 and 001) in the UK 
has been offset by an increase in all other ribotypes (Figure 1.2).  Recently emerging 
strains include the toxin A
-
B
+
 variant strains, which invariably belong to ribotype 
017, 053 and 078.  Outbreaks due to toxin A
-
B
+
 strains are increasing globally with 
strains generally resistant to fluroquinolones and associated with severe CDI.  
Interestingly, PCR RT078 is predominantly associated with CDI in animal species 
(pigs, horses, calves) and has also been found in contaminated food, indicating 
C. difficile is a zoonotic disease (Rupnik, 2007) and two-way transmission between 
humans and animals/food sources occurs (Dawson et al., 2009; He et al., 2012).  
Although to date, there has been no confirmed case of CDI to be of zoonotic or 
foodborne origin (Rodriguez-Palacios et al., 2013) 
 
 
Figure 1.2: Distribution of PCR ribotypes in England and Northern Ireland.   
Isolates were typed by the PCR ribotyping method at the Anaerobe Reference Unit or 
the C. difficile Ribotyping Network (CDRN).  Adapted from (Brazier et al., 2007; 
Brazier et al., 2008; Health Protection Agency, 2008, 2009, 2010). 
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have evolved resistance to fluroquinolones, which has facilitated the global spread of 
these strains (He et al., 2012).   
1.1.4 Risk Factors for Clostridium difficile Infection  
Disturbance to the microflora, as a consequence of antibiotic exposure is recognised 
as the primary risk factor for CDI (Kyne et al., 2001a; Drekonja et al., 2011), with 
the elderly (>65 years) found to be more susceptible (Kim et al., 2010).  Other risk 
factors include proton pump inhibitors and histamine H2-blockers (Dial et al., 2005; 
Akhtar and Shaheen, 2007; Aseeri et al., 2008; Kim et al., 2010), those with 
underlying chronic conditions such as solid organ transplant or immunosuppression, 
(Zilberberg et al., 2010).  Increasingly, those previously classified in the low risk 
group; patients with minimal or no recent exposure to healthcare facilities, 
peripartum women and children are experiencing CDI (Ananthakrishnan, 2010).   
 
Based on the changing epidemiology and risk factors of CDI, it is likely that 
C. difficile will prevail for the foreseeable future, with the 027 strain replaced by 
other epidemic strains.  Whether these emerging strains represent a new stage in the 
evolution of C. difficile (particularly in regards to transmission, survival and 
virulence) is yet to be seen. 
 
1.2 Clostridium difficile Germination, Colonisation and 
Toxin Production 
There are three main facets to the C. difficile lifecycle; the spore, the vegetative cell 
and toxin production.  For CDI to occur the spore must adhere and germinate, the 
vegetative cells must adhere to the mucosal surface and colonise the intestinal tract 
followed by toxin production.  The following section will summarise aspects related 
to these mechanisms, highlighting the virulence factors associated with each of these 
facets. 
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1.2.1 Clostridium difficile Spore Adherence and Germination 
Bacterial endospores are of central importance in the transmission, persistence and 
pathogenesis of C. difficile, enabling the organism to survive in both endogenous 
(within the host) and exogenous environments.  C. difficile spores are shed into the 
hospital environment by both symptomatic patients and asymptomatic carriers 
(Gerding et al., 1995; Muto, 2007; Riggs et al., 2007; Lawley et al., 2009).  
Transmission is primarily mediated via the hands of patients and healthcare workers 
via the faecal-oral route (Guerrero et al., 2012). 
 
Initial research in spore adherence to Caco-2 cells (intestinal epithelial cells) has 
indicated a positive correlation between spore hydrophobicity and adherence, with 
two spore-surface proteins of ~40-45 kDa implicated in surface hydrophobicity and 
adherence.  Although the C. difficile spore receptor(s) is yet to be elucidated, four 
candidate proteins have been identified, with spore adherence regarded as a key step 
in pathogenesis (Paredes-Sabja and Sarker, 2012).  As the spore is metabolically 
inactive, for CDI to occur the spore must germinate into a vegetative cell.  This is 
achieved by sensing specific germinants, for example nutrients (amino acids, sugars) 
or non-nutrient (lysozyme, salts) sources via germinant (Ger) receptors (Setlow, 
2003).  Analogs of spore specific proteins have been reported in all sequenced 
Bacillus and Clostridia, indicating germination proteins are conserved in both 
species (Howerton et al., 2011).   In C. difficile, the absence of the GerA, B and K 
receptor analogs (Paredes et al., 2005; Sebaihia et al., 2006; Sarker and Paredes-
Sabja, 2012) indicates the presence of either divergent, uncharacterised receptors 
and/or germinants (Ramirez et al., 2010; Howerton et al., 2011).  Bile salts (sodium 
taurocholate and sodium cholate) have been reported to trigger germination of 
C. difficile spores in nutrient-rich media (Wilson et al., 1982; Wilson, 1983), with 
glycine (Sorg and Sonenshein, 2008), l-phenylalanine, l-arginine (Howerton et al., 
2011) and histidine (Wheeldon et al., 2011) acting as co-germinants with cholate 
derivatives.  In vivo, spores are suspected to interact with bile salts, amino acids and 
lysozyme (Paredes-Sabja and Sarker, 2011) along the GI tract, wherein multiple 
interactions stimulate germination.  These interactions with host derived factors 
highlight the ability of C. difficile to survive in the human gut. Further to this the 
ability of the spore to survive within macrophages (72 hours) and persist on surfaces 
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for prolonged periods (>5 months), highlights the significance of the spore in the 
pathogenesis, dissemination and transmission of C. difficile (Kramer et al., 2006; 
Paredes-Sabja et al., 2012; Janoir et al., 2013) 
 
1.2.2 Clostridium difficile Vegetative Cell Adherence and 
Colonisation 
Fundamental to C. difficile colonisation is adherence; the mechanism by which this is 
achieved is yet to be fully elucidated.  Colonisation factors include; capsule (Davies 
and Borriello, 1990), Cell Wall Protein 66 (Waligora et al., 2001), flagellins, FliC 
and FliD (Tasteyre et al., 2001a), Fbp68 (Hennequin et al., 2003; Lin et al., 2011), 
GroEL (Hennequin et al., 2001b) and the S-layer proteins (Slp).   
 
The Gram-positive cell envelope is composed of a single cytoplasmic membrane 
surrounded by a thick peptidoglycan layer, forming a physical barrier with the 
environment and providing a scaffold for the attachment of cell wall teichoic acid, 
capsular polysaccharides or proteins (Scott and Barnett, 2006; Emerson and 
Fairweather, 2009; Schneewind and Missiakas, 2012; Freudl, 2013).  In 
Gram-positive bacteria, surface proteins can be covalently or non-covalently bound 
to the peptidoglycan or secondary cell wall (Navarre and Schneewind, 1999).  Those 
which are covalently bound to the cell wall contain a C-terminal sorting signal which 
is recognised and cleaved by sortase enzymes (sortase-dependent mechanism), 
allowing for subsequent linkage to the peptidoglycan (Freudl, 2013).    The transport 
of cell wall proteins across the membrane is mediated by the general secretory 
system (Sec); ATP hydrolysis (SecA ATPase), which allows protein translocation 
through the aqueous channel (SecYEG), followed by the removal of the signal 
peptide.  In Gram-positive bacteria a second accessory Sec system has been 
described, SecA2, in C. difficile it is this system which is responsible for the 
transport of S-layer proteins (SlpA, CwpV, Cwp2, Cwp66 and Cwp84) and hence is 
essential for C. difficile viability (Fagan and Fairweather, 2011).  This is in contrast 
to other bacteria where the SecA2 system is largely associated with the transport of 
virulence and colonization factors.   
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1.2.2.1 S-Layer Proteins (Slp) 
Surface proteins are composed of a LPxTG (Leu-Pro-X-Thr-Gly) motif, a 
hydrophobic domain and tail of (mostly positive) charged residues (Navarre and 
Schneewind, 1999).   Most C. difficile CWPs are non-covalently anchored to the cell 
wall by an as yet uncharacterized mechanism and hence are not members of the 
LPxTG protein family (Emerson et al., 2009).  LPxTG-like motifs have been 
identified in C. difficile (SPXTG or PPXTG) (Pallen et al., 2001).  C. difficile is 
composed of 28 SLP paralogs, each containing a conserved cell wall anchoring 
domain and a function specifying domain (Sebaihia et al., 2006).  The predominant 
protein in the C. difficile S-layer is SlpA, which is post-translationally cleaved by the 
cysteine protease, Cwp84 (Kirby et al., 2009; Dang et al., 2010), resulting in the 
formation of a 45 kDa, high molecular weight protein (HMW SLP) and 32 kDa, low 
molecular weight protein (LMW SLP).  The resulting S-layer consists of a thick 
hexagonally arranged inner S-layer and a squarely arranged outer lattice (Kawata et 
al., 1984; Cerquetti et al., 2000).  The LMW SLP is highly divergent, although a 
high degree of conservation has been identified in the C-terminal domain, which is 
necessary for the interaction with the N-terminus of the HMW SLP (Fagan et al., 
2009).  Although there is some inter-strain variability, SLPs have been detected in all 
C. difficile strains, forming a core component of the bacterium aiding in colonisation 
and adherence (Karjalainen et al., 2001; Calabi et al., 2002; Cerquetti et al., 2002).  
During the course of CDI, antibodies to both the HMW and LMW SLPs have been 
shown (Drudy et al., 2004; Péchiné et al., 2005a; Wright et al., 2008).   Whilst the 
humoral response to the HMW SLP is conserved across strains, the response to the 
LMW SLP is only similar within the same serogroup (Cerquetti et al., 2000; Calabi 
et al., 2001).  The SLP has also been shown to be a protective factor against the 
immune response and as such is regarded as a target for therapeutic development. 
 
1.2.2.2 Cell Wall Protein66 (Cwp66) 
Cwp66 displays homology to the autolysin CwlB of Bacillus subtilis, it has been 
identified as an immunogenic adhesion and is genetically diverse (Waligora et al., 
2001; Péchiné et al., 2005a).  Interestingly, cwp66, slpA and SecA2 form a 10 kB S-
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layer cassette which has co-evolved and through homologous recombination twelve 
diverse variants are recognised.  Such system are comparable to capsular switching 
in other bacteria, hence S-layer switching would aid in evasion of the host immune 
system and susceptibility to bacteriophages (Dingle et al., 2013).   
1.2.2.3 Cell Wall Protein V (CwpV) 
CwpV is a surface expressed phase variable protein, capable of autoproteolysis 
(Emerson et al., 2009; Reynolds et al., 2011; Dembek et al., 2012).  In the OFF 
orientation, the inverted region between the cwpV promoter and open reading frame 
forms a stem loop terminator preventing full length transcription, this recombination 
and inversion is mediated by RecV (Emerson et al., 2009).  The presence of variable 
number repeats in the C-terminal of CwpV confers antigenic variability between 
C. difficile strains, with at least five antigenically variable types identified to date, 
this combined with the proteins ability to promote bacterial aggregation and be 
expressed in a phase variable manner, suggests CwpV is important for immune 
evasion and colonization (Reynolds et al., 2011).   
 
1.2.2.4 Collagen Binding Protein A (CbpA) 
Binding to host extracellular matrices (ECM), such as fibronectin, fibrinogen, and 
collagen, is mediated by bacterial surface proteins known as MSCRAMMs 
(microbial surface components recognizing adhesive matrix molecules).  These 
proteins contain a surface sorting signal which is recognised by sortase, resulting in 
the surface localisation of the protein.  In C. difficile the surface exposed Collagen 
Binding Protein A (CbpA), has been described as a member of the MSCRAMM 
family, containing a NVQTG motif at its C-terminus and may well be the substrate 
for the putative sortase B.  CbpA is hypothesised to function as an adhesion 
facilitating C. difficile-host interaction (Tulli et al., 2013). 
 
1.2.2.5 GroEL 
GroEL is a heat shock protein which can be both surface located and released 
extracellularly post-heat shock.  Incubation of C. difficile cells with GroEL 
polyclonal antibodies was found to reduce adherence of C. difficile to Vero cells 
(Hennequin et al., 2001a; Hennequin et al., 2001b; Jain et al., 2011), whilst mice 
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immunised with recombinant GroEL displayed a reduced level of intestinal 
colonisation, the same was not apparent in the hamster model (Péchiné et al., 2013).  
The authors suggest this may be due to only a partial inhibition of colonization in the 
hamster model, which is neither sufficient nor efficient enough to limit the action of 
toxin A and B.  Alternatively the differences observed in the two animal models may 
be due to experimental differences in the immunization regime and bacterial 
challenge employed, challenge with 2x10
3
 spores vs. challenge with 10
9
 C. difficile 
cells in the hamster and mouse model, respectively. 
 
1.2.2.6 Flagella 
In many bacterial pathogens, flagella mediate swimming motility contributes to 
pathogenesis.  In C. difficile the flagellin structural monomer (FliC) and the cap 
protein (FliD) have been reported to aid in biofilm formation and attachment to the 
intestinal mucus layer and host cells (Tasteyre et al., 2001a; Tasteyre et al., 2001b; 
Dingle et al., 2011; Ðapa et al., 2013).  Although in the latter study flagella were not 
required for virulence in hamsters (Dingle et al., 2011).  More recently a study 
comparing the flagella of 630Δerm and R20291 has identified differences in the 
production and adherence properties of the two strains, with the latter strain 
producing a single flagellum and the R20291 flagella mutant displaying reduced 
adherence in vitro as compared to the wildtype (Baban et al., 2013).  The generation 
of serum antibody responses in CDI patients (Péchiné et al., 2005a; Péchiné et al., 
2005b) and the variability in flagellar protein glycosylation between strains (Twine et 
al., 2009) suggests flagella are important virulence factors during the course of CDI, 
contributing to the evasion of the immune system and virulence.  Furthermore, the 
flagella regulon has been shown to influence the transcription of the PaLoc genes 
(Aubry et al., 2012; Baban et al., 2013).   The role of flagella in colonisation, toxin 
expression and secretion in C. difficile is yet to be determined, and may well display 
strain-strain variations.   
 
1.2.2.7 Capsule 
Capsules have long been regarded as prominent virulence factors aiding in 
adherence, preventing dehydration, impairing phagocytic uptake into the cells of the 
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innate immune system and protecting against bacteriophage infection (Foster and 
Popham, 2002).  The major component of capsules is water and is typically 
composed of polysaccharides of varying structure or amino acid homopolymers 
(Foster and Popham, 2002).  The first indirect demonstration of capsulated 
C. difficile cells was presented by Strelau et al., (1989), however the suggestion that 
a capsule could serve as an antiphagocytic factor in C. difficile was proposed two 
years earlier (Dailey et al., 1987).  Dailey et al., (1987) identified that phagocytosis 
of C. difficile by human polymorphonuclear leukocytes (PMN) (the first line of 
defence of the innate immune system) was dependant on opsonisation of the bacteria 
and was independent of the toxins.  Confirmation and further characterisation of 
capsules was provided by Davies and Borriello (1990) who identified two 
morphologically distinct capsules in different strains of C. difficile.  This study 
identified there was no correlation between the presence of capsule and the 
toxigenicity status of the strain.  Later research conducted by Baldassarri et al., 
(1991) identified that glucose enhanced capsule production, with strains more 
frequently associated with disease able to produce thicker capsules even in the 
absence of glucose in the media.  The role of the capsule in C. difficile and its 
contribution to virulence is yet to be fully investigated. 
 
Undoubtedly the cell surface of C. difficile contributes to adherence, colonisation and 
evasion of the host immune system.  The presence/regulation of multiple components 
(SlpA, CwpV, flagella, capsule) and their precise role in the pathogenesis of this 
organism is yet to be fully elucidated.  Microarray analysis indicates that C. difficile 
alters its cell surface envelope upon contact with Caco-2 cells, resulting in 
up-regulation of several virulence factors, including capsular proteins and 
down-regulation of flagellar proteins and Cwp84 (Janvilisri et al., 2010).  Although 
insights have been made in assessing the role of the vegetative cell surface in the 
pathogenesis of C. difficile, it is clear that much is yet to be deciphered. 
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1.2.3 Clostridium difficile Toxin A, Toxin B and Binary Toxin  
1.2.3.1 Binary Toxin 
In addition to the production of toxins A and B some C. difficile strains are capable 
of producing a binary toxin, CDT (Popoff et al., 1988) which is unrelated to the 
Large Clostridial Toxins (LCT).  CDT binds to lipolysis-stimulated lipoprotein 
receptor (LSR), irreversibly ADP-ribosylates actin, disrupting the host cell 
cytoskeleton (Papatheodorou et al., 2011).  CDT is capable of inducing a 
non-haemorrhagic fluid response and thus possesses enterotoxic activity.  In a 
hamster model, animals infected with A
-
B
-
CDT
+
 strains became colonized but did 
not display symptoms of CDI (Geric et al., 2006).  More recently, hamsters infected 
with an isogenic mutant (A
-
B
-
CDT
+
), generated using the ClosTron technology, 
found 38% (3 of 8) of animals died, although these animals displayed atypical 
symptoms of CDI, the study does indicate a potential role of the binary toxin in 
C. difficile pathogenesis (Kuehne et al., 2014).  The destruction of the actin 
cytoskeleton and induction of microtubule protrusions suggests CDT enhances 
bacterial adherence and colonization (Schwan et al., 2009).  
 
1.2.3.2 Toxin A 
Historically, toxin A has been regarded as the primary virulence factor of C. difficile, 
responsible for the pathophysiological effects of infection.  Notably toxin A was 
viewed as essential for facilitating the exit of toxin B from the gut into the 
sub-mucosal areas (Lyerly et al., 1988; Du and Alfa, 2004).  Toxin A is a potent 
enterotoxin with slight cytotoxic activity, responsible for the release of inflammatory 
mediators, including infiltration of neutrophils (Kelly et al., 1994), the production of 
cytokines (He et al., 2002) and chemokines (Castagliuolo et al., 1998), reactive 
oxygen intermediates (He et al., 2002) and substance P (Mantyh et al., 1996), the 
activation of mast cells (Wershil et al., 1998) and sub-mucosal neurons (Hurley and 
Nguyen, 2002) resulting in fluid accumulation and extensive tissue necrosis.   
 
1.2.3.3 Toxin B 
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Depending on the cell type, toxin B is a 100–10,000 times more potent than toxin A 
(Tucker et al., 1990; Chaves-Olarte et al., 1997), is involved in the depolymerisation 
of filamentous actin, causing destruction in the cell cytoskeleton and cell rounding 
(Pothoulakis et al., 1986).  The isolation of A
-
B
+
 strains from PMC patients has 
established that toxin B is capable of causing severe disease and death, even in the 
absence of toxin A (Limaye et al., 2000; Johnson et al., 2001).  Early research 
indicated toxin B possessed no enterotoxic activity, (Borriello, 1998; Borriello and 
Wilcox, 1998), it has since been shown toxin B induces fluid secretion and factors 
associated with enterotoxic and pro-inflammatory action in the human intestine, 
including epithelial cell damage, release of interlukin-8 (IL-8), neutrophil infiltration 
and mucosal inflammation (Savidge et al., 2003).  The C-terminal region of TcdB 
has been shown to exhibit cytotoxic effects and in A
-
B
+
 strains this region is 
suspected to facilitate access of TcdB to the basolateral surface (Zemljic et al., 
2010).     
 
1.2.4 Large Clostridial Cytotoxins 
C. difficile toxins A (TcdA) and B (TcdB), the alpha toxin of C. novyi (TcnA), the 
lethal (TcsL) and haemorrhagic toxins (TcsH) of C. sordellii and the TpeL toxin of 
C. perfringens are members of the Large Clostridial Cytotoxin (LCT) family 
(Table 1.3).  This is a unique and still emerging group of bacterial toxins that share 
common sequence similarity, primary structure and enzymatic activity (Table 1.3).  
Members are recognised by the production of large single chained proteins ranging 
between 191 to 308 kDa (Rupnik and Just, 2006).  A number of LCT variants have 
been reported to occur in both C. difficile and C. sordellii, with strains only 
producing TcdB or TcsL, respectively (Table 1.3).  Even in the absence of TcdA and 
TcsH, both organisms are still able to cause disease.  To date, no A
+
B
-
 strain of 
C. difficile has been isolated.  With a genetically engineered A
+
B
 -
 strain, Lyras et al., 
(2009) found TcdB was essential for pathogenesis.  Since this report, Kuehne et al., 
(2010) have reported the importance of both TcdA and TcdB in the pathogenesis of 
CDI.  Until the roles of TcdA and TcdB can be unequivocally determined it would be 
rational to assume, both TcdA and TcdB are required for virulence and pathogenesis.  
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Table 1.3: Properties of large clostridial toxins and those homologous to LCTs. 
Toxin Organism Size 
kDa 
CROPS
a
 Location Substrate Target GTPases
b
 Homology 
(%)
c
 
Biological 
Activity
 d
 
Lethal dose
e 
TcdA C. difficile  
(VPI 10463) 
308 32 Chromosome 
(PaLoc) 
UDP-glucose Rho, Rac Cdc42, 
RhoG, TC10, Rap 
60 D 50 ng 
TcdB C. difficile 
(VPI 10463) 
270 19 Chromosome 
(PaLoc) 
UDP-glucose Rho, Rac Cdc42, 
RhoG, TC10 
100 D 50 ng 
TcsH C. sordellii 
(VPI 9048) 
300 * * UDP-glucose Rho, Rac Cdc42 * D 75 ng 
TcsL C. sordellii 
(6018) 
270 19 Chromosome UDP-glucose Ras, Rac, Rap, 
Ral,  (Cdc42)f 
75 S 5 ng 
TcnA C. novyi 
(ATCC 19402) 
250 14 Phage UDP-N-
acetyl-
glucosamine 
Rho, Rac Cdc42 27 D 5 – 10 ng 
TpeL C. perfringens  
(Type B and C)  
191 * Plasmid UDP-glucose 
UDP-N-
acetyl-
glucosamine 
Ha-Ras, RalA, 
Rap1B, Rac1 
38 D/S 16 µg 
TcdB1470 C. difficile1470 270 19 Chromosome 
(PaLoc) 
UDP-glucose Ras, Rac, Rap, 
Ral,  Cdc42 
93 S 50 ng 
TcdB8864 C. difficile8864 270 19 Chromosome 
(PaLoc) 
UDP-glucose Rac, Rap, Ral 85 S 50 ng 
a
Number of Clostridial Repetitive Oligopeptides (CROPs). 
b
Target proteins belong to the Ras superfamily of small GTP-binding proteins. 
c
Amino acid sequence similarity when compared with that of TcdB10463. 
d
Biological activity, D: C. difficile-like, S: C. sordellii-like. 
e
Lethal dose 
based on intraperitoneal injection of a mouse. 
f
Glucosylation of CDC42 is strain specific in C. sordellii. UDP-Glucose, glucose-uridine-
diphosphate, UDP-N-acetyl-glucosamine, N-acetylglucosamine-diphosphate, * Unknown.  Adapted from (Rupnik and Just, 2006; Pruitt and 
Lacy, 2012). 
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1.2.5 Clostridium difficile Toxin A and B Expression and 
Secretion 
The primary virulence factors of Clostridia are toxins and it is the secreted toxins 
which are the primary mediators of pathogenesis.  Secreted toxins are released into 
the external media and can act on sites distant from the site of bacterial colonization.  
This is in contrast to invasive bacteria which survive intracellularly by directly 
injecting virulence factors into cells, usually by means of a Type III secretion system.  
Gram-negative bacterial toxins are exported across the inner cytoplasmic membrane, 
periplasmic space, peptidoglycan and outer membrane whilst in Gram-positive 
bacteria upon crossing the cytoplasmic membrane the toxin is present in the external 
media (Popoff and Stiles, 2005).  Gram-negative bacteria utilise a range of systems 
for the secretion of proteins, which are summarised in Table 1.4.    
Table 1.4: Toxin secretion in Gram-negative bacteria 
 Mechanism Examples 
Type I 3 membrane proteins:  ATPase, adaptor protein, TolC 
form a trimeric structure which forms pore through the 
outer membrane of Gram-negative bacteria 
E. coli α-hemolysin  
leukotoxins 
hydrolytic enzymes 
Type II Contain N-terminal sequence and use the general 
secretion pathways to cross inner membrane, cleavage 
of signal peptide and release of protein into periplasmic 
space. Protein folding and assembly. 
Cholera toxin 
ExoA 
Aerolysin 
Hydrolytic enzymes 
Type III 14 proteins that assemble to form a pore through the 
inner and outer bacterial membrane and eukaryotic 
membrane. 
Contact with eukaryotic cell initiates synthesis of Type 
III secretion proteins and injection of effector proteins. 
EPEC/EHEC – 
EspA,B,D 
Type IV Evolved from conjugation pili to transport DNA or 
proteins to target cell. 
10 proteins that form a central pore connecting the 
bacterial cytoplasm with the extracellular medium or 
cytosol of targeted cell. 
Pertussis toxin 
Type V N-terminal signal peptide mediates export of the protein 
across the inner membrane via the general secretion 
pathway.  C-terminus generates pore in the outer 
membrane, C-terminus is cleaved and protein released 
into extracellular medium 
Helicobacter pylori 
Vacuolating toxin 
Modified from Popoff and Stiles (2005). 
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The precise mechanism by which C. difficile secretes toxins A and B is unclear, 
extracellular proteins generally carry a secretion signal located at either the N or 
C-terminus or a Tat-signal; neither toxin A or B contain such secretion signals.  It 
was previously believed the toxins were released as a consequence of bacterial lysis, 
however this does not appear to be true with the extracellular protein proportion 
accounting for 50% of the total toxin produced in stationary phase cells, whilst <1% 
of typical cytoplasmic proteins were released (Mukherjee et al., 2002).  
 
In C. difficile, TcdA and TcdB are chromosomally located on a 19.6 kb pathogenicity 
locus (PaLoc) (Hammond and Johnson, 1995; Braun et al., 1996), which is 
composed of five genes; tcdA, tcdB, tcdC, tcdR and tcdE (Figure 1.3).  In 
non-toxigenic strains, the integration site of the PaLoc is a highly conserved, 115 bp 
non-coding region which lies between cdu1 and cdd1 (Hammond and Johnson, 1995; 
Braun et al., 1996).  Unique to strain 8864, is an additional ORF, named tcdF (Soehn 
et al., 1998), located at the intergenic region of tcdA-8864 and tcdE.  Amino acid 
sequence analysis of TcdF has not revealed significant homology with any known 
proteins and the function of the protein and its role, if any in pathogenesis is yet to be 
elucidated (Song et al., 1999), Figure 1.3. 
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Figure 1.3: Genetic arrangement of the C. difficile pathogenicity locus (PaLoc).   
Schematic diagram of the PaLoc in non-toxigenic (A
-
B
-
), toxigenic strains (A
+
B
+
) 
and variant8864 (A
-
B
+
) strains.  In non-toxigenic strains the PaLoc is replaced by 115 
bp non-coding sequence.  The variant strain 8864 has an insertion (tcdF) and 
truncated tcdA and tcdC.  Black arrows indicate promoters for tcdR, tcdA and tcdB.  
 
Genes tcdRBEA form a transcriptional unit, with expression peaking during the late 
stationary growth phase, suggesting the toxins serve as a means of nutrient 
scavenging. Transcriptional analysis of the PaLoc has revealed the genes are 
transcribed in a unified manner in response to a number of environmental stimuli 
including phase of growth, antibiotics, temperature, nutrient sources and amino acids 
(Yamakawa et al., 1998; Karlsson et al., 1999; Karlsson et al., 2000; Karlsson et al., 
2003).  It is suggested toxin production is a cell-density dependent process, with 
quorum sensing molecules shown to play an important role in transcriptional 
regulation (Carter et al., 2005; Lee and Song, 2005; Darkoh, 2012). 
 
1.2.5.1 TcdR – Positive Regulator 
The tcdR gene encodes a 22 kDa protein with a helix-turn-helix DNA motif, 
homologous with the BotR, TetR and UviA positive regulators of C. botulinum, 
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C. tetani and C. perfringens, respectively (Mani and Dupuy, 2001).  TcdR is a sigma 
(σ) factor, directing RNA polymerase to its own promoter and to the promoters of the 
toxin genes (Moncrief et al., 1997; Mani and Dupuy, 2001; Mani et al., 2002).   
 
1.2.5.2 TcdC – Negative Regulator? 
TcdC is a membrane associated protein (Govind et al., 2006) believed to function as 
an anti-σ factor, negatively regulating tcdR-dependent transcription (Dupuy et al., 
2008), by preventing the formation of the TcdR-RNA polymerase holoenzyme 
(Moncrief et al., 1997; Mani and Dupuy, 2001; Matamouros et al., 2007).  Deletions 
and frame shift mutations in tcdC have been implicated in contributing to 
hypervirulence, resulting in increased toxin production and severity of disease 
(Warny et al., 2005; Freeman et al., 2006; Carter et al., 2011).  However, the role of 
TcdC as a negative regulator of toxin expression is questionable, with studies 
reporting no correlation between the expression levels of the toxins and TcdC 
(Merrigan et al., 2010; Vohra and Poxton, 2011; Bakker et al., 2012; Cartman et al., 
2012).  In the aforementioned studies TcdC is hypothesised to have a modulatory 
role in regulating toxin expression.   
 
1.2.5.3 TcdE – Holin-Like Protein? 
TcdE is predicted to be highly hydrophobic, with three transmembrane domains, a 
hydrophilic region at the N-terminus and a series of charge rich residues at the 
C-terminus, indicative of holin proteins (Tan et al., 2001).  Sequence analysis and 
structural similarities between TcdE and a family of bacteriophage holin proteins, 
suggests TcdE may be involved in holin-mediated cell lysis, facilitating the release of 
toxins A and B into the extracellular environment (Tan et al., 2001).  The role of 
TcdE is currently under debate with a TcdE-deficient strain displaying no increase in 
the level of secreted enzyme or delay in toxin release (Olling et al., 2011).  These 
findings are in contrast to the study conducted by Govind and Dupuy (2012), who 
have proposed TcdE is expressed in sufficient quantities in C. difficile, to allow pore 
formation, facilitating the release of toxins without causing cell lysis.  Direct 
comparisons between the two studies are complicated by differences in growth 
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media, experimental time point analysis and significantly the parental strain (Govind 
and Dupuy, 2012) 
1.2.5.4 Other Regulators of Toxin Expression 
Other regulators of toxin synthesis include; CodY (Dineen et al., 2007; Dineen et al., 
2010), Spo0A (Underwood et al., 2009), bacteriophage mediated (Govind et al., 
2009; Sekulovic et al., 2011),  CcpA (Antunes et al., 2011), SigH (Saujet et al., 
2011) and flagella (Aubry et al., 2012; Baban et al., 2013).   
 
1.2.6 Clostridium difficile TcdA and TcdB Structure and 
Uptake 
Structural analysis of TcdA and TcdB has revealed a modular structure (Figure 1.4), 
with amino acid sequence analysis identifying extensive sequence homology 
(49% identity and 63% similarity) (Pruitt and Lacy, 2012).  Due to the structural and 
functional homologies of the toxins it has been postulated that TcdA and TcdB arose 
due to a gene duplication event, with subsequent mutation and recombination (von 
Eichel-Streiber et al., 1992a).  The toxins resemble AB-toxins, containing an 
enzymatic domain and a binding/translocation domain (von Eichel-Streiber et al., 
1995; von Eichel-Streiber et al., 1996).  The AB model has since been extended to 
the ABCD model (A, biological activity; B, binding; C, cutting; D, delivery), (Jank 
and Aktories, 2008), Figure 1.4.   
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Figure 1.4: Diagrammatic representation of the structure of C. difficile toxins.   
A) Toxin A and B) Toxin B. The glucosyltransferase activity is located at the 
N-terminus of the protein, the putative transmembrane domain involved in 
membrane translocation is located in the middle and the C-terminus represents the 
receptor binding domain, composed of CROPs.  Adapted from Jank et al., (2007).  
 
1.2.6.1 C-Terminal 
The C-terminus of TcdA and TcdB is composed of multiple repeat regions, termed 
Combined Repetitive Oligopeptides (CROPs) (Dove et al., 1990; von Eichel-Streiber 
et al., 1992b).  In TcdA, this region accounts for one third of the toxin spanning 
amino acid residues 1832-2710.  The TcdA CROPs are composed of 32 short repeats 
(20 or 21 amino acids) and seven long repeats (30 amino acids).  For TcdB four long 
repeats (30 amino acids) and 19 short repeats (20 or 21 amino acids) make up the 
CROPs (Wren, 1991; von Eichel-Streiber et al., 1992a; von Eichel-Streiber et al., 
1992b).  It is via the CROPs that TcdA and TcdB bind to sugar moieties on the 
surface of host cells (von Eichel-Streiber et al., 1992a; von Eichel-Streiber et al., 
1992b).  The C-terminus of TcdA shows homology with ligand binding proteins of 
Streptococci (Wren, 1991).  Crystal structure analysis of 127 and 255 residues at the 
C-terminus of TcdA (Ho et al., 2005; Greco et al., 2006) has revealed a solenoid-like 
structure with 7 carbohydrate binding sites (Ho et al., 2005; Greco et al., 2006).  
Early studies have reported a protein-carbohydrate interaction for TcdA (Krivan et 
al., 1986; Tucker and Wilkins, 1991), with binding occurring in a multivalent, 
lectin-like manner (Krivan et al., 1986).  The carbohydrate, α-Gal epitope 
(Galα1-3Galβ1-4GlcNAc) has been shown to bind TcdA, however, this structure is 
absent in human intestinal receptors (Krivan et al., 1986; Tucker and Wilkins, 1991).  
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Thus, 3Galβ1-4GlcNAc, which is present in humans is proposed as the receptor for 
TcdA (Krivan et al., 1986; Tucker and Wilkins, 1991; Jank and Aktories, 2008; 
Olling et al., 2011).  Additionally TcdA has been reported to bind the human blood 
antigens I (Galb1-14GlcNAcb1-3Galb1-4(Glc)), X (Galb1-4[Fua1–3]GlcNAc) and Y 
(Galb1-4GlcNAcb1) (Tucker and Wilkins, 1991), human glycosphingolipid 
(Teneberg et al., 1996) and human gp96 and sucrose-isomaltase (Na et al., 2008). 
 
The receptor for toxin B is yet to be characterised.  Its ability to bind to a wide range 
of cells indicates that the toxin B receptor is ubiquitous.  Toxin B’s ability to bind to 
cell lines in a saturated manner and bind more efficiently to some cell lines than 
toxin A, suggests that the two toxins recognise different receptors (Chaves-Olarte et 
al., 1997).  Studies have also indicated that the toxin B receptor is located on the 
basolateral side, whilst the toxin A receptor is present on the apical side (Jank et al., 
2007).  Dingle et al., (2008) assessed the cell binding properties of the repeat regions 
in TcdA and TcdB, revealing both toxins can withstand structural variations in the 
carbohydrate binding sites.  Microarray screening of fragment TcdA-A2 (amino acid 
residues 2456-2710) and TcdB-B1 (amino acid residues 2248-2367) against 350 
carbohydrate sequences identified a second receptor for TcdA-A2 
(Le
a
-LacNAc and Sia-Le
a
-Le
x
); surprisingly no receptor was found for TcdB-B1.  
Studies have also suggested domains other than the C-terminus of TcdA and TcdB 
may be important for cell surface binding (Dingle et al., 2008; Gerhard et al., 2013).  
This notion is supported by the generation of TcdA and TcdB mutants which are 
devoid of the CROPSs but still retain cytopathicity (Barroso et al., 1994; 
Genisyuerek et al., 2011; Olling et al., 2011).   
 
1.2.6.2 Endocytosis and Translocation 
Upon binding to the host cell receptor(s) the toxins undergo clathrin-mediated 
endocytosis (Papatheodorou et al., 2010)  (Figure 1.5).  The acidic nature of the 
endosome enables the toxin to undergo conformational changes, allowing it to 
interact with the endosomal membrane, enabling pore formation and the insertion of 
the hydrophobic toxin domain (Florin and Thelestam, 1986; Qa'Dan et al., 2000; 
Barth et al., 2001).  In TcdB the minimum pore forming region resides between 
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amino acids 830-990, with the glutamate residues at 970 and 976 crucial for pore 
formation (Genisyuerek et al., 2011).  It is hypothesised that protonation of the acidic 
glutamate residues occurs at low pH, neutralising the amino acid and allowing for 
pore formation.   Although not conserved in LCTs the presence of other acidic amino 
acids at these positions suggest a similar mechanism may exist in other LCTs.  
Differences have been observed in the processing of the C. difficile toxins, with 
TcdA, unlike TcdB, requiring cholesterol for pore-formation (Giesemann et al., 
2006).  Furthermore, toxins from different strains of C. difficile display different 
processing mechanism, for example TcdB of R20291 (PCR RT027) has been shown 
to enter cells more quickly, undergoes acid induced conformational changes at a 
higher pH and is more efficiently auto-processed than TcdB from the prototypical 
630 strain (Lanis et al., 2010; Lanis et al., 2012).   
 
1.2.6.3 Autoproteolysis 
In the case of toxin B the enzymatic toxic domain is detectable in the cytosol 
whereas the translocation and binding domains remain in the endosome (Rupnik et 
al., 2005).  Hence, an important step of internalisation is proteolytic cleavage, 
resulting in the translocation of the enzymatic domain (Pfeifer et al., 2003).  The 
cleavage site for toxin B lies between Leu 543 and Gly 544 (Rupnik et al., 2005).  
The host cytosolic molecule, inositol hexakisphosphate (InsP6) induces autocatalytic 
cleavage and is essential for the biological activity of both toxins (Reineke et al., 
2007; Egerer et al., 2009), although TcdB is more susceptible to InsP6-induced 
cleavage than TcdA (Kreimeyer et al., 2011). 
 
Two protease motifs have been identified in toxin B; aspartate protease (DXG) and 
cysteine protease (CPD) (Figure 1.4).  The DXG motif in toxin B resides at aspartate 
1665 and has been identified as the site for protease activity (Reineke et al., 2007).  
This motif has also been identified in TcdA and TcsL but not in TcnA, even though 
all the LCTs undergo InsP6-induced auto-catalytic cleavage.  Although processing of 
toxin B can be inhibited with an aspartate inhibitor (Reineke et al., 2007), the DXG 
motif is located nearer to the C-terminal domain (Figure 1.4).  This suggests the 
protease remains in the endosome as opposed to being translocated into the cytosol 
with the enzymatic region.  A second motif that has been identified is a cysteine 
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protease domain (CPD) (Egerer et al., 2007).   The CPD domain has been identified 
in the RTX (repeats-in-toxin) toxin of Vibrio cholerae and is also present in all the 
LCTs.  It is located between the enzymatic and translocation domains (Figure 1.4) 
and is activated by InsP6 facilitating the release of the enzymatic domain into the 
target cell.  CPD is recognised as essential for toxin processing and represents a 
target for the development of toxin inhibitors (Puri et al., 2010). 
 
1.2.6.4 Enzymatic Activity 
Like all LCTs, toxins A and B are glucosyltransferases which catalyse the transfer of 
a glucose moiety to Rho and Ras-GTPases (Table 1.1 and Figure 1.5B).  GTPases 
function as molecular switches in a wide range of signalling pathways and are 
present in all eukaryotic cells (Pruitt and Lacy, 2012).  In the cytosol, the 
glucosyltransferase effector domain of the toxins utilises cellular UDP-glucose to 
monoglucosylate RhoA, Rac1, and CDC42 (Just et al., 1995a; Just et al., 1995b; Just 
and Gerhard, 2004).  In the inactive, GDP-bound form, the GTPases associate with 
the guanine nucleotide dissociation inhibitor (GDI) and remain in the cytosol.  
Activation of GTPases by guanine nucleotide exchange factors (GEF) results in the 
regulation of a range of host cell functions, including cell proliferation, 
differentiation and organisation of the actin cytoskeleton (Barth and Aktories, 2005).  
Hence, the wide ranging impact on downstream signalling and regulatory pathways, 
following inactivation.  Analysis of the structure of the glucosyltransferase domain 
of TcdA and TcdB has revealed differences in GTPase binding surface and hence 
substrate specificities (Reinert et al., 2005; Pruitt et al., 2012) of the two toxins.  
Figure 1.5 summarises the processing of toxins A and B. 
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Figure 1.5: Diagrammatic representation of pathogenesis of CDI.   
A) Toxin A and B processing. Receptors of TcdA and TcdB are yet to be defined.  
TcdA receptors are located on the apical surface, the TcdB receptors are 
hypothesised to be located on the basolateral surface, which are exposed following 
intestinal damage.  B) Toxin-mediated monoglucosylation of GTPases. GDI; guanine 
nucleotide dissociation inhibitor, GAP; GTPase-activating protein, GEF; guanine 
nucleotide exchange factor, Glc; glucose. Adapted from Keel and Songer (2006) and 
Just and Gerhard (2004). 
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1.3 Treatment and Therapy 
1.3.1 Antibiotics  
In susceptible individuals, CDI develops post-antibiotic treatment as the protective 
gut flora is compromised.  Initial steps in treatment focus on stopping the offending 
antibiotic.  Almost all antibiotics, including metronidazole and vancomycin have 
been associated with CDI (Saginur et al., 1980; Hecht and Olinger, 1989).  These 
two antibiotics have been the main stay for CDI treatment for over three decades, 
despite a relapse rate of 15-20%.   
 
1.3.1.1 Vancomycin 
Vancomycin binds with high afﬁnity to the d-Ala-d-Ala moiety of the C-terminus of 
the MurNAc-pentapeptide, thus blocking the addition of muropeptide precursors in 
the periplasm by transglycosylation and transpeptidation (Courvalin, 2006; 
Hakenbeck et al., 2010).  C. difficile is an intraluminal pathogen entirely contained in 
the colon lumen, hence vancomycin, which is concentrated in the colon is 
pharmacologically ideal (Bartlett, 2006, 2008) demonstrating a 84-94% cure rate 
(Tart, 2013).  When administered orally vancomycin is not metabolised and has 
limited absorption, thus reaching levels which are several-fold higher than the 
minimum inhibitory concentration (MIC) recorded for C. difficile.  The 
recommended dosage of oral vancomycin is 125 mg four times daily.  Due to its 
potent antimicrobial activity, the recovery of the indigenous microflora is delayed 
resulting in a 17% recurrence rate (Louie et al., 2011; Tart, 2013).  In an attempt to 
curb the emergence of vancomycin-resistance Enterococci (VRE), the use of 
vancomycin in CDI is limited to incidences of treatment failure or severe disease 
(Tart, 2013).  
 
1.3.1.2 Metronidazole 
The recommended metronidazole dose is 500 mg three times daily or 250 mg four 
times daily for 10 to 14 days.  In contrast to vancomycin, metronidazole is highly 
absorbed from the colon resulting in modest faecal concentration.  It is currently 
unclear why there are an increasing number of treatment failures (22%) and 
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recurrences (28%) (Musher et al., 2005; Pépin et al., 2005) following metronidazole, 
given that clinically relevant metronidazole resistant isolates are yet to emerge.  
Although it should be noted that in vitro 3-6% of isolates were found to be 
metronidazole resistant (Barbut et al., 1999; Pelaez et al., 2008).  Whether this is due 
to the presence of a sub-population of cells with increased resistance is yet to be 
determined (Moura et al., 2013b).  Further to this, two (Louie et al., 2007; Zar et al., 
2007) out of three (Bouza et al., 2008) trials have shown metronidazole to be inferior 
to vancomycin for the treatment of severe CDI.  In spite of this metronidazole 
remains the preferred drug for mild and moderate CDI primarily due to its reduced 
cost. 
 
1.3.1.3 Fidaxomicin 
Fidaxomicin (FDX) administered 200 mg orally twice daily for 10 days, has been 
shown to be superior to vancomycin in providing sustained clinical response 
(response without recurrence of disease).  The drug inhibits the activity of bacterial 
RNA polymerase, has a narrow-spectrum of activity against Gram-positive bacteria 
(Finegold et al., 2004; Hecht et al., 2007), is minimally absorbed from the intestinal 
tract (Hecht et al., 2007) and inhibits sporulation (Babakhani et al., 2012), thus 
making it an ideal antibacterial agent for CDI (Ackermann et al., 2004a; Credito and 
Appelbaum, 2004; Finegold et al., 2004; Hecht et al., 2007; Karlowsky et al., 2008; 
Shue et al., 2008; Miller, 2010; Louie et al., 2011; Babakhani et al., 2012).  
 
The use of antibiotics to treat CDI appears to be contradictory; by their very nature 
antibiotics will hinder the re-establishment of the protective microflora and have 
been implicated in triggering a supershedder (10
8
 CFU C. difficile/g faeces)  state 
facilitating spore mediated transmission (Lawley et al., 2009).  Given that 25% of 
patients suffer recurrence following initial antimicrobial treatment and that 35-45% 
of patients with a first recurrence are likely to have a second recurrence, there is a 
need for new effective therapies (Kelly and LaMont, 2008).   
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1.3.2 Bacterial Agents 
1.3.2.1 Probiotics  
Probiotics are live non-pathogenic yeast and bacteria, that resemble the protective 
microflora of the gut; intended to restore the microbial balance (Pillai and Nelson, 
2008).  Given that CDI is attributed to the destruction of the protective gut flora, 
following antibiotic treatment, probiotics such as Lactobacillus rhamnosus GG, 
Lactobacillus acidophilus, Lactobacillus plantarum, Bifidobacterium, 
Bacillus clausii, Sacchromyces boulardii and Sacchromyces cerevisiae (Dendukuri et 
al., 2005; McFarland, 2005, 2006; Miller, 2007; Pillai and Nelson, 2008) appear to 
be a valid and logical means of treatment.  In a mouse model the use of a 
Bacteroides/Lactobacillus mixture representing the traditional probiotic bacterial 
groups failed to suppress the supershedder state and restore recipients’ microbiota 
(Lawley et al., 2009).  To date the trials conducted with probiotics for the treatment 
of CDI have been in addition to standard antibiotic therapy;  one trial has lacked 
controls in antibiotic dose, type and duration of probiotic (McFarland et al., 1994) 
whilst a second trial has shown a beneficial effect of probiotics in patients treated 
with a high dose of oral vancomycin (2 g/day) but not in patients treated with 
metronidazole (1 g/day) or with a lower dose of oral vancomycin (500 mg/day) 
(Surawicz et al., 2000).  The potential benefit of probiotics in the treatment of CDI is 
inconclusive and requires further research (McFarland, 2009; Miller, 2009).  
 
1.3.2.2 Faecal Infusion 
As CDI manifests as a consequence of disruption to the normal intestinal microflora, 
restoration of said microflora has long been viewed as a viable option for treating 
CDI, particularly in the case of recurrent infection (Rohlke et al., 2010; Russell et al., 
2010; Yoon and Brandt, 2010; Landy et al., 2011; Rohlke and Stollman, 2012; 
Garborg et al., 2010).  As early as 1958, severe antibiotic-associated diarrhoea was 
treated with faecal infusions from healthy donors (Eiseman et al., 1958).  Infusions 
contain living protective bacteria which are infused into the bowel of the patient via 
colonoscopy, enema or through a nasogastric tube.  This approach although 
‘unappealing’ has been reported to have a 91–100% cure rate (van Nood et al., 2009; 
Rohlke et al., 2010; Yoon and Brandt, 2010).  A small randomised study 
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investigating the effect of duodenal infusion of donor faeces in patients with 
recurrent CDI, concluded that infusion with donor faeces was significantly more 
effective than the use of vancomycin alone or vancomycin with bowel lavage, with 
cure rates of 81%, 31% and 23% respectively (van Nood et al., 2013).  Results from 
the two phase III randomized trials (FECAL trial and ClinicalTrials.gov, 
NCT01226992) currently underway, will shed more light on the validity of faecal 
therapy.  Although promising, it is important to note the differences in stool dose 
(number of infusions and concentration), route of administration and definition of 
cure/success rate when comparing studies.  Given the variability in the composition 
of donor faecal infusions coupled with the practicalities associated with preparing 
and screening donor samples, the use of a standardised, defined mixture of bacteria 
would be beneficial.  Such an approach has been utilised in a murine model, in which 
a mixture of 6 defined bacteria was administered to mice infected 
with C. difficile PCR RT027, resulting in the displacement of the 027 strain and 
restoration of a healthy microbiota (Lawley et al., 2012). 
 
1.3.2.3 Non-toxigenic Clostridium difficile (NTCD) 
The use of non-toxigenic C. difficile was demonstrated in the early 1980’s (Wilson 
and Sheagren, 1983; Borriello and Barclay, 1985), when it was found to prevent 
ileocaecitis by toxigenic C. difficile in hamsters.  A single dose of NTCD spores 
(10
5 
CFU) from naturally colonized humans protected hamsters from challenge with 
toxigenic C. difficile strains (Sambol et al., 2002; Merrigan et al., 2003; Merrigan et 
al., 2009).  Phase I studies have shown NTCD spores to be safe and well tolerated 
resulting in colonisation of healthy volunteers pre-treated with vancomycin.  NTCD 
spores are currently being studied in a phase II clinical trial to prevent recurrent CDI 
following treatment (Villano et al., 2012).  Recent hamster studies have 
demonstrated the protection afforded by the administration of NTCD varies between 
NTCD strains (Nagaro et al., 2013).  Furthermore it has recently been demonstrated 
that the PaLoc can be transferred to non-toxigenic C. difficile, resulting in the 
formation of a toxin producing strain (Brouwer et al., 2013).  Given that mixed 
infections of C. difficile occur (Eyre et al., 2012; Eyre et al., 2013), the presence of 
toxigenic and non-toxigenic C. difficile strains within a host could result in the 
transfer of virulence genes.  
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1.3.3 Toxin-Binding Agents 
Toxin A and B are the causative agents for CDI, responsible for the pathological 
effects of infection, hence ion-exchange resins, oligosaccharides and various types of 
polymers which bind the toxins have been developed for treatment. 
 
1.3.3.1 Ion-Exchange Resins 
Cholestyramine is a bile acid sequestrant used to prevent diarrhoea in Crohn’s 
disease; its ability to bind vancomycin (McFarland, 2005) and lack of clinical 
evidence supporting its use in CDI has limited it therapeutic applications (Weiss, 
2009).  Colestipol was shown to delay death in the hamster model, although a 
placebo-controlled, randomized trial found the resin to be no better than the placebo, 
with no difference in faecal excretion of the C. difficile toxins (Mogg et al., 1982).   
 
1.3.3.2 Oligosaccharides 
SYNSORB is an inert support clay with a synthetic trisaccharide sequence 
(Galα1-3Galβ1–4GlcNAc) which binds toxin A (Heerze et al., 1994; Castagliuolo et 
al., 1996).  In a placebo-controlled trial no significant difference in recurrence of 
CDI was observed with SYNSORB (McFarland, 2011).  No further trials with 
SYNSORB were conducted and development was abandoned. 
 
1.3.3.3 Polymers 
Tolevamer (GT160-246) is an anionic binder of toxins A and B, it does not alter the 
gut flora, does not bind vancomycin, and will not result in the development of 
resistance (Weiss, 2009).   An initial phase II trial showed tolevamer to be equivalent 
to vancomycin in cure and recurrence rates (Louie et al., 2006).  In the subsequent 
phase III trial only 47% of the tolevamer group had diarrhoea resolved by the end of 
treatment, compared to 81% in the vancomycin group.  Based on this, development 
of tolevamer was terminated, despite only 3% of the tolevamer group suffering 
recurrence versus 23% and 27% in the vancomycin and metronidazole groups, 
respectively (Louie et al., 2007; Bouza et al., 2008). 
32 
 
1.3.4 Immunotherapy 
Although the introduction of antimicrobials saw an end to serum therapy, 
antibody-based therapies still provide a viable option for the treatment of infectious 
diseases.  Historically, antibodies target microbial antigens (SLP, polysaccharides) or 
microbial products (toxins) and have been utilised against a number human of 
infectious diseases, including; Bacillus anthracis, C. tetani, C. botulinum, 
Mycobacterium tuberculosis and Streptococcus pneumonia (Casadevall and Pirofski, 
2004).  Currently, approved therapeutic antibodies are used for the treatment of 
cancer and autoimmune disorders; antibodies targeting virulence factors of infectious 
agents are undergoing clinical trials.  The presence of detectable serum IgG and IgA 
to toxins A and B in 60% of the healthy adult population (Viscidi et al., 1983) has 
prompted research in the therapeutic activity of Intravenous Immunoglobulin (IVIg) 
preparations and orally administered anti-C. difficile antibodies and vaccines.   
 
1.3.4.1 Intravenous Immunoglobulin (IVIg) 
IVIg preparation of pooled human donor serum containing high titres of IgG 
antitoxin A and B have been administered to patients with severe and recurrent 
episodes of CDI (Kelly and Kyne, 2011).  Thus far, studies have reported conflicting 
results, with Juang et al., (2007) reporting no beneficial response, Wilcox (2004), 
O’Horo and Safdar, (2009) and Abougergi et al., (2010), reporting variability 
between patients and extent of CDI.  Whilst Leung et al., (1991), Salcedo et al., 
(1997) and McPherson et al., (2006) have reported successful treatment with IVIg in 
children and adults with severe or relapsing CDI.  The contradictory results of 
published studies is attributed to a four-fold variability in antitoxin A and B antibody 
titres in commercially available IVIg preparations (Grossman et al., 2010).  
Standardisation of the IVIg preparation and a randomized controlled clinical trial to 
assess the effectiveness of IVIg for CDI, would determine its validity as a therapeutic 
for CDI. 
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1.3.4.2 Anti-Clostridium difficile Bovine Immunoglobulin 
Concentrate (BIC) 
Bovine colostrum is a rich source of antibodies composed of IgG (approximately 
92%), IgA (7.5%) and IgM (0.5%) (Kelly et al., 1996), BIC is prepared from cows 
immunized with toxoided C. difficile culture filtrate.  The oral administration of 
hyper-immune bovine IgG conferred protection against CDI (Lyerly et al., 1991), 
blocked toxin A-receptor binding and neutralised the cytotoxicity of toxins A and B 
in animal models (Kelly et al., 1996).  The preparation was also found to survive 
passage through the human intestinal tract (Kelly et al., 1997; Warny et al., 1999).  
Human clinical trials are yet to be conducted. 
 
1.3.4.3 Anti-Clostridium difficile Bovine Whey Protein 
Whey (mature cow milk) is composed of anti-C. difficile bovine immunoglobulin 
secretory IgA, developed from cows immunized with formaldehyde-inactivated 
whole C. difficile cells and toxoid prepared from the C. difficile culture filtrate (van 
Dissel et al., 2005).  The preparation (MucoMilk) was found to be safe, well 
tolerated (van Dissel et al., 2005) and as effective as metronidazole in reducing 
recurrent CDI in uncontrolled trials (Numan et al., 2007; Mattila et al., 2008).  A 
phase III trial has since been discontinued due to a lack of funding. 
 
1.3.4.4 Monoclonal Antibodies 
At present two human monoclonal antibodies directed against toxins A and B have 
been developed, CDA-1 is directed against toxin A and CDB-1 
(formerly MDX-1388) is directed against toxin B (Babcock et al., 2006; Leav et al., 
2010; Lowy et al., 2010).  A phase II trial revealed a lack of efficacy when CDA-1 
alone was administered to CDI patients (Leav et al., 2010).  The administration of 
both CDA-1 and CDB-1, resulted in a reduction in recurrence as compared to 
standard antibiotic  therapy, however a reduction in the severity and duration of CDI 
was not observed (Lowy et al., 2010).  The clinical development of this product has 
subsequently been put on hold.  Despite the cost associated with monoclonal 
antibodies and the likelihood that protection may be transient, they still represent a 
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valid therapeutic option for the treatment of recurrent CDI.  The above studies 
emphasise the role of antitoxin antibodies in CDI and lend support to their 
application as a prophylactic for high risk patients (McFarland, 2005; Kelly and 
Kyne, 2011). 
 
1.3.4.5 Vaccines 
Current research in potential vaccine targets has focused on toxins A and B the 
S-layer proteins and cell surface polysaccharides, PSI and PSII.  In the case of the 
S-layer proteins, PSI and PSII, research is still in the early stages, in contrast 
vaccines targeting the C. difficile toxins have been in development for the last decade 
(Torres et al., 1995; Giannasca et al., 1999).  Although protection in hamsters has 
been demonstrated there has been limited studies completed in humans.  Hamsters 
have been found to be protected when administered with either a formalin-
inactivated C. difficile culture filtrate or toxoid, by nasal, peritoneal, subcutaneous, 
(Torres et al., 1995) intramuscular, rectal (Giannasca et al., 1999) routes, and  
intraperitoneal injection (Siddiqui et al., 2012).  In mice, transcutaneous 
immunization with toxoid A induced  both IgG and IgA serum antibodies, although 
the mechanism by which this is achieved is unknown (Ghose et al., 2007).  The use 
of an injectable toxoid vaccine in patients has shown promise in the three patients 
vaccinated (Sougioultzis et al., 2005).  The parenteral administration of a toxoid A 
and B vaccine, in healthy volunteers has been reported to be safe and immunogenic, 
capable of eliciting a systematic antibody response relating to increase in serum 
antitoxin A and B antibodies (Kotloff et al., 2001; Aboudola et al., 2003).   
 
Thus far studies have focussed on either formalin-inactivated culture filtrate or 
toxoided A and B.  Other vaccine approaches include, a DNA vaccine expressing the 
C-terminal of toxin A (Gardiner et al., 2009) and N-terminal of toxin B (Jin et al., 
2013), the oral administration of Bacillus subtilis spores expressing a single toxin A 
C-terminal domain (Permpoonpattana et al., 2011), an injectable fusion protein 
consisting of the toxin A and B C-terminal domains (Tian et al., 2012), a chimeric 
protein composed of the C-terminal domain of toxin A and the enzymatic and 
translocation domains of toxin B (Wang et al., 2012).   
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Although a vaccine approach appears viable for CDI and is calculated to be cost 
effective (Lee et al., 2010a), pertinent questions include; the choice of antigen (toxin 
vs. non-toxin), toxoid vs. recombinant, toxin A vs. toxin B, the route of 
administration, type of antibody response (mucosal IgA vs. systemic IgG), use of 
adjuvants, who and when to vaccinate, ability to confer long term protection and 
efficacy in the at risk population (Gerding, 2012). 
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1.4 Aims and Objectives 
The aims of this research are as follows;  
1. Clone and express regions of C. difficile toxins A and B in an E. coli based 
expression system. 
2. Characterise the immunogenicity of native, toxoided and recombinant toxin 
A and B using animal and human immune sera, with a view to identify potential 
targets for therapeutic development.   
3. Characterise the variability of vegetative C. difficile colonies. 
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CHAPTER TWO 
GENERAL MATERIALS AND METHODS 
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2.1 Materials and Methods 
Unless otherwise stated all reagents were of molecular biology grade and purchased 
from Fisher Scientific, UK or Sigma-Aldrich, UK. 
 
2.2 Protein  
2.2.1 Protein Precipitation 
Prior to protein precipitation 1 M sodium hydroxide (NaOH) was added to the 
protein samples.  Proteins were precipitated by the addition of equal volumes of 
10% (w/v) trichloroacetic acid (TCA), incubated on ice for 1 hour and centrifuged at 
14,000 g for 5 minutes at 4°C (Avanti, JA-14, Beckman Coulter, Inc.).  The pellet 
was washed twice with ice cold acetone and centrifuged as above.  The pellet was air 
dried at 37°C for approximately 5 minutes and re-suspended in collection buffer 
(8 M urea, 40 mM tris-base, 0.5% (v/v) ampholytes, 1% (w/v) ASB-14) overnight at 
4°C. 
 
2.2.2. Protein Quantification – Bicinchoninic Acid Assay 
(BCA)  
A series of bovine serum albumin standards ranging from 0.05-1.0 mg/mL were 
prepared in either collection buffer or PBS, where required unknown samples were 
diluted 1/10.  All samples were prepared in triplicate.  To prepare a BCA working 
solution 50 parts BCA solution was added to 1 part 4% (w/v) copper sulfate.  To 
each standard or protein sample, 1 mL of BCA working solution was added and the 
mixture vortexed.  Following incubation at 37°C for 30 minutes, the samples were 
placed on ice and absorbance was read at OD562 (Ultraspec 3100pro, GE Healthcare).  
A standard curve was constructed by plotting the mean absorbance at OD562 of the 
standards against the concentration.  The final concentration of the sample was 
corrected for the dilution factor. 
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2.3 Sodium Dodecyl Sulfate Polyacrylamide Gel 
Electrophoresis (SDS-PAGE) 
For 1D SDS-PAGE, protein samples were analysed using either 4-20% Criterion™ 
TGX™ Gel, mini-Protean TGX gels, or 5% Criterion™ TGX™ Gel (Bio-Rad, UK). 
Unless otherwise stated samples were combined with 2x SDS-PAGE buffer 
(0.09 M Tris-HCl, pH 6.8, 20% (v/v) glycerol, 2% (w/v) SDS, 0.02% (w/v)  
bromophenol blue, 0.1 M DTT) and boiled for approximately 7 minutes at 95°C 
(Techne Dri-Block® DB-3D, Fisher Scientific, UK).  For 2D SDS-PAGE samples 
were analysed using 4-20%, 11 cm IPG Criterion™ TGX™ Gel (Bio-Rad, UK).   
Electrophoresis was carried out in 1x running buffer (per litre diH2O, 3.03 g tris base, 
14.4 g glycine, 1.0 g SDS) at 150 volts, 30 watts, 400 mA in a mini-Protean Tetra 
tank or a Criterion™ Cell (Bio-Rad, UK) powered by a GE Healthcare EPS-601 
power supply for approximately 1.5 hours.  Gels were fixed and double-stained with 
colloidal Coomassie and silver (Section 2.5). 
 
2.4 2-Dimensional Sodium Dodecyl Sulfate 
Polyacrylamide Gel Electrophoresis (2D SDS-PAGE) 
2.4.1 Reduction and Alkylation  
Protein samples were reduced and alkylated according to the protocol for the 
ProteoPrep Reduction and Alkylation Kit (Sigma-Aldrich, UK).  The protein sample 
(pH >7.5) was reduced by adding 2.5 µL tributyl phosphine (TBP) solution per 
100 µL of sample and incubated at room temperature for 30 minutes.  The sample 
was alkylated in 3.0 µL of iodiacetamide solution per 100 µL sample and incubated 
for 1 hour at room temperature.  TBP (2.5 µL per 100 µL of sample) was added to 
the sample and incubated for 15 minutes.  The sample was centrifuged at 20,000 g 
for 5 minutes at 20°C (Eppendorf 5417R, UK).   
 
2.4.2 First Dimension Isoelectric Focusing 
For cell surface proteome analysis 100 µg of bacterial cell extract was combined 
with isoelectric focusing buffer (IEF) (7 M urea, 2 M, thio urea, 40 mM tris-base, 
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0.5% (v/v) ampholytes, 1% (w/v) ASB-14, 0.0002% (w/v) bromophenol blue) in a 
final volume of 200 µL.  For toxin digest analysis 10 µg of protein was combined 
with 200 µL IEF.  ReadyStrip IPG Strips, pH 3–10 nonlinear, 11 cm (Bio-Rad, UK), 
were rehydrated overnight in a rehydration tray at room temperature overlaid with 
2-3 mL mineral oil per strip.  IEF was carried out in the Amersham (GE Healthcare) 
IPGphor 2 at 8,000 volts peak voltage, 50 mA peak current for 30,000 volt-hours. 
 
2.4.3 Second Dimension 
Focused strips were equilibrated in buffer (0.375 M Tris-HCl pH 8.8, 6 M urea, 
2% (w/v) SDS, 20% (v/v) glycerol, 0.0002% (w/v) bromophenol blue) on a 
Stuart gyro-rocker (Fisher Scientific, UK) rocker for 20 minutes at 30 r.p.m.  The 
strips were dipped in 1x running buffer overlaid with agarose (125 mg agarose in 
25 mL 1x running buffer containing 0.0002% (w/v) bromophenol blue) and 
electrophoresis completed as above (Section 2.3). 
 
2.5 Staining  
2.5.1 Colloidal Coomassie 
All solutions were prepared just prior to use and all incubations were carried out on a 
Stuart gyro-rocker (Fisher Scientific, UK) at 30 r.p.m at room temperature.  
Following SDS-PAGE, gels were washed in diH2O for 2 x 5 minutes.  Gels were 
fixed in 100 mL of fixing solution (20% (w/v) trichloroacetic acid (w/v)) overnight; 
post fixation gels were washed in diH2O for 3 x 5 minutes.  
Brilliant Blue G-Colloidal Concentrate (Sigma-Aldrich, UK) was dissolved in 
800 mL diH2O to give a 1x working solution and stored at 4°C.  Prior to staining 
4 parts working solution was combined with 1 part methanol.  Staining was carried 
out for 24 hours and de-stained with 25% (v/v) methanol overnight at room 
temperature with constant rocking.  
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2.5.2 Silver Staining 
Following imaging of Coomassie stained gels, gels were silver stained, all solutions 
were prepared just prior to use.  Incubations were carried out at room temperature 
following the method outlined by Dunn, (2002).  The gel was rehydrated by washing 
in diH2O for 2 x 20 minutes and soaked in 10% (v/v) glutaraldehyde solution for 
30 minutes followed by 3 x 20 minutes washes in diH2O.  Staining was carried out 
using silver diamine solution, which comprised the following, 73.6 mL diH2O, 
21 mL, 0.36% (w/v) NaOH and 1.4 mL, 35% (v/v) ammonia were mixed, to which 
4 mL 20% (w/v) silver nitrate was added drop wise with constant stirring.  Gels were 
stained for 30 minutes followed by 3 x 5 minutes diH2O washes.  The developing 
solution (2.5 mL, 1% (w/v) citric acid, 0.26 mL, 36% (v/v) formaldehyde in 500 mL 
diH2O) was added for 7-10 minutes and terminated by immersing the gel in stopping 
solution (40% (v/v) ethanol, 10% (v/v) acetic acid).   
 
2.6 Semi-Dry Transfer 
Gels were transferred onto nitrocellulose membranes using a Trans-Blot Turbo Midi 
Nitrocellulose Transfer Packs and a Bio-Rad Trans-Blot® Turbo™ (Bio-Rad, UK).  
The transfer sandwich was assembled as follows; filter paper, membrane, gel, and 
filter paper.  A blot roller was used to remove air bubbles between the assembled 
layers.  Transfer conditions were 25 volts, 1.0 A for 30 minutes.   
 
2.7 Ferrozine/Ferrocyanide Stain 
Ferrozine/Ferrocyanide staining was completed following the method of Patton et 
al., (1994).  Wet membranes were equilibrated for 15 minutes in 2% (v/v) glacial 
acetic acid at room temperature on a Stuart gyro-rocker.  The blot was incubated for 
15 minutes in 0.1% (w/v) Poly (vinylpyridine) in 2% (v/v) acetic acid followed by 
rinsing for 5 minutes in 2% (v/v) acetic acid.  Blots were stained with ferrozine stain 
(0.75 mM ferrozine, 30 mM iron (III) chloride, 5 mM thioglycolic acid in 2% (v/v) 
acetic acid) for 30 minutes and rinsed with ferrozine stain base (2% (v/v) acetic acid) 
5 times for 30 seconds with hand agitation.  To achieve greater stain sensitivity, blots 
were equilibrated in ferricyanide stain base (100 mM sodium acetate, pH 4.0) for 
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15 minutes at room temperature on a rocker.  Followed by staining with ferricyanide 
stain (100 mM potassium ferrocyanide, 60 mM iron (III) chloride) for 30 minutes 
and rinsing with ferricyanide stain base 5 times for 30 seconds.  The blot was 
allowed to dry at room temperature for 1 hour.  Membranes were de-stained with 
ferricyanide elution solution (200 mM sodium carbonate, 100 mM 
ethylenediaminetetraacetic acid, pH 9.6) for 10 minutes.  
 
2.8 Western Blotting 
All steps were carried out on a roller mixer (Stuart SR6) at 33 r.p.m., all wash steps 
were performed in PBST (PBS + 0.1% (v/v) Tween® 20) four times for 5 minutes.  
Primary and secondary antibodies were diluted in 1% (w/v) dry skimmed milk 
(Marvel) in PBST.   Membranes were washed for 5 minutes with diH2O, followed by 
PBST.  Membranes were blocked in 5% (w/v) dry skimmed milk in PBST for 1 hour 
at room temperature and washed in PBST.  Membranes were incubated with the 
primary antibody overnight at 4°C.  Following washing the secondary antibody was 
applied for 1 hour at room temperature and washed.   
 
2.9 Image Capture and Chemiluminescence  
Visibly stained gels and membranes were imaged with the Chemi Doc xrs+ system, 
faint band exposure and analysed using Image Lab™ Software, v.3.0, with a band 
detection sensitivity of 100. Gels were imaged under white light trans illumination.   
 
All membranes were imaged with SuperSignal West Pico, Dura and Femto; solutions 
were prepared as per the manufacturer’s instructions (Thermo Scientific Pierce, UK).  
The working solution contained a 1:1 ratio of luminol/enhancer solution and 
peroxide solution sufficient to cover the membrane.  Membranes were incubated for 
5 minutes and imaged with a Chemi Doc xrs+ system (Bio-Rad, UK).  Membranes 
were thoroughly washed with PBST prior to the addition of the next detector 
solution. 
 
43 
 
2.10. Mass Spectrometry 
Mass Spectrometry was performed by Dr. Ian Brewis (CBS Proteomics Facility, 
Cardiff University) using the method detailed below. 
 
2.10.1 Trypsin Digestion 
Spots were manually excised from gels generating 1.5 mm gel plugs.  Trypsin 
digestion was completed by a modified Shevchenko et al., (1996) method.  Gel plugs 
were incubated at 37ºC for 3 hours with 6.25 ng/µL sequencing grade modified 
trypsin (Promega, UK) in 25 mM ammonium bicarbonate (NH4HCO3).  Dried 
peptides were re-suspended in 50% (v/v) acetonitrile in 5 µL of 0.1% (v/v) 
trifluoroacetic acid for mass spectrometry analysis.  An aliquot (0.5 µL) was spotted 
onto a 384 well MS plate. The samples were allowed to dry and overlaid with 
α-cyano-4-hydroxycinnamic acid (CHCA, Sigma-Aldrich, UK; 0.5 µL prepared by 
mixing 5 mg matrix with 1 mL of 50% (v/v) acetonitrile in 0.1% (v/v) TFA).    
 
2.10.2 MALDI TOF Analysis of Trypsin Digested Proteins 
Mass spectrometry was performed using a MALDI TOF/TOF mass spectrometer 
(Applied Biosystems 4800 MALDI TOF/TOF Analyzer; Foster City, CA, USA) with 
a 200 Hz solid state laser operating at a wavelength of 355 nm (Medzihradszky et al., 
2000; Bienvenut et al., 2002; Glückmann et al., 2007; Brennan et al., 2009).  
MALDI mass spectra and subsequent MS/MS spectra of the 8 most abundant 
MALDI peaks were obtained following routine calibration. Common trypsin 
autolysis peaks and matrix ion signals and precursors within 300 resolution of each 
other were excluded from the selection and the peaks were analysed with the 
strongest peak first. For positive-ion reflector mode spectra 800 laser shots were 
averaged (mass range 700-4000 Da; focus mass 2000).  In MS/MS positive ion mode 
4000 spectra were averaged with 1 kV collision energy (collision gas was air at a 
pressure of 1.6 x 10-6 Torr) and default calibration.  
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Combined PMF and MS/MS queries were performed using the MASCOT Database 
search engine v.2.1 (Matrix Science Ltd, London, UK) (Perkins et al., 1999) 
embedded into Global Proteome Server (GPS) Explorer software v.3.6 
(Applied Biosystems) on the Swiss-Prot database.  Searches were restricted to the 
bacteria domain with trypsin specificity (one missed cleavage allowed), the 
tolerances set for peptide identification searches at 50 ppm for MS and 0.3 Da for 
MS/MS. Cysteine modification by iodoacetamide was employed as a fixed 
modification with methionine oxidation as a variable modification.  Search results 
were evaluated by manual inspection and conclusive identification confirmed if there 
was high quality tandem MS (good y-ion) data for ≥2 peptides (E value p <0.05 for 
each peptide; overall p <0.0025) or one peptide (only if E value was p <0.0001).
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3.1 Introduction 
Although the causative role of toxins A and B in CDI has been firmly established, 
there is much debate as to the contribution of each toxin in pathogenesis and which of 
the toxins is a primary virulence factor (Lyras et al., 2009; Kuehne et al., 2010).  The 
ability to access and work with pure preparations of each toxin is a key requirement for 
any researchers attempting to develop new therapeutic agents and diagnostic tools.  
 
The isolation of native C. difficile toxins from the culture supernatant of the pathogen 
has been achieved, but to date this approach has necessitated the use of complex, 
multi-step processes.  One such approach, thyroglobulin affinity chromatography has 
been successfully used to recover 0.07 mg/mL of pure (single band on an SDS-PAGE 
gel) toxin A (Krivan and Wilkins, 1987).  While yields of toxin B have been as much as 
tenfold higher (0.765 mg/mL), using ammonium sulfate precipitation, the resulting 
preparation is frequently associated with multiple contaminated proteins (Pothoulakis et 
al., 1986).  While approaches such as Fast Performance Liquid Chromatography 
(FPLC), can produce purer proteins of higher yields (0.574 and 0.940 mg/mL for 
toxin A and B, respectively) (von Eichel-Streiber et al., 1987), there is a requirement 
for specialist equipment, technical expertise and a high starting culture volume (750 
mL).  Furthermore any method pertaining to the natural production of toxin A and 
toxin B in C. difficile, will require the decontamination of heat-resistant spores 
(Donald et al., 2013).       
 
Due to the problems faced in recovering native toxin from C. difficile, alternative hosts 
from which to produce recombinant toxin have been investigated.  An approach which 
has had some success is the use of members of the Bacillus spp., such as 
Bacillus megaterium.  Burger  et al. (2003) successfully expressed tcdA from a 
B. megaterium system and were able to achieve a yield between 300-500 µg/L of 
culture.  Although the presence of multiple bands in the purified preparation maybe 
indicative of extensive degradation (as determined by Western blot analysis).  More 
recently, Yang et al.,(2008) were able to recover between 5-10 mg/L of recombinant 
toxin A and B from B. megatarium at a purity of 70-80%, as determined by Coomassie 
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stained SDS-PAGE gels.  Purity was further enhanced to >80% using a thyroglobulin 
column and anion-exchange fractionation.  
In this chapter the potential to use Escherichia coli as an easy to use recombinant protein 
expression system was assessed.  This Gram-negative bacterium is the most commonly 
used system for the high level production of heterologous proteins (Makrides, 1996; 
Terpe, 2006; Fernández and Vega, In Press).  The ability of the bacterium to grow 
rapidly to high cell densities, in inexpensive media coupled with the ease of 
purification with affinity columns (e.g. Ni-NTA, Glutathione-Sepharose) has added 
to the popularity of this expression host.  Furthermore the availability of the 
complete genomic sequence and ability to safely produce recombinant protein by 
large-scale fermentation has insured E. coli remains a popular expression host (Rai 
and Padh, 2001; Terpe, 2006).   
 
Previous attempts to develop E. coli based expression systems for these toxins have been 
hampered by their size, with the gene encoding tcdA comprising 8133 nucleotides while 
that encoding tcdB comprising 7098 nucleotides (Dove et al., 1990; Sauerborn and von 
Eichel-Streiber, 1990; von Eichel-Streiber et al., 1992a).   As a consequence, the cloning 
of each gene required a strategy in which individual fragments of the sequence were 
inserted into the vector in a step-wise manner  which resulted in the eventual 
reconstruction of the entire gene (Johnson et al., 1990; Phelps et al., 1991).  While 
effective such approaches are time consuming and with the multiple restrictions, 
ligations and amplification steps can result in sequence errors.  More recent attempts to 
clone full length tcdB and tcdA using high fidelity Taq polymerase based approaches 
have proved to be equally problematic.  Using the EXPAND™ Long Template PCR 
cloning system Tang-Feldman et al. (2002) observed  low cloning efficiency (3/120 
clones analyzed), with the positive clones demonstrating variable cytotoxic activity.  In a 
subsequent study using the same approach  Ackermann and colleagues (2004b) found 
that only 50% of their clones showed cytotoxicity (10 clones screened)  and that in the 
majority of cases the insert was lost upon subculture, thus highlighting the unstable 
nature of tcdA. 
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Indeed attempts to clone and express various regions of TcdA and TcdB in E. coli have 
encountered a range of problems; including the instability of the gene insert, poor protein  
expression, purification and yield (Craggs, 1999; Zimmer et al., 2002; Letourneur et 
al., 2003; Castagliuolo et al., 2004; Ho et al., 2005).  One possible explanation for 
these problems is the pronounced difference in the codon usage of the donor gene and 
that of the host. While C. difficile has a genome with a low GC content (30%) 
(Sebaihia et al., 2006), the GC content of E. coli is approximately 50% (Riley et al., 
2006). 
 
The genetic code employs 61 codons to represent 20 amino acids and three codons 
for translation termination (Osawa et al., 1992).  Amino acids can be encoded by 
multiple codons with alternate codons referred to as synonyms or synonymous 
(Gustafsson et al., 2004).  Synonymous codons frequently vary at the third codon 
position by one nucleotide.  A subset of the cell’s tRNA is able to recognise each of 
these codons.  This redundancy permits the organism to develop its own codon usage 
preference which is mirrored by the makeup of the tRNA pool (Osawa et al., 1992; 
Peden, 1999; Gustafsson et al., 2004).  It is suggested this bias allows for improved 
translational efficiency/accuracy, particularly in the context of highly-expressed 
genes (Rocha, 2004; Shao et al., 2012).  Consequently codon usage plays an important 
role in determining the level of gene expression, particularly when the gene in question 
has been derived from a different organism (Kurland, 1987; Kudla et al., 2009; Sharp 
et al., 2010).  In situations where the codon usage of the donor gene differs markedly 
from that of the expression host it may be necessary to modify either the composition 
of the host’s tRNA pool or the codon usage of the donor gene sequence. 
 
Genetically engineered strains of E. coli which over-express rare tRNA’s such as 
BL21-CodonPlus® (http://www.genomics.agilent.com/) and Rosetta™ 
(http://www.emdmillipore.com/) are commercially available and have been used to 
express problematic genes (Zdanovsky and Zdanovskaia, 2000; Lu et al., 2009; Lin 
et al., 2010).  Alternatively altering the codon usage of the donor nucleotide 
sequence has enhanced the expression of clostridial toxin genes by 2-fold for the 
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tetanus toxin (Makoff et al., 1989) and the botulinum neurotoxins (Zdanovsky and 
Zdanovskaia, 2000). 
 
In this chapter, the steps taken to develop an E. coli based recombinant protein 
expression system capable of producing the non-toxic translocation and receptor 
binding domains of TcdA (amino acid residues 900-2710) and TcdB (amino acid 
residues 547-2366) are described.  The receptor binding domain has been shown to 
be the most antigenic, with toxin neutralising antibodies elicited against this region 
(Corthier et al., 1991; Kink and Williams, 1998; Genth et al., 2000).  Identification 
of immunogenic regions, particularly within the receptor binding domain would aid 
in the development of therapeutics.  
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3.2 Aims and Objectives 
The overall aim of this chapter is to express codon optimised regions of C. difficile 
toxin A (TcdA900-2710) and toxin B (TcdB547-2366) from an E. coli based expression 
system to support further studies. 
 
The experimental objectives are to: 
1. To design and construct an E. coli based protein expression system capable of 
expressing recombinant TcdA900-2710 and recombinant TcdB547-2366. 
2. Express and purify sufficient quantities of rTcdA900-2710 and rTcdB547-2366 from 
E. coli to support future studies. 
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3.3 Materials and Methods 
All plasticware was purchased sterile; DNase, RNase and pyrogen free 
(Fisher Scientific, UK).  Unless otherwise stated all reagents were of molecular 
biology grade and purchased from Fisher Scientific, UK.  Unless otherwise noted, 
cultures were incubated at 37°C, 300 r.p.m. in an orbital shaker (MaxQ 4450, 
Thermo Scientific, UK).  All centrifugation steps were completed as follows; for 
1.5 mL microcentrifuge tubes; Eppendorf 5417R centrifuge, fixed angle rotor 
F45-30-11, for 50 mL centrifuge tubes, <5,000 g Heraeus Primo R, Thermo, UK and 
for 50 mL centrifuge tubes, >5,000 g (Avanti, JA-14, Beckman Coulter, Inc.). 
 
3.3.1 Project Approval   
This project was approved for containment Level 2 by Cardiff University Genetic 
Modification Safety Committee (GMSC) and the Health and Safety Executive 
(HSE).   
 
3.3.2 Nucleotide Sequences  
The nucleotide sequences encoding TcdA900-2710 and TcdB547-2366 were identified 
within the published genome sequence of C. difficile 630 strain (A
+
B
+
, PCR RT012) 
(Sebaihia et al., 2006) using NCBI (http://www.ncbi.nlm.nih.gov/)  The following 
software packages were used to analyse the nucleotide and protein sequences of 
native and codon optimised TcdA900-2710 and TcdB547-2366. 
 The Rare Codon Analysis Tool (www.genscript.com). 
 EMBOSS isochore (http://www.ebi.ac.uk/Tools/emboss/cpgplot/). 
 Graphical Codon Usage Analyser, GCUA (http://gcua.schoedl.de/). 
 
The main features of the sequences encoding each gene are summarised in Table 3.1.   
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Table 3.1: Summary of recombinant toxin A and B sequence regions. 
 Nucleotide Amino Acid Gene Length 
(bp) 
MW 
(kDa) 
pI 
TcdA900-2710 2701–8101 900–2710 5445 204 6.05 
TcdB547-2366 1641–7081 547–2366 5472 206 4.63 
 
3.3.3 Vector Construction 
3.3.3.1 Restriction Site Optimisation 
To assist in the subsequent cloning of TcdA900-2710 and TcdB547-2366, each sequence 
was screened for the presence of restriction enzyme sites which could facilitate or 
hinder cloning.  This was achieved using NEBcutter v.2.0 (Vincze et al., 2003).  
Using this software the nucleotide sequences for tcdA and tcdB were analysed for the 
presence of restriction sites recognised by commercially available restriction 
enzymes.   
 
3.3.3.2 Codon Optimisation 
Codon analysis of the native nucleotide sequences of TcdA900-2710 and TcdB547-2366 
was performed using the GenScript Rare Codon Analysis Tool 
(www.genscript.com).  Codon optimised versions of each gene region were designed 
in silico in Cardiff to include the BamHI and SalI restriction sites at the 5’ and 
3’ ends of the insert.  The newly synthesised sequences were cloned into pQE30 
(Qiagen Ltd, UK) by GenScript, Inc., forming pQE30-TcdA900-2710 and 
pQE30-TcdB547-2366.  The pQE plasmids are derived from the pDS56/RBSII and 
pDS781/RBSII-DHFRS plasmids.  DNA sequencing was undertaken by GenScript to 
confirm the correct orientation and fidelity of the insert.  Expression was under the 
control of an inducible T5 promoter and the gene insert was fused at its N-terminus 
to a 6x Histidine tag (Figure 3.1). 
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Figure 3.1: A representational map showing the major features of pQE30.    
Codon optimised nucleotide sequences of TcdA900-2710, and TcdB547-2366 were cloned 
into pQE30 at the multiple cloning sites so that a 6xHis affinity tag was inserted at 
the N-terminus of the protein. PT5: T5 promoter, lac O: lac operator, 
RBS: ribosome-binding site, ATG: start codon, 6xHis: 6xHis tag sequence, MCS: 
multiple cloning sites with restriction sites indicated, Stop codon, Col E1: Col E1 
origin of replication, Ampicillin: ampicillin resistance gene (Qiagen Ltd, Crawley, 
UK). 
 
3.3.4 Escherichia coli Expression  
All strains were stored on PROTECT beads (Fisher Scientific, UK) at -80°C.  Strains 
were routinely cultured at 37°C on LB agar plates and broth supplemented with the 
appropriate antibiotics (Table 3.2).  All three strains are derived from E. coli K12.  
Details of each strain are shown in Table 3.2.    
 
pQE-30 
3.4 kb 
54 
 
 
Table 3.2: Escherichia coli strain details 
E. coli Strain Phenotype/Genotype Source Antibiotic 
M15 and 
SG13009
* 
F
-
, NaI
S
, Str
S
, Rif
S
, Thi
-
, Lac
-
, 
Ara
+
, Gal
+
, Mtl
-
, RecA
+
, Uvr
+
, 
Lon
+
. 
Qiagen, Ltd Kanamycin 
25 µg/mL 
DH5α™ F- φ80lacZ∆M15 ∆(lacZYA-
argF)U169, recA1, endA1, 
hsdR17(rk
-
, mk
+
), phoA supE44 
thi
-1
, gyrA96, relA1, λ- 
Invitrogen, Ltd Naldixic acid 
32 µg/mL 
*
contains pREP4 plasmid confers kanamycin resistance and encodes the lacI gene 
expressing the lac repressor protein. 
 
3.3.5 Preparation of Competent Cells 
Competent cells were generated using the method based on Hanahan (1983) and 
Sambrook et al. (1989).  A single colony of E. coli M15[pREP4], SG13009[pREP4] 
or DH5α™ was inoculated in 10 mL LB supplemented with the appropriate 
antibiotic(s) (Table 3.2) and cultured overnight at 37°C in a 50 mL centrifuge tube.  
From this overnight culture, 5 mL was added to 100 mL of pre-warmed antibiotic 
supplemented LB in a 250 ml flask, sealed with a foam bung and incubated at 37°C 
in an orbital shaker until the culture reached an OD600 of 0.5 
(Ultraspec 3100 pro, GE Healthcare).  The culture was then cooled on ice for 
5 minutes, prior to centrifugation at 4,000 g for 5 minutes at 4°C.  Cells were gently 
re-suspended in 30 mL cold transformation buffer (TFB-1: 100mM rubidium 
chloride, 50 mM manganese chloride, 30 mM potassium acetate, 10 mM calcium 
chloride, 15% (v/v) glycerol, pH 5.8, sterile-filtered) and placed on ice for a further 
90 minutes.  Cells were centrifuged as above and gently re-suspended in 4 mL 
ice-cold TFB-2 buffer: 10 mM MOPS, 10 mM RbCl2, 75 mM CaCl2, 15% (v/v) 
glycerol, pH 6.8 adjusted with potassium hydroxide, sterile-filtered).  Competent 
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cells were divided into 200 µL aliquots, placed in cold sterile cryovials, flash frozen 
in liquid nitrogen and stored at -80°C.   
 
3.3.6 Transformation of Escherichia coli 
Competent cells were thawed on ice and 100 μL of cells were mixed with 10 ng of 
pQE30-TcdA900-2710 or pQE30-TcdB547-2366 in 20 μL Tris-EDTA buffer (pH 8.0) 
(Sigma-Aldrich, UK) in cold sterile 0.5 mL thin wall microcentrifuge tubes and 
placed on ice for 20 minutes.  The suspension was then placed in a 42°C water bath 
(Fisher Scientific, UK) for 90 seconds.  The cells were then added to 600 μL of cold 
SOC medium (2% (w/v) tryptone, 0.5% (w/v) yeast extract, 0.05% (w/v) sodium 
chloride, 250 mM KCl, 2 M MgCl2, plus 2 mL of 1 M filter-sterilised glucose) and 
incubated for 90 minutes at 37°C in an orbital shaker.  Transformation efficiency was 
checked by transforming competent cells with 10 ng of pQE30 lacking either cloned 
gene in 20 μL TE buffer (pH 8.0).  The culture was diluted with SOC broth and 
100 μL was plated onto LB plus appropriate antibiotic plates in duplicate.  Negative 
controls were transformed with 20 μL TE buffer and plated.  All plates were 
incubated overnight at 37°C.       
 
Transformation efficiency was determined using the following calculation: 
 
 
 
 
Transformed strains were stored frozen at -80°C on PROTECT beads. 
 
3.3.7 Plasmid Purification 
Following transformation plasmids were purified from bacterial cultures using the 
QIAprep® Spin Miniprep kit as per the manufacturer’s instructions 
(Qiagen Ltd, Crawley, UK).  A single colony was inoculated in 5 mL of antibiotic 
supplemented LB media and incubated overnight at 37°C, 300 r.p.m. in a 50 mL 
centrifuge tube.  Bacterial cells were centrifuged at 5,000 g for 10 minutes at 4°C and 
the cell pellet was re-suspended in 250 µL P1 Buffer containing 200 µg RNaseA.  
Transformation efficiency (µg)   =    Number of colonies on agar plate 
     Amount of DNA spread on agar plate  
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An equal volume of P2 Buffer was added and the sample gently mixed, followed by 
the addition of 350 µL of N3 Buffer.  Samples were centrifuged at 10,000 g for 
10 minutes at room temperature.  The supernatant was then applied to a QIAprep 
spin column and centrifuged for 1 minute.  The column was then washed with 
0.5 mL Buffer PB and centrifuged for 1 minute.  PE Buffer (0.75 mL) was added to 
the column and centrifuged twice.  DNA was eluted into a sterile microcentrifuge 
tube with the addition of 50 µL EB Buffer.  The quality and quantity of the plasmid 
was confirmed by measuring the absorbance at A260/A280 (Eppendorf Biophotometer, 
Cambridge, UK).  Purified plasmids were subjected to restriction digest 
(Section 3.3.8) and agarose gel analysis (Section 3.3.9). 
 
3.3.8 Restriction Digestion 
Plasmid extracted from transformed cells was subjected to restriction digestion.  In a 
0.5 mL thin wall microcentrifuge tube in 2 µL of 10x FastDigest® Green Buffer 
(Fermentas, UK).  FastDigest® BamHI (1 µL/10 Units) and FastDigest® SalI 
(1 µL/10 Units) (Fermentas, UK) were used to digest 1 µg of pQE30-TcdA900-2710, 
pQE30-TcdB547-2366 or pQE30.  Reactions were incubated in a dry heat block at 37°C 
(Techne, UK) for 5 minutes.   
 
3.3.9 Agarose Gel Electrophoresis 
Agarose gels (1.2% (w/v)) were prepared in 1x TBE (90 mm tris base, 90 mM boric 
acid, 2 mM EDTA, pH 8.0) using electrophoresis grade agarose.  The agarose 
solution was heated in a microwave oven (Sanyo, EM-S1067, Fisher Scientific, UK) 
for approximately 5 minutes, the solution was gently swirled every 30 seconds to 
suspend un-dissolved agarose and prevent super-heating.  The agarose was cooled 
and 0.05 µg/mL of Ethidium bromide was added.  Gels were cast on a horizontal 
perspex plate (7 x 7 cm) at a thickness of 1.0 cm (Bio-Rad, UK).  Once set gels were 
placed in a tank and submerged with 1x TBE.  To load samples one part Sample 
Loading Buffer (Bioline, UK) was combined with 4 parts DNA sample.  
Electrophoresis was performed at 100 V (constant) in a Bio-Rad Sub-Cell® powered 
by a Bio-Rad PowerPac™ Basic power supply for approximately 1 hour.  Gels were 
imaged under UV light using the Chemi Doc xrs+ system (Bio-Rad, UK).  
57 
 
 
3.3.10 Recombinant Protein Expression and Purification 
SDS-PAGE gels were completed as detailed in Chapter 2, Section 2.3, stained with 
colloidal Coomassie (Chapter 2, Section 2.5.1) and silver nitrate (Chapter 2, 
Section 2.5.2) and imaged using a Chemi Doc xrs+ System (Bio-Rad, UK). 
 
3.3.10.1 Small Scale Expression Trials-Time Course Analysis of 
Recombinant Protein Expression 
A single colony of transformed E. coli was inoculated into 5 mL antibiotic 
supplemented LB and cultured overnight in a 50 mL centrifuge tube.  To 100 mL of 
pre-warmed media 5 mL of the overnight culture was added and the culture was 
incubated at 37°C until the OD600 reached 0.6.  Protein expression was induced by 
the addition of 1 mM Isopropyl-beta-D-thiogalactopyranoside (IPTG: Invitrogen Ltd, 
UK).  A time course of expression and protein solubility was determined by taking 
1 mL samples prior to induction and at 0, 1, 2, 3 and 4 hours post-IPTG induction.  
For all samples the OD600 was recorded and samples were centrifuged for 30 minutes 
at 5,000 g, 4°C.  To ensure even gel loading of the samples the crude extracts were 
standardised to 10 OD600/mL (~10
9
 CFU/mL) and re-suspended in the appropriate 
volume of 5x SDS-PAGE buffer using the following calculation; 
 
 
 
For protein solubility studies cell pellets were stored at -20°C until analysis.   
 
3.3.10.2 Recombinant Protein Solubility 
To determine if rTcdA900-27120 and rTcdB547-2366 were soluble in the cytoplasm or 
were aggregated into insoluble cytoplasmic inclusion bodies, protein solubility was 
assessed as described in The QIAexpressionist™ handbook (Qiagen Ltd, 2003).   
 
3.3.10.2.1 Soluble Expression in the Cytoplasm  
Re-suspension volume (mL) = Absorbance at OD600 x 1 mL 
10 OD600/mL 
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The cell pellet was thawed on ice for 20 minutes and re-suspended in native lysis 
buffer (50 mM Na2HPO4, 300 mM NaCl, 10 mM imidazole, pH 8.0) supplemented 
with 1 mg/mL lysozyme, 10 µL (25 U/µL) Benzonase® Nuclease and 
Roche Complete EDTA-free protease inhibitor cocktail.  The lysate was incubated 
on ice for 30 minutes and gently inverted every 10 minutes.  The cell lysate was 
sonicated for eight cycles, per bursts of 60 seconds at 14 amplitude microns with a 
30 second cooling period on ice (Soniprep 150, MSE, UK).  The lysate was then 
centrifuged at 14,000 g for 30 minutes at 4°C.  The supernatant containing the 
soluble cytoplasmic fraction was combined with 2x SDS-PAGE buffer; the insoluble 
cytoplasmic inclusion body fraction was stored at -20°C for subsequent analysis 
 
3.3.10.2.2 Cytoplasmic Inclusion Bodies 
The inclusion body fraction pellet was re-suspended in native lysis buffer, incubated 
and sonicated as detailed above.  Following the sonication cycles, denaturing buffer 
(native lysis buffer plus 8 M urea, Roche complete EDTA free inhibitor, pH 8.0) was 
added and the cell lysate incubated at room temperature for 60 minutes with gentle 
inversion every 20 minutes.  The lysate was centrifuged at 10,000 g for 20 minutes at 
room temperature.  The supernatant containing the protein extracted from the 
inclusion bodies was combined with 2x SDS-PAGE buffer. 
 
3.3.10.3 Media Optimisation 
To assess the effect of media composition on the efficiency of recombinant protein 
production, the constructs were expressed in six different media.  A single colony of 
M15[pREP4]-pQE30-TcdA900-2710 or M15[pREP4]-pQE30-TcdB546-27366 was 
inoculated into 100 mL antibiotic supplemented LB in a 250 mL culture flask.  
Five mL of the overnight culture was used to inoculate 100 mL of the following 
media: LB (Fisher Scientific, UK), Superior Broth™, Turbo Broth™, Power 
Broth™, Glucose M9Y, and Hyper Broth™ (AthenaES®).  All media were 
supplemented with the appropriate antibiotics and prepared as per the manufacturer’s 
instructions, Glucose M9Y, Hyper Broth™ were supplemented with filter-sterilised 
Glucose Nutrient Mix (20 mL and 50 mL per L, respectively) post-autoclaving.  
Turbo Broth™ and Power Broth™ were supplemented with 4 mL glycerol (per L) 
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pre-autoclaving.  Time course of expression and protein solubility were determined 
as above (Section 3.3.10.1 and Section 3.3.10.2).  
3.3.10.4 Temperature Optimisation 
To further increase the yield of recombinant protein recovered from the soluble 
fraction, the effect of altering the incubation temperature was investigated.  A single 
colony of transformed M15[pREP4]-pQE-30-TcdA900-2710 was inoculated into 
100 mL antibiotic supplemented LB in a 250 mL culture flask.  Five mL of the 
overnight culture was then used to inoculate 100 mL of antibiotic supplemented 
Superior Broth™.  Cultures were grown to an OD600 of 0.6, induced with IPTG and 
transferred to a 16°C (static) incubator.  A time course of expression and solubility 
was determined as detailed in Sections 3.3.10.1 and 3.3.10.2. 
 
3.3.10.5 Biomass and Chaperone Induction  
Augmedium™ (AthenaES®) and LB*Booster™ (AthenaES®) were used as 
additives to induce expression of chaperone proteins and increase biomass 
production, respectively.  Experiments were conducted with the Protein Expression 
and Rescue Kit (PERK™) following the manufacturer’s instructions (Athena 
Enzyme Systems™).  A single colony of transformed M15[pREP4]-pQE30-
TcdA900-2710 was inoculated into 10 mL antibiotic supplemented LB in a 50 mL 
centrifuge tube.  Five mL of the overnight culture was then used to inoculate 250 mL 
antibiotic supplemented Superior Broth™ in a 500 mL culture flask.  Cultures were 
grown to an OD600 of 0.6 at 37°C, after which 10 mL aliquots of this culture were 
dispensed into 50 mL centrifuge tubes.  Augmedium™ was added (Table 3.3), and 
cultures were transferred to either 30°C or 37°C for 20 minutes.   IPTG and 
LB*Booster were added to the cultures as detailed in Table 3.3 and incubated for 
3 hours.  Samples were processed for solubility as detailed above, Section 3.3.10.2 
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Table 3.3: PERK™ Optimisation design matrix for rTcdA900-2710.  
Culture No. IPTG 
(mM) 
Temp 
(°C) 
LB*Booster™ 
(µL) 
Augmedium™ 
(µL) 
1 1 37 500 20 
2 1 30 500 20 
3 0.05 37 500 20 
4 1 37 500 200 
5 1 30 50 20 
6 0.05 37 50 20 
7 0.05 37 50 200 
8 0.05 30 500 200 
9 1 37 50 200 
10 1 37 50 20 
11 0.05 37 500 200 
12 0.05 30 50 200 
13 1 30 500 200 
14 1 30 50 200 
15 0.05 30 50 20 
16 0.05 30 500 20 
Numbers represent final volume in 10 mL cultures.  Stock IPTG, 1 M; Stock 
LB*Booster™, x20; Stock Augmedium™, x50. 
 
3.3.11 Recombinant Protein Purification  
Purification columns (Thermo Scientific, UK) were prepared as follows; a 
polyethylene porous disc (15 mm diameter, 30 µm pore size) was placed in the 
bottom of a 10 mL polypropylene column (70 x 15 mm (h x d)).  Columns were 
packed with 1.5 mL of Ni-NTA (Qiagen Ltd, UK) and equilibriated in the 
appropriate buffer. 
 
3.3.11.1 Purification of rTcdA900-2710 
Purification of soluble rTcdA900-27120 was completed as outlined in The 
QIAexpressionist™ handbook  (QIAgen, UK).  Ni-NTA slurry was pre-equilibriated 
in lysis buffer (50 mM Na2HPO4, 300 mM NaCl, 10 mM imidazole, Roche Complete 
EDTA-free protease inhibitor cocktail, pH 8.0) and the cleared lysate was applied to 
the top of the column.  The column was washed twice with 4 mL of Wash buffer 
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(50 mM Na2HPO4, 300 mM NaCl, 20 mM imidazole, Roche Complete EDTA-free 
protease inhibitor cocktail, pH 8.0).  The protein was eluted with Elution buffer 
(50 mM Na2HPO4, 300 mM NaCl, 250 mM imidazole, Roche Complete EDTA-free 
protease inhibitor cocktail, pH 8.0), collecting four 1 mL fractions.  The flow 
through, wash and elution fractions were collected and analysed by SDS-PAGE 
(Chapter 2, Section 2.3).  
 
To recover rTcdA900-2712 from insoluble inclusion bodies, the purification lysis, wash 
and elution buffers were supplemented 8 M Urea, pH 8.0.  Following application of 
the cleared bacterial lysate the Ni-NTA column was washed twice with 4 mL of 
wash buffer (Ni-NTA Wash buffer plus 8 M Urea, Roche Complete EDTA-free 
protease inhibitor cocktail, pH 8.0).  The protein was eluted with Elution buffer 
(Ni-NTA elution buffer plus 8 M Urea, Roche Complete EDTA-free protease 
inhibitor cocktail, pH 8.0), collecting four 1 mL fractions.  The flow through, wash 
and elution fractions were collected and analysed by SDS-PAGE 
(Chapter 2, Section 2.3). 
 
Following IMAC (Immobilized Metal Affinity Chromatography) protein purification 
of rTcdA900-27120 the eluted fractions were pooled and buffer exchanged 
(Section 3.3.12).  Further purification of the recombinant protein was performed 
using the method detailed by Krivan and Wilkins (1987) and Kamiya et al. (1989).  
In a 50 mL centrifuge tube, 150 mg of bovine thyroglobulin (Sigma-Aldrich, UK) 
was dissolved in 30 mL of 0.1 M morpholinepropanesulphonic acid buffer (MOPS) 
(pH 7.0) and filtered through a 0.22 µm membrane filter.  The solution was reacted 
with 6 mL of activated Affi-Gel® 15 (Bio-Rad, UK) overnight at 4°C on a roller 
mixer at 33 r.p.m.  Any remaining active sites were blocked with 30 mL chilled 
0.1 M ethanolamine for 30 minutes at 4°C.  Purification columns were prepared as 
detailed above; the column was washed with pre-warmed 10 mL 0.1 M 
glycine-sodium hydroxide buffer containing 0.5 M NaCl, pH 10.0 and 0.1 M glycine 
hydrochloride containing 0.5 M NaCl, pH 2.0.  The column was washed with chilled 
10 mL TBS (0.05 M Tris-HCl, 0.15 M NaCl, pH 7.0) at 4°C and equilibriated with 
appropriate elution buffer.  The elution fractions were chilled at 4°C and applied to 
the column at 4°C.  The column was then washed twice with 30 mL cold TBS.  The 
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protein was eluted with 30 mL of pre-warmed TBS at 37°C.  All fractions were 
collected and analysed by SDS-PAGE (Chapter 2, Section 2.3). 
3.3.11.2 Purification of rTcdB547-2366 
Purification of soluble rTcdB547-2366 was completed as for rTcdA900-27120, with the 
following modification.  To maximise recovery of unbound rTcdB547-2366 protein lost 
in the flow through, the purification steps were repeated eleven times.  
 
For rTcdB547-2366 recombinant protein recovered from cytoplasmic inclusion bodies 
was purified as outlined in The QIAexpressionist™ handbook  (2003).  Cleared 
lysate was applied to the column.  The column was washed twice with 4 mL of 
1x Ni-NTA Wash buffer (100 mM Na2HPO4, 10 mM Tris-Cl, 8 M Urea, Roche 
Complete EDTA-free protease inhibitor cocktail, pH 6.3).  The protein was eluted 
Elution buffer D (100 mM Na2HPO4, 10 mM Tris-Cl, 8 M Urea, Roche Complete 
EDTA-free protease inhibitor cocktail, pH 5.9), collecting four 1 mL fractions, 
followed by elution with Elution buffer E (100 mM Na2HPO4, 10 mM Tris-Cl, 8 M 
Urea, Roche Complete EDTA-free protease inhibitor cocktail, pH 4.5), collecting 
four 1 mL fractions.  The flow through, wash and elution fractions were collected 
and analysed by SDS-PAGE (Chapter 2, Section 2.3).  
 
3.3.12 Buffer Exchange and Recombinant Protein 
Concentration 
Elution fractions from native purification were buffer exchanged with PBS using a 
10 mL Zeba™ Spin DeSalting column (Thermo Scientific, UK).  All centrifugations 
were carried out at 4°C at 1,000 g following the manufacturer’s instructions.  Buffer 
exchange columns were prepared by centrifugation as follows, removal of storage 
solution for 2 minutes; two 2 minute washes with PBS; sample application, a 
6 minute wash and a 4 minute sample recovery step.  Samples were concentrated 
using a Pierce® Concentrator centrifugal device, with a 150 kDa molecular weight 
cut off (MWCO) (Thermo Scientific, UK).  Samples were centrifuged at 2,000 g at 
room temperature for 5 minutes.  Protein concentrations were determined by BCA 
assay as outlined in Chapter 2, Section 2.2.2. 
 
63 
 
3.3.13 Detection of rTcdA900-2710 and rTcdB547-2366 Anti-His 
Antibodies 
The 6x Histidine tag attached to the N-terminus of each recombinant protein can be 
used to identify the recombinant protein through the use of histidine specific 
antibodies. Nitrocellulose membranes were prepared as detailed in Chapter 2.0, 
Section 2.8.  Membranes were blocked with 3% (w/v) BSA in PBS-0.1% (v/v) 
Tween (PBST), washed four times in PBST for 20 minutes and incubated at 4°C 
overnight on a roller mixer with the antibodies detailed in Table 3.4, diluted to a 
working concentration of 1:1,000.  Following incubation membranes were washed 
and incubated with goat anti-mouse IgG-HRP-conjugate (Thermo Scientific, UK) 
diluted 1:10,000 in 5% (w/v) dried skimmed milk (Marvel) for 1 hour.  Negative 
controls included soluble protein from cultures of E. coli M15[pREP4], non-induced 
M15[pREP4]-pQE30-TcdA900-2710 and M15[pREP4]-pQE30-TcdB547-2366 grown for 
3 hours LB supplemented with appropriate antibiotics.  Positive control included 
non-toxic, 6xHis-tagged dihydrofolate reductase (DHFR).  Membranes were imaged 
by chemiluminescence as detailed in Chapter 2.0, Section 2.9.  
 
Table 3.4: Anti-His antibody epitopes.   
All antibodies were purchased from Qiagen Ltd, UK, diluted 1:1,000 in 1% (w/v) 
BSA in PBST. 
 RGS-His Ab Penta-His Ab Tetra-His Ab 
Epitope RGSHHHH HHHHH HHHH 
Detects Protein expressed from 
pQE30 
Protein with a His 
tag 
Proteins with a His 
tag 
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3.4 Results 
3.4.1 Codon Optimisation of Gene Sequences Encoding 
TcdA900-2710 and TcdB547-2366 
Expression of clostridial genes in E. coli is frequently associated with low protein 
yields and the subsequent incorporation of the recombinant protein into insoluble 
inclusion bodies (Craggs, 1999; Letourneur et al., 2003; Davies et al., 2013).  
A comparison of the overall codon usage of C. difficile and E. coli is shown in 
Figure 3.2.  In E. coli a low usage codon is a codon which displays a lower usage 
frequency than the smallest value amongst the optimal codons for Met, Trp, Leu, Ile, 
Val, Ser, Pro, Thr, Ala, Arg, Gly and Gln (Chen and Texada, 2006).  The Codon 
Adaption Index (CAI) enables the analysis of codon bias based on the codon usage in 
a set of highly expressed genes.  For example, in E. coli the preferred triplet 
encoding Proline is CCG (20.9) whereas in C. difficile it is CCA (15.4) (Figure 3.2).  
Analysis of the codon usage patterns of TcdA900-2710 and TcdB547-2366 revealed the 
presence of a number of codons which are rarely used in E. coli, primarily the codons 
CTA, ATA, AGA, and GGA which encode leucine, isoleucine, arginine and glycine 
respectively.  Given that the codon usage of a gene sequence can affect the efficiency 
of its translation, codon optimisation of the TcdA900-2710 and TcdB547-2366 sequences 
was undertaken to maximise expression from E. coli.  Following codon optimisation, 
the CAI was increased to 0.87 and 0.88 for TcdA900-2710 and TcdB547-2366, 
respectively.  In addition the GC content of the re-synthesised codon optimised genes 
was closer to that of E. coli as displayed in the GC skew plots (Figures 3.3 and 3.4). 
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Figure 3.2: Comparison of codon usage in E. coli and C. difficile.   
E. coli K-12 (blue) and C. difficile 630 (red).   Codon usage frequency table for E. coli is available from (http://www.genscript.com/). Codon 
usage frequency table for C. difficile 630 is available from (http://www.kazusa.or.jp/codon/). Axis value is off-set to the right and represents 
frequency of occurrence per 1000 codons.  
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Figure 3.3: A GC content plot for TcdA900-2710 and rTcdA900-2710.  
GC percentage was calculated in a 100 bp sliding window using the EMBOSS isochore software.  The GC content before and after optimisation 
was 27.42% and 44.51%, respectively.  
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Figure 3.4: A GC content plot for TcdB547-2366 and rTcdB547-2366.  
GC percentage was calculated in a 100 bp sliding window using the EMBOSS isochore software.  The GC content before and after optimisation 
was 27.22% and 44.57%, respectively.  
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3.4.2 DNA Manipulations 
Confirmation of the gene sequences into the pQE30 expression vector was 
undertaken by GenScript. 
 
3.4.2.1 Transformation 
Transformation of E. coli expression strains, M15[pREP4] and SG13009[pREP4] 
with pQE30-TcdA900-2710 and pQE30-TcdB547-2366 was successful but at a lower rate 
than that seen for the positive control, pQE30 (Table 3.5).  In the case of 
pQE30-TcdA900-2710 only after four attempts was transformation possible.  To assess 
if the transformation efficiency was associated with problems with the donor DNA, 
the pQE30-TcdA900-2710 plasmid was extracted from SG13009[pREP4] and used to 
transform DH5α™, a previously non-transformable strain.  With this approach a 
transformation efficiency of 2.25 x 10
2
 CFU/µg DNA was obtained. 
 
Table 3.5: Transformation efficiency of rTcdA900-2710 and rTcdB547-2366.  
E. coli 
Strain 
pQE30 
(CFU/µg DNA) 
rTcdA900-2710 
(CFU/µg DNA) 
rTcdB547-2366 
(CFU/µg DNA) 
M15 
[pREP4] 
1.81 x 10
4 
9.00 x 10
2
 1.73 x 10
3 
SG13009 
[pREP4] 
4.02 x 10
4 
1.84 x 10
3
 1.55 x 10
3 
DH5α™ TNTC 0 ND 
All experiments were completed with a negative control of 20 µL of TE buffer and a 
10 ng of pQE30 as a positive control.  E. coli strains were transformed with 10 ng of 
plasmid DNA.  TNTC – Too Numerous To Count at a 1/100 dilution.  ND – not done 
 
The incorporation of antibiotics into the culture media enables the selection of 
positively transformed cells.  To confirm that the expression plasmid had been 
successfully introduced into the E. coli host, transformed cells were subjected to 
alkaline lysis and the plasmids isolated with a purification column.  As can be seen 
from Figure 3.5, digestion with BamH1 and Sal1 yielded DNA fragments of the 
expected sizes of ~5.4 kb for rTcdA900-2710 and rTcdB547-2366.  The multiple bands 
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observed in the undigested pQE30 lane represents the different forms of the plasmid 
(supercoiled, nicked).  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.5: Restriction digest analysis. 
Lane 1; Undigested pQE30, Lane 2; Digested pQE30A and pQE30B digested with 
BamHI and SalI.  Samples were combined with x5 sample loading buffer, analysed 
on a 1.2% (w/v) agarose gel and stained with 0.5 µg/mL ethidium bromide.  Solid 
arrow indicates insert and dashed arrow indicates digested pQE30. M; Marker in bp. 
 
3.4.3 Expression and Purification of rTcdA900-2710 
In an initial series of experiments, the ability of the constructs to produce 
recombinant protein either as a soluble product (located in the cytoplasm) or as an 
insoluble product (located in cytoplasmic inclusion bodies) in a range of media was 
determined.  Aliquots were collected pre-IPTG induction and post-IPTG induction 
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every hour for 4 hours.  The optical density was recorded and whole cell crude 
extracts, soluble and insoluble fractions were analysed by 1D SDS-PAGE.  
 
For the six media analysed no difference in optical density was observed during the 
course of the experiment (Figure 3.6) suggesting that differences in media 
composition did not influence the growth rate of M15[pREP4]-pQE30-TcdA900-2710.  
The positive (6xHis-tagged dihydrofolate reductase (DHFR) and negative 
(non-induced M15[pREP4]-pQE30-TcdA900-2710) controls were grown in LB media 
supplemented with appropriate antibiotics.    
  
 
Figure 3.6: Time-course analysis of rTcdA900-2710 expression in a range of media.  
The optical density (OD600) pre and post-IPTG induction was recorded. The positive 
control was non-toxic, 6xHis-tagged dihydrofolate reductase (DHFR) and the 
negative was non-induced M15[pREP4]-pQE30-TcdA900-2710.  
 
Analysis of the time course of recombinant protein expression by 1D SDS-PAGE 
(Figure 3.7) found that a band corresponding to the size of rTcdA900-2710 (~205 kDa) 
was detected in the insoluble fraction of all of the cultures and that production 
peaked at 3 hours post-IPTG induction.  Unusually the recombinant protein band was 
not detected at 4 hours post-IPTG induction in the insoluble fraction in LB and 
SB media, it is unclear if this is associated with incomplete lysis.  Clearly the band 
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intensity of rTcdA900-2710 was not comparable to that of the positive control, DHFR, 
from which protein could be recovered from both the soluble and insoluble fractions. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.7: 1D SDS-PAGE time-course analysis of rTcdA900-2710 expression in a 
range of media.  
Aliquots were removed pre and post-IPTG induction subjected to lysis, analysed on a 
4-20% SDS-PAGE gel and stained with colloidal Coomassie. Controls included 
pQE30 (positive) and non-induced rTcdA900-2710 (negative). LB; LB Fisher, SB; 
Superior Broth™, Turbo Broth™, M9Y; Glucose M9Y, PB; Power Broth™, HB; 
Hyper Broth™, Positive; DHFR, Negative; M15[pREP4], C; crude, S; Soluble, I; 
Insoluble.  Arrows indicate predicted protein size (205 kDa and 26 kDa for 
rTcdA900-2710 and DHFR, respectively). 
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To compare the proportion of rTcdA900-2710 produced at three hours, samples from all 
culture media were analysed on a single SDS-PAGE gel and volume intensity 
analysis conducted.  This allowed for direct comparison of the media at a specific 
time point without introducing gel-to-gel variations in terms of electrophoresis run, 
staining and de-staining.  Gel images were captured with a 12-bit CCD 
(charge-coupled device) camera and analysed with the in-built software, Image Lab 
(Bio-Rad, UK) allowing for quantification and comparisons to be made.  Using this 
software an area corresponding to 1.4mm² was drawn around the 205 kDa band.  
Adjusted volume intensity values were plotted (Figure 3.8) as this took into account 
the presence of non-data background pixels within each area.  Superior Broth™ was 
identified as the media which generated the highest intensity per 1.4 mm
2
 and 
utilised for subsequent expression of rTcdA900-2710.   
 
 
 
 
 
 
 
 
 
 
 
Figure 3.8: Volume intensity analysis of rTcdA900-2710 expressed in a range of media.  
Aliquots 3 hours post-IPTG induction were subjected to lysis, analysed on a 4-20% 
SDS-PAGE gel and stained with colloidal Coomassie. Gel images were captured 
with a 12-bit CCD camera and analysed with Image Lab. Adjusted volume intensity 
values correspond to 1.4 mm² (LB; LB Fisher, SB; Superior Broth™, Turbo Broth™, 
M9Y; Glucose M9Y, PB; Power Broth™, HB; Hyper Broth™, C; crude, S; Soluble, 
I; Insoluble.  Arrow indicates predicted protein size (205 kDa). 
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The media optimisation experiment revealed rTcdA900-271 was predominantly located 
in cytoplasmic inclusion bodies.  Inclusion bodies refer to insoluble protein 
aggregates, which are formed by non-specific hydrophobic interactions between 
polypeptides (Ventura and Villaverde, 2006).  Although the precise physiochemical 
parameters necessary for inclusion body formation are unknown, a reduction in 
growth temperature has been reported to reduce inclusion body formation (Schein, 
1989; Vera et al., 2007).  A reduction in culture temperature to 16°C and the 
incubation of the culture without shaking (Figure 3.9) produced recombinant protein 
in both the soluble and insoluble fractions at 2 hours post-IPTG induction.  The 
205 kDa recombinant band was only detectable in all the soluble fractions upon 
silver staining.  
 
 
 
 
 
 
 
 
Figure 3.9: Temperature optimisation of rTcdA900-2710. 
Culture was grown at 16°C, static, aliquots were removed post-IPTG induction at the 
times indicated and analysed on a 5% SDS-PAGE gel, double stained with colloidal 
Coomassie+silver stain.  Gels were imaged with the Chemi Doc xrs+ system, under 
white light trans illumination, faint band exposure. C; crude, S; Soluble, I; Insoluble, 
NI; Non-induced.  Arrow indicates predicted protein size (205 kDa). 
 
The potential yield of recombinant protein attainable is dependent, in part, on 
achieving a high cell concentration (biomass).  For biomass production to be at its 
maximum, an alternative carbon source to glucose, the most commonly used sugar, 
must be used, thus LB*Booster™, a fructose based carbon source was assessed.  
Inclusion body formation is frequently associated with incorrectly folded proteins 
thus the addition of chaperones may assist in the folding of recombinant proteins and 
thus enhance recovery from the soluble fraction.  Augmedium™ triggers chemical 
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and oxidative stress responses in E. coli, inducing expression of chaperone proteins.  
Using a commercially available assessment protocol the effect of IPTG, 
LB*Booster™ and Augmedium were assessed in a series of small scale expression 
experiments (50 mL culture volume).  The crude, soluble and insoluble fractions 
were analysed (Figure 3.10).  From this analysis 1 mM IPTG, x0.1 LB*Booster™ 
and x1 Augmedium™ incubated at 30°C in Superior Broth was utilised for 
expression of rTcdA900-2710. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.10: Protein Expression and Rescue (PERK™) optimisation of 
rTcdA900-2710.  
A) Crude, B) Soluble C) Insoluble.  IPTG, LB*Booster™, Augmedium™ and 
Temperature were assessed as detailed in Table 3.3.  Aliquots were removed 3 hours 
after IPTG induction, analysed on a 4–20% SDS-PAGE gel and stained with 
colloidal Coomassie. Gels were imaged with the Chemi Doc xrs+ system, under 
white light trans illumination, faint band exposure and analysed using Image Lab™ 
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Software, v 3.0, with a band detection sensitivity of 100.  Arrows indicate predicted 
protein size (205 kDa).  
 77 
 
3.4.3.1 Recovery and Purification of rTcdA900-2710 
To maximise the production and recovery of rTcdA900-271, the influence of a range of 
factors on protein recovery and purification were assessed.  Small scale expression 
experiments were conducted in 100 mL of Superior Broth™ incubated at 37°C for 
3 hours.  Using this approach a band corresponding to 205 kDa was not visible in the 
soluble fraction on a Coomassie stained gel.  Increasing the culture volume to 1 L did 
result in a faint band at 205 kDa (Figure 3.11).    
 
 
 
 
Figure 3.11: Recovery of soluble rTcdA900-2710 based on culture volume.  
Cultures were incubated at 37°C; 300 rpm in Superior Broth™, soluble purification 
was conducted 3 hours post-IPTG induction.   The cleared lysate was analysed on a 
4–20% SDS-PAGE gel and stained with colloidal Coomassie. Gels were imaged 
with the Chemi Doc xrs+ system, under white light trans illumination, faint band 
exposure and analysed using Image Lab™ Software, v 3.0, with a band detection 
sensitivity of 100.  Arrow indicates predicted protein size (205 kDa).  
 
To further enhance the recovery of the recombinant protein from the bacteria, a lysis 
approach consisting of a combination of lysozyme and sonication was used to 
liberate soluble recombinant protein.  The insoluble recombinant protein, trapped 
within inclusion bodies was recovered using a combination of lysozyme, sonication 
and urea.  Based on the visible intensity of the 205 kDa band in the cleared lysate, 
this new lysis approach increased the amount of recombinant protein recovered from 
both the soluble and inclusion body fractions (Figure 3.12).   
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Figure 3.12: Effect of sonication on recovery of rTcdA900-2710. 
Lane 1; Soluble fraction, lysozyme, Lane 2; Insoluble fraction, lysozyme and urea, 
Lane 3; Soluble fraction, lysozyme and sonication, Lane 4; Insoluble fraction, 
lysozyme, sonication and urea.  Aliquots were analysed on a 4–20% SDS-PAGE gel, 
stained with colloidal Coomassie, imaged with the Chemi Doc xrs+ system, under 
white light trans illumination, faint band exposure and analysed using Image Lab™ 
Software, v 3.0, with a band detection sensitivity of 100.  Arrow indicates predicted 
protein size (205 kDa). 
 
Recovery of recombinant protein from the Ni-NTA column requires the 
disassociation of the 6x His tag, which is located at the N-terminus of the 
recombinant protein from the Ni ions present in the affinity column.  Recovery of 
His-tagged recombinant protein can be achieved either with an increasing imidazole 
concentration (100–250 mM) or by reducing the pH (4.5-5.3) gradient.  Elution with 
the pH gradient revealed rTcdA900-2710 was likely to be present as an aggregate, with 
the protein being eluted at pH 4.5.  The lower pH disassociates the protein aggregates 
allowing the protein to be eluted from the column.  Aggregate formation could have 
further been reduced by the incorporation of reducing agents (dithiothreitol or 
2-Mercaptoethanol) in the buffers to disrupt disulphide bonds.  In addition to the 
205 kDa band corresponding to the recombinant protein, a number of additional 
proteins (ranging from ~150-20 kDa) were recovered from the elution fractions with 
both the imidazole and pH gradient (Figure 3.13).  These protein bands may 
represent truncated and/or degraded rTcdA900-2710, or E. coli proteins. 
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Figure 3.13: Purification of rTcdA900-2710 by imidazole and pH gradient. 
Post lysis recombinant protein was recovered from the Ni affinity column by 
imidazole or pH gradient. E1-E4, Elution by 250 mM imidazole, EE1-EE4; Elution 
by pH 5.9, ED1-ED4; Elution by pH 4.5, M; molecular weight maker in kDa and 
analysed on a 4–20% SDS-PAGE gel and stained with colloidal Coomassie. Gels 
were imaged with the Chemi Doc xrs+ system, under white light trans illumination, 
faint band exposure and analysed using Image Lab™ Software, v 3.0, with a band 
detection sensitivity of 100.  Red boxes indicate predicted protein size (205 kDa) and 
right brace indicates additional proteins present in elution fractions. 
 
Both elution methods gave similar results (Figure 3.13), however the pH gradient 
was found to be more labour intensive and as a consequence the imidazole gradient 
was utilised in subsequent purification studies (Figure 3.14).   
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Figure 3.14: Optimized purification of rTcdA900-2710 by imidazole gradient. 
Post lysis recombinant protein was recovered from the Ni affinity column by 
imidazole gradient. CL; Cleared lysate, FT; Flow through, W; Wash, E1-E4, Elution 
by imidazole.  Molecular weight maker in kDa and analysed on a 4–20% SDS-PAGE 
gel and stained with colloidal Coomassie. Gels were imaged with the Chemi Doc 
xrs+ system, under white light trans illumination, faint band exposure and analysed 
using Image Lab™ Software, v 3.0, with a band detection sensitivity of 100.  
 
To remove the additional bands seen following elution from the Ni-NTA column, a 
further affinity purification stage, utilising thyroglobulin was employed.  This 
approach exploits the presence of the Galα1-3Galβl-4GlcNAc sugar moiety present 
in bovine thyroglobulin, which is known to bind the C-terminal of native toxin A 
(Krivan et al., 1986; Krivan and Wilkins, 1987; Kamiya et al., 1989).  As the 
C-terminal is also present in the recombinant protein expressed herein, purification 
by thyroglobulin affinity chromatography was feasible.  Although this additional step 
did result in a 50% reduction in the presence of contaminated proteins, based on the 
pixel intensity of protein bands in the wash fractions and those <200 kDa in elution 1 
(E1), multiple bands were still observed following thermal elution (Figure 3.15). 
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Figure 3.15: Thyroglobulin purification of rTcdA900-2710. 
Post Ni-affinity column purification rTcdA900-2710 was subjected to thyroglobulin 
affinity chromatography.  W1-W5; Wash, E1-E4, Elution.  Molecular weight maker 
in kDa and analysed on a 4–20% SDS-PAGE gel and double stained with colloidal 
Coomassie+silver. Gels were imaged with the Chemi Doc xrs+ system, under white 
light trans illumination, faint band exposure and analysed using Image Lab™ 
Software, v 3.0, with a band detection sensitivity of 100.   
 
As the recombinant protein is a large protein (205 kDa), size exclusion 
chromatography seemed a logical step to further purify the protein.  However, in 
spite of this, coomassie staining revealed the purified preparations still contained 
multiple protein bands <150 kDa (Figure 3.16). 
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Figure 3.16: Purified rTcdA900-2710 following size exclusion. 
Post size exclusion aliquots were analysed on a 4–20% SDS-PAGE gel and stained 
with colloidal Coomassie. Gels were imaged with the Chemi Doc xrs+ system, under 
white light trans illumination, faint band exposure and analysed using Image Lab™ 
Software, v 3.0, with a band detection sensitivity of 100. Molecular weight maker in 
kDa.  Arrow indicates predicted protein size (205 kDa) and right brace indicates 
additional proteins present following purification. 
 
In an attempt to determine if the contaminating proteins in the elution preparation 
represented truncated and/or degraded rTcdA900-2710, or host derived E. coli proteins, 
Western blot analysis was conducted.  The commercial availability of antibodies 
capable of recognising the 6xHis affinity tag incorporated into the N-terminus of the 
recombinant protein enabled the identification of some of the protein bands.  Three 
commercially available anti-His antibodies (Penta, Tetra and RGS-His) were utilised, 
the latter antibody is specifically designed to detect the RGS-His4 epitope encoded 
by the pQE30 expression vector (Figure 3.1).  
 
In order to assess if these bands represent contaminated protein from the E. coli host, 
and may interfere in downstream application, the soluble protein from the 
non-induced control and M15[pREP4] strain were also assessed (Figure 3.17).  
Immunoreactive bands could be seen in both controls as indicated by the red boxes, 
but at a low intensity.  This suggests histidine rich sequences or metal binding motifs 
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maybe present in E. coli host proteins (Bolanos-Garcia and Davies, 2006; Robichon 
et al., 2011).  Alternatively as these proteins were also observed in the elution 
fraction following thyroglobulin purification and size exclusion filtration, they may 
represent proteins which are bound to the recombinant protein and subsequently 
resolved as individual proteins following SDS-PAGE (heating and DTT treatment).  
 
 
 
 
 
 
 
 
 
 
Figure 3.17: Western blot of rTcdA900-2710, non-induced cultures and 
M15[pREP4].  
Membranes were probed with RGS-His (left), Tetra-His (centre) and Pent-His 
(right), at a 1/1000 dilution and detected with SuperSignal Femto. Soluble fractions 
from Non-induced cultures (NI) and M15[pREP4] serve as negative controls and 
soluble DHFR as a positive control. Blots were imaged with the Chemi Doc xrs+ 
system. Blue box predicted rTcdA900-2710, red boxes possible E. coli derived host 
proteins. 
 
A very faint band at the predicted molecular weight was observed (Figure 3.17, blue 
box) Repeating of the western blot with a longer lasting ECL reagent (SuperSignal 
West Dura), showed the presence of rTcdA900-2710 (Figure 3.18).   
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Figure 3.18: Western blot of rTcdA900-2710.  
Membranes were probed with RGS-His (left), Tetra-His (centre) and Pent-His 
(right), at a 1/1000 dilution and detected with SuperSignal Dura. Blots were imaged 
with the Chemi Doc xrs+ system.  Red boxes indicate predicted protein size 
(205 kDa) and right brace indicates additional proteins detected by anti-His 
antibodies. 
 
The final yield of rTcdA900-2710 was determined by BCA assay to be 1 mg/L, with 
300 µg/L derived from the soluble and 700 µg/L from the insoluble fraction.  This 
yield did include multiple additional proteins, some of which represent degraded 
rTcdA900-2710 and E. coli host proteins.  
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3.4.4 Expression and Purification of rTcdB547-2366 
3.4.4.1 Growth Conditions of rTcdB547-2366 
Expression and purification of rTcdB547-2366 was relatively easy when compared to 
rTcdA900-2710.   In stark contrast to rTcdA900-2710, rTcdB547-2366 was recovered 
predominantly in the soluble fraction, with only a very faint band being detected in 
the insoluble fraction (Figure 3.19).  A faint band could also be observed in the crude 
fraction of the non-induced control which became more apparent 3 hours post 
induction.   Expression from M15[pREP4] in LB media at 37°C was observed to 
peak at 3 hour post-IPTG induction.  
  
 
 
 
 
 
 
 
 
 
Figure 3.19: Time-course analysis of rTcdB547-2366 expression in LB media. 
Aliquots were removed post-IPTG induction at the times indicated and analysed on a 
5% SDS-PAGE gel and stained with colloidal Coomassie.  Gels were imaged with 
the Chemi Doc xrs+ system, under white light trans illumination, faint band 
exposure.  A non-induced crude sample was analysed as a negative control.  Red box 
indicates predicted protein size (207 kDa) and right brace indicates additional 
contaminating proteins. 
 
To verify if the composition of the media influenced the level of expression of 
rTcdB547-2366, in a similar manner to rTcdA900-2710, the expression of recombinant 
toxin B from M15[pREP4]  was analysed at 3 hours post-IPTG induction 
(Figure 3.20A).  Variations in recombinant protein expression can be observed 
(Figure 3.20B).  As protein was recoverable from the soluble fraction, the insoluble 
fraction was not analysed by SDS-PAGE, therefore the influence of media recovered 
from the insoluble fraction was not determined. 
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A) 
 
 
 
 
 
 
B) 
 
Figure 3.20: Media optimisation of rTcdB547-2366 soluble fraction.  
A) 1D SDS-PAGE analysis of rTcdB547-2366 and B) Volume intensity analysis of 
rTcdB547-2366 soluble fraction.  Aliquots were removed 3 hour post-IPTG induction 
and analysed on a 4-20% SDS-PAGE gel, stained with colloidal Coomassie.  Gel 
images were captured with a 12-bit CCD camera and analysed with Image Lab. 
Adjusted volume intensity values correspond to 2.3 mm². C; crude, S; Soluble. 
 
Based on the results presented above LB media was utilised for large scale 
expression of rTcdB547-2366.   
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The cleared lysate of both the soluble and insoluble fractions showed a heavily 
stained band at the expected molecular weight (207 kDa), Figure 3.21.  Analysis of 
the elution fraction by Coomassie stained 1D SDS-PAGE revealed the presence of 
multiple additional protein bands.  Unsurprisingly purification of the inclusion body 
fraction produced purer protein, with few additional proteins (<200 kDa) detected in 
the eluted fractions.  This is probably due to fewer proteins being present in the 
inclusion body coupled with more stringent wash and elution steps based on pH. 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.21: rTcdB547-2366 purification under native (soluble) and denaturing 
(insoluble inclusion body) conditions. 
Expression was induced with 1 mM IPTG for 3 hour and purified using Ni-NTA 
agarose.  Proteins were analysed on a 5% SDS-PAGE gel and stained with colloidal 
Coomassie.  CL, Cleared lysate; FT, Flow through; W1, Wash 1; W2, Wash 2.  
Elution of rTcdB547-2366 was achieved with 250 mM imidazole, pH 8.0, pH 5.9 or 
pH 4.5 as indicated above. Arrow indicates predicted protein size (207 kDa) and blue 
box highlight presence of additional protein bands in elution fractions. 
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Given the visual intensity of the 207 kDa recombinant protein band in the cleared 
lysate fraction, the proportion of recombinant protein in the elution fractions 
recovered from the inclusion bodies appears to be disproportionate.  This can partly 
be attributed to the loss of protein in the flow through and wash steps.  It may also be 
an indication of the protein remaining in the purification column, as it has not been 
disassociated from the Ni ions.  The pI of rTcdB547-2366 is 4.6 which is close to the pH 
of the elution buffer (pH 4.9).  Thus it is possible a significant proportion of protein 
was not eluted from the column and as such elution by pH is not appropriate for 
recombinant toxin B, recovered from the inclusion body fraction.   
 
Following the initial binding of the recombinant protein to the Ni-NTA column, a 
proportion of recombinant protein was lost in the flow through and subsequent wash 
fractions (Figure 3.21).  In order to maximise the recovery of soluble rTcdB547-2366, 
the flow though was re-applied to the Ni-NTA column and the purification process 
repeated (Figure 3.22).  While analysis of the eluted fractions following this second 
passage revealed the presence of purer protein, protein continued to be lost in the 
flow through and wash fractions.   
 
 
 
 
 
 
 
 
 
 
 
Figure 3.22: Re-application of soluble rTcdB547-2366 flow through. 
Purification was completed by re-applying the flow through, through a pre-
equilibriated Ni-NTA column.  Proteins were analysed on a 4–20% SDS-PAGE gel, 
stained with colloidal Coomassie and imaged under white light trans illumination, 
faint band exposure with the Chemi Doc xrs+ system. Arrow indicates predicted 
protein size (207 kDa) and blue box highlight presence of additional protein bands in 
elution fractions.  
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The presence of multiple bands in the elution fractions tends to be associated with 
non-specific binding interaction, truncated or degraded protein.   In the latter case 
protease mediated degradation of protein was limited by the use of protease 
inhibitors in the lysis, wash and elution buffers.  However proteolytic degradation 
can occur inside the cell following the production of the soluble recombinant protein, 
even protease deficient expression strains still have some level of protease activity. 
 
As with rTcdA900-2710 the use of a size exclusion filter did not remove all proteins 
<150 kDa, which was particularly evident when the purified fractions were 
concentrated.  Western blotting revealed the presence of proteins present between 
100-200 kDa which were likely to be truncated and/or degraded recombinant protein 
as they were absent from the E. coli expression strain (M15[pREP4]) and the 
non-induced negative control (Figure 3.23).   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.23: Western blot of purified rTcdB547-2366.  
A nitrocellulose membrane, probed with RGS-His (left), Tetra-His (centre) and 
Pent-His (right), at a 1/1000 dilution and detected with SuperSignal Femto. 
Non-induced cultures (NI) and soluble protein from M14[pREP4] were included as 
negative controls and soluble DHFR protein as a positive control. Blots were imaged 
with the Chemi Doc xrs+ system. Blue boxes indicate predicted protein size 
(207 kDa). 
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 The final yield of rTcdB547-2366 from the soluble fraction was 4–6 mg/L.  A similar 
yield was achieved when the recombinant protein was recovered from the insoluble 
fraction.  
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3.5 Discussion 
3.5.1 Codon Optimisation 
The total (soluble and insoluble) purified yields of rTcdA900-2710 and rTcdB547-2366 
were ~1 mg/L and ~12 mg/L, respectively.    Both purified preparations contained 
multiple additional protein bands as detected by colloidal Coomassie staining.  As 
non-codon optimised versions of each gene were not expressed during this study, it is 
not possible to draw any direct conclusions, as to whether codon optimisation has 
enhanced recombinant protein expression. 
 
In a previous study the yield of non-codon optimised C-terminal domains of TcdA 
and TcdB  in E. coli were reported as being 45-89 mg/L and 40 mg/L for TcdA and 
TcdB respectively (Letourneur et al., 2003).  Both the TcdA and TcdB preparations 
contained multiple additional proteins as detected by Coomassie stained SDS-PAGE.  
In an early study, Craggs (1999) expressed and purified ten overlapping fragments 
encompassing the complete tcdA gene in E. coli BL21 (DE3).  Yielding between 
5-25 µg/mL (depending on fragment expressed) from different volumes of starting 
culture, ranging from 10–1000 mL.   The same author also attempted to increase the 
yield of soluble recombinant protein by the inclusion of a plasmid (pDC952) 
expressing the rare argU gene encoding the amino acids AGA/AGG.   Unfortunately 
in the coding sequence of native TcdA the frequency of AGA and AGG are 23 and 
0 per 1000 codons, respectively, and had no effect on the yield of recombinant 
protein produced, possibly due to the presence of other rare codons in the sequence.   
 
A study conducted by Davies et al., (2013) expressed a total of 14 codon optimised 
fragments from the C-terminal receptor binding domains of TcdA and TcdB, which 
ranged in size between 14.9–48.1 and 15.9-61.5 kDa, respectively.  For the TcdA 
fragments expressed, 56% (5 out of 9) were found to be located in the insoluble 
fraction, this is in contrast to 20% of TcdB fragments  (1 out of 5).  These results are 
similar to those seen in this study with rTcdA900-2710 expressed predominantly in the 
insoluble fraction and rTcdB546-2366 easily recoverable from the soluble fraction.    
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Although the regions expressed in the aforementioned papers are significantly 
smaller than the >200 kDa fragments presented in this study, the two studies do 
highlight the problems of expressing TcdA in E. coli.  Although the expression of 
such a large protein in a host in which the largest reported protein is 151 kDa (as per 
the annotated SWISS-2D database) (Hoogland et al., 2004), may account for some of 
the problems encountered in this study.  However the fact that TcdB (207 kDa) was 
successfully expressed whilst TcdA (205 kDa) was problematic suggests the protein 
itself is problematic as opposed to the size of the protein.  
 
Codon optimisation is a computer driven process in which the codons of a gene is 
modified to that seen in genes which are highly expressed in E. coli during optimum 
growth.  Given that the introduction and subsequent expression of a foreign protein 
in E. coli does not represent optimum growth, the genes which are highly expressed 
and hence the optimum codons are likely to be different.  Thus the codon 
optimisation programme utilised in this and indeed in other studies may not be 
appropriate. 
 
What is evident from this and other studies is expression of the C. difficile toxin 
fragments; particularly TcdA is problematic in E. coli.  A notion supported by other 
researchers who have advocated the use of other expression systems such as 
Baculovirus (Heinrichs et al., 2012) or Bacillus spp. (Tang-Feldman et al., 2002; 
Ackermann et al., 2004b; Wang et al., 2012).  The work conducted by Heinrichs and 
colleagues (2012) indicates, that regardless of the host utilised the resulting 
recombinant toxin is immunogenic, thus can be utilised as surrogates for therapeutic 
development. 
 
3.5.2 Transformation Efficiency of rTcdA900-2710 and 
rTcdB547-2366 
The transformation of pQE30-rTcdA900-2710 into various strains of E. coli was 
problematic, with attempts to directly transform DH5α, being unsuccessful, 
suggesting that the insert was either unstable or toxic to some E. coli strains.   
Similar problems pertaining to the stability of plasmids containing the TcdA 
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sequence or regions thereof have been reported in the literature (Phelps et al., 1991; 
Craggs, 1999; Ackermann et al., 2004b). Transformation of M15[pREP4] and 
SG13009[pREP4] with pQE30-rTcdA900-2710 was only achieved following repeated 
efforts.  In order to assess whether the failure to transform consistently was due to 
problems with the donor DNA, plasmid was extracted from a transformed strain of 
SG13009[pREP4] and used as donor DNA for a second transformation.  This proved 
successful with DH5α, be it at a very low efficiency (2.25 x 102 CFU/µg DNA).  The 
donor DNA following propagation through an E. coli host may have been modified 
in a manner which enhanced its transformation ability.  It has previously been 
reported that transformation of B. anthracis was possible only after the propagation 
of the plasmid through a dam deficient E. coli strain (Marrero and Welkos, 1995).  
Although the reported research does not entirely mirror our findings it does support 
the notion of propagating plasmids through strains to improve transformation 
efficiency.  Alternatively Tsen et al. (2002) and Etchuuya et al., (2011) have 
suggested that the uptake of plasmid DNA (during the natural transformation process 
in E. coli) is promoted by the presence of cell contents released from E. coli lysates, 
such as DNA-associating molecules.  During the cell lysis process it is possible such 
molecules were released, and in their presence, transformation of DHα became 
possible. 
 
The transformation problems encountered with TcdA900-2710 and TcdB547-2366 may be 
associated with the size of the inserts (5445 and 5471 bp for TcdA900-2710 and 
TcdB547-2366, respectively), transformation efficiency has been shown to decrease 
with an increase in plasmid size (Hanahan, 1983).  Although it was not in the remit 
of this research it would have been interesting to assess the transformation efficiency 
following electroporation, as electroporation is known to facilitate the uptake of large 
molecules of DNA (inserts >3 kb) and provides the highest transformation 
efficiencies (Woodall, 2003).   
 
3.5.3 Expression and Purification of rTcdA900-2710 
Expression and purification of TcdA in E. coli is frequently associated with low 
yields and the formation of inclusion bodies necessitating the optimisation of 
 94 
 
induction conditions and purification procedures (Phelps et al., 1991; Craggs, 1999; 
Letourneur et al., 2003; Ackermann et al., 2004b).  Similarly, our attempts to express 
and purify rTcdA900-2710 required optimisation at every stage. 
 
Historically, LB media has been used for the cultivation of E. coli and expression of 
recombinant genes from E. coli (Aristidou et al., 1999; Broedel Jr et al., 2001).  The 
results from our study are in agreement with those of Broedel Jr et al. (2001) who 
demonstrated that the composition of the growth media effected the accumulation of 
recombinant proteins.  While rTcdA900-2710 was expressed in all of the media assessed 
during this study, the level achieved varied and maximum expression was seen in 
Superior Broth™.  As this media is proprietary, it was not possible to decipher the 
composition of the media. 
 
Maximising the yield of recombinant protein is dependent on achieving a high cell 
concentration (biomass).  For biomass production to be at its maximum, an 
alternative carbon source to glucose - the most commonly used sugar - must be used.  
During E. coli culture, glucose is converted to acidic by-products (such as acetic 
acid) which inhibit cell growth (limiting biomass production) and have been reported 
to impede recombinant protein expression (Aristidou et al., 1999).  Although not 
investigated in this study, the effect of non-metabolisable sugars could provide a 
means of increasing the yield of soluble protein.  Bowden and Georgiou (1988) 
reported that the addition of non-metabolisable sugars (sucrose and raffinose) to the 
growth media increased the recovery of soluble protein by reducing inclusion body 
formation and improving folding.  The presence of non-metabolisable sugars either 
increases the osmolarity of the media (Schein, 1989) or the sugars exert a direct 
stabilising effect on the polypeptides, forming soluble protein and reducing 
aggregation (Bowden and Georgiou, 1988).    
 
In E. coli, Hsp70 (DnaK, DnaJ and GrpE) and Hsp60 (GroEL and GroES) are the 
major chaperone families involved in protein folding in the cytoplasm.  A number of 
studies have demonstrated that the overproduction of GroESL increases the yield of 
correctly folded soluble proteins (Goloubinoff et al., 1989; Makrides, 1996), 
although these observations appear to be protein specific.  It is difficult to establish 
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which, if any, chaperones truly effected protein expression.  It is believed E. coli has 
optimised its chaperone content with regards to the expression of host cell proteins 
(Makrides, 1996).  Thus, the chaperones (or the ratio) which are available for the 
expression of heterologous proteins may not be sufficient and as such would need 
optimisation.   
 
All other researchers who have experienced difficulties expressing TcdA have 
performed expression in shake flasks (Phelps et al., 1991; Craggs, 1999; Letourneur 
et al., 2003; Ackermann et al., 2004b).  To date, only one research group (Tian et al., 
2012) have reported utilising a fed-batch process for the expression of a recombinant 
fusion protein, containing the C-terminal regions of TcdA and TcdB, although the 
authors fail to provide data on the protein yield achieved.  Based on the methods 
provided, it appears soluble protein was extracted, with no reported difficulties 
encountered in expression or purification (Tian et al., 2012). 
 
The E. coli host strain used in this study to express rTcdA900-2710 M15[pREP4] 
produces a cytoplasmic protease, La, which is known to degrade non-native proteins  
(Beerens et al., 1963).  Thus, it is possible that rTcdA900-2710 has undergone host cell 
mediated proteolysis. Strategies for minimising proteolysis include use of 
protease-deficient strains, altering the culture media, temperature, co-expression of 
chaperones and construction of fusion proteins.  The successful transformation of 
three E. coli strains (M15[pREP4], SG13009[pREP4] and DH5α), all of which are 
Lon
+
, limited the assessment if an increase in expression would have occurred with a 
protease-deficient strain. 
 
More recently Donald and colleagues (2013) have overexpressed full-length 
genetically inactivated toxin A and B in a non-toxigenic, non-sporogenic C. difficile 
strain.  Utilisation of two genetic tools, the ClosTron mutagenesis and 
Escherichia coli–Clostridium plasmid shuttle vector system, enabled inactivation of 
spore formation (Heap et al., 2007; Underwood et al., 2009) and episomal expression 
of recombinant proteins (Heap et al., 2009).  These recombinant toxins were found to 
be immunogenic, although they did retain cytotoxicity (Donald et al., 2013).  The 
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advancements in genetic technology and further optimisation of this method may 
facilitate the safe expression of toxin A, in high yields. 
 
3.5.4 Expression and Purification of rTcdB547-2366 
In contrast to the situation with rTcdA900-2710, a high level expression system in 
which equal quantities of protein were recovered from the soluble and insoluble 
fractions was developed for rTcdB546-2366.   The total average yield of rTcdB547-2366 
was 8-12 mg/L of bacterial culture, representing a purity of 80%, as determined by 
colloidal Coomassie stain.  This yield is similar to that reported by Yang et al. (2008) 
(5-10 mg/L), who expressed full length TcdA and TcdB in a B. megaterium 
expression host.  However, the reported expression levels are substantially lower 
than the 40 mg/L  (C-terminal TcdB) reported by Letourneur et al. (2003).  The high 
yield reported by Letourneur and colleagues is most likely attributed to the size of 
the insert expressed (71 kDa), which is ~1/3 of the size of the insert expressed herein, 
generally proteins >60 kDa are difficult to express in E. coli (Bell, 2002; Structural 
Genomics Consortium et al., 2008).   
 
Although the yield and purity of recombinant protein produced in this study was 
comparable to that reported in the literature, purification of the protein required 
multiple re-applications through the Ni-NTA column.  Analysis of the purification 
fractions revealed that protein corresponding to the correct molecular weight was 
being lost in the flow through and wash steps.   The presence of protein in the flow 
through is usually attributed to the protein not binding to the Ni-NTA, either due to 
protein degradation or inaccessibility of the 6x His tag.  The repeated application of 
the flow through, resulted in further binding of the His tagged protein to the Ni ions 
on the columns.  However as this protein is so large (>200 kDa) it may have rendered 
the remaining Ni sites inaccessible resulting in the continued loss of recombinant 
protein in the flow through.  Although the re-purification of the protein appears to be 
tedious, it does provide purer protein through each subsequent passage. 
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As the strains and vectors used for the expression of rTcdA900-2710 and rTcdB547-2366 
are the same, we can conclude that the problems experienced with expression of 
rTcdA900-2710 was associated with this protein alone. 
 
3.6 Conclusion 
This chapter aimed to develop a high yield recombinant expression system for 
rTcdA900-2710 and rTcdB547-2366.  Unsurprisingly, analysis of the sequences identified 
differences in the codon usage patterns of the original genes.  Replacement of these 
codons was possible through de novo synthesis.  With regards to rTcdB547-2366, a high 
yield recombinant expression system was developed; with 8-12 mg/L of protein 
produced displaying 80% purity following colloidal Coomassie staining.  However, 
this was not the case for rTcdA900-2710, with significant optimisation required at every 
stage of the process from transformation, expression to purification.  In spite of such 
optimisations, the yield (1 mg/L) and purity (10% colloidal Coomassie) of protein 
produced rTcdA900-2710 was disappointing.  Subsequent analysis of the sequence was 
unable to definitively identify which, if any, aspects were responsible for the reduced 
yields obtained.  Despite the advancements in recombinant expression technology for 
E. coli, this chapter highlights that the successful expression of genes (particularly 
large genes) is reliant on a number of factors.  Simply altering a presumed key factor 
may not have any bearing on the expression level obtained.  Although there is an 
array of bioinformatic software available for the analysis of gene sequences, the data 
generated must be regarded with caution as it may not necessarily reflect 
experimental outcomes. 
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CHAPTER FOUR 
THE IDENTIFICATION OF 
IMMUNODOMINANT REGIONS OF 
TOXIN A AND TOXIN B 
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4.1 Introduction 
Toxins are the primary virulence factors of many  clostridial diseases (Introduction, 
Section 1.2.4, Table 1.1) and the generation of serum antitoxin immune responses 
following infection has been documented for C. tetani, C. botulinum, C. perfringens, 
C. septicum and C. difficile (Johnson, 1997).  This anti-toxin response can be used as 
an indicator of immunity, a measure of the extent of infection in a population or 
serve as a diagnostic marker.  Studies suggest that individuals who succumb to 
recurrent infections do so as a consequence of being unable to mount a robust toxin 
neutralising, protective antibody response (Johnson et al., 1992; Kelly et al., 1992; 
Kelly, 1996; Johnson, 1997; Kyne et al., 2000; Kyne et al., 2001a; Kyne et al., 
2001b; Johnson, 2009).   
   
Patients infected with C. difficile display an array of symptoms, ranging from 
asymptomatic carriage, moderate, self-limiting diarrhoea to life-threatening 
pseudomembranous colitis (Kyne et al., 2001a).  It is hypothesised that the range of 
symptoms is attributed, in part, to the generation (or lack) of an adequate immune 
response.  It is estimated that 1-3% of the healthy adult population is colonised with 
C. difficile (Kelly and LaMont, 1998), with the number increasing to 7-11% for 
hospital in-patients and 20% following antibiotic usage (McFarland et al., 1989).  
Despite the relatively low level of colonisation recorded in healthy adults, the serum 
IgA and IgG antibodies to toxins A and B have been detectable in approximately 
60% of the population (Viscidi et al., 1983; Johnson et al., 1992; Kelly et al., 1992; 
Warny et al., 1994), with the prevalence of antibodies greater after the age of two 
and falling in the elderly population (Viscidi et al., 1983; Bacon and Fekety Jr, 
1994).   
 
The presence of an antitoxin antibody response may be an indicator of prior exposure 
to toxigenic C. difficile in childhood, or may have occurred as a consequence of 
sub-clinical infection in adults.  The importance of an anamnestic toxin immune 
response has been documented in several studies (Johnson et al., 1992; Warny et al., 
1994; Kyne et al., 2000; Loo et al., 2011), with the inability to generate a robust 
immune response following exposure to C. difficile shown to correlate with the 
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severity and duration of disease and significantly increase the risk of reinfection 
(Aronsson et al., 1983, 1985; Warny et al., 1994).   
 
As can be seen from Figures 4.1 and 4.2 the C. difficile neutralising antibodies 
generated/reported in the literature predominantly target the C-terminal domains of 
each toxin.  It is hypothesised the antibodies block binding of the toxins to the host 
receptor, thus preventing toxin uptake.  The precise regions (epitopes) recognised by 
these antibodies can be linear or conformational and are yet to be fully elucidated.  
Whilst the region of toxin A recognised by PCG-4, has been narrowed down to 
44 amino acids, this is not the case for the majority of other neutralising antibodies.  
The ability to precisely define the regions (epitopes) within toxin A and B which 
bind toxin neutralising antibodies would aid in the development of therapeutics 
(vaccines and antibodies) and diagnostics.  As part of this project the 
immunogenicity of the C-terminal and translocation domain of recombinant toxin A 
and B (as described in Chapter 3), the native toxins and toxoid A were assessed.  
Regions were identified by probing both the full length and protease digests of each 
protein with serum from C. difficile infected patients and with commercially 
available toxin neutralising animal serum derived from horse and goat.  The latter of 
which has been derived from the toxoided culture filtrate of a toxin A and B infected 
C. difficile isolate. 
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Figure 4.1: Location of TcdA antibodies.   
Schematic representation of antibodies currently targeting regions of TcdA.  Numbers represent amino acid position based on C. difficile 630 toxin A (EMBL 
CAJ67494.1). ?; amino acid region unknown. CDA1 is also known as MK3415 and MDX006.   
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Figure 4.2: Location of TcdB antibodies.   
Schematic representation of antibodies currently targeting regions of TcdB. Numbers represent amino acid position based on C. difficile 630 toxin B 
(EMBL CAJ67492.1). ?; amino acid region unknown.  CDB1 is also known as MK6072 and MDX1388. 
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Recombinantly expressed proteins, may be subjected to forms of post-translational 
processes in their new host, which differ from those they would encounter in 
C. difficile and as a consequence could affect their ability to be recognised by 
antibodies stimulated in response to infection (Kyne and Kelly, 1998).  For this 
reason the ability of antisera to recognise both recombinant and native toxins were 
assessed.   
 
In addition, the ability of antisera to recognise formaldehyde inactivated toxins was 
also investigated.  It is highly likely that, in addition to eliminating toxicity, the 
process has also altered their immunogenicity.  Formaldehyde inactivation of toxins, 
such as those produced by C. botulinum, V. cholera, Corynebacterium diptheriae, 
C. tetani and C. difficile, have been employed as a means of generating immunogens 
which can be used as vaccines or to generate antitoxins (Baxter, 2007; Jones et al., 
2008).  The loss of toxicity is a consequence of the formation of cross links between 
amino acids, primarily at lysine residues, altering the structure of the protein (Jones 
et al., 2008).  Given that antibodies recognise linear as well as conformational 
structures, a by-product of the toxoiding process may be the loss of protective 
epitopes.  Although toxoids are reported to be highly immunogenic in terms of total 
antibody titres, studies have shown the level of neutralising antibodies stimulated 
against the toxoid are low as reflected in the level of protection conferred (Fiock, 
1962; Libby and Wilkins, 1982; Siegel, 1988; Nencioni et al., 1991).  This suggests 
the toxoiding process alters the confirmation of the antigen such that, certain 
neutralising epitopes are absent.  Given that toxoids are being considered as potential 
vaccine candidates, this raises issues as to their ability to stimulate a robust 
protective antibody response (Torres et al., 1995; Sougioultzis et al., 2005; 
Greenberg et al., 2012; Siddiqui et al., 2012; Anosova et al., 2013). 
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4.2 Aims and Objectives 
The aim of this chapter is to identify immunodominant regions of toxins A and B 
using toxin neutralising immune sera from animals and sera collected from 
C. difficile infected patients. 
 
The experimental objectives are to: 
1. Optimise the enzymatic digestion conditions for native, toxoided and 
recombinant toxins A and B. 
2. Compare the digestion patterns of native, toxoided and recombinantly produced 
toxin A and toxin B.  
3. Develop a Western blot assay to identify immunogenic toxin regions. 
4. To collect human immune sera from C. difficile infected individuals under an 
ethically approved protocol.   
5. Identify immunogenic toxin fragments recognised by sera from C. difficile 
infected patients and compare the responses to those seen with animal 
neutralising sera. 
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4.3 Materials and Methods 
Unless otherwise stated, all reagents were of molecular biology grade and were 
purchased from Fisher Scientific, UK.  Clostripain, 
N-α-Benzoyl-D-arginine p-nitroanilide hydrochloride (BAPNA) and 
4-Morpholinepropanesulfonic acid sodium salt (MOPS) were purchased from 
Sigma Aldrich, UK.    Native toxin A, toxin B and toxoid A were purchased from 
List Biological Laboratories, Inc. (California, USA).  
 
4.3.1 Human Sera Immune Study 
A research study was designed based on literature searches of peer-reviewed journals 
and in collaboration with Drs. Robin Howe and Lim Jones, from the University 
Hospital of Wales.  Research Ethics Committee (REC), Research and Development 
(R&D) and Site-Specific Information (SSI) forms were completed using the 
Integrated Research Application System (IRAS) 
(https://www.myresearchproject.org.uk/).   
 
4.3.2 in silico Protease Identification 
The protein sequences for C. difficile 630 toxin A (EMBL CAJ67494.1) and toxin B 
(EMBL CAJ67492.1) were obtained from Swiss-Prot/TrEMBL database at the 
ExPASy Molecular Biology Server (http://www.expasy.org).   Protease cleavage 
sites were identified in silico using the PeptideCutter software 
(http://www.expasy.ch/tools/peptidecutter/).  The pI and MW of the predicted 
fragments were estimated with Compute pI/MW Tool 
(http://www.expasy.ch/tools/pi_tool.html).     
 
4.3.3 Clostripain Activation  
Unless otherwise stated, all solutions were prepared in 10 mM MOPS buffer 
(pH 7.4).  Clostripain (226 U/mg) was re-suspended, aliquoted and stored at -20°C.  
BAPNA was re-suspended in 10 mL DMSO.  A working solution of 80 μM was 
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prepared by diluting in MOPS.  Clostripain was activated in MOPS buffer containing 
10 mM CaCl2 and 2.5 mM DTT at 25±0.2°C for 3 hours 
(Techne Dri-Block
® 
DB-3D).  Following activation, 1U of clostripain was added to 
80 μM BAPNA.  The reaction was carried out in cuvettes of 1 cm light-path at room 
temperature.  The formation of p-nitoaniline was monitored as an increase in 
absorbance at OD410 for 20 minutes using an automated spectrometer 
(Helios, Thermo Scientific, UK).  All data was recorded in duplicate with a negative 
control. 
 
4.3.4 Digestion Conditions 
rTcdA900-2710, rTcdB547-2366, TcdA, TcdB or toxoid A (5 µg) were digested with 1U of 
activated clostripain.  All digestions were carried out at 25±0.2°C 
(Techne Dri-Block® DB-3D), for 30 minutes, 2, 4, 24, 36 and 48 hours.  Digestion 
was inhibited with Roche Complete mini protease inhibitor cocktail and samples 
were combined with 2 parts 1x SDS-PAGE buffer.  Controls are listed in Table 4.1. 
Samples were briefly centrifuged (200 g, 10 seconds) and stored at -80°C until 
further use. 
 
Table 4.1: Enzyme digestion controls 
Control Abbreviation 
Inactive enzyme IE 
Active enzyme, 3 hours AE, 3 hours 
Active enzyme, 3 hours plus inhibitor AEI, 3 hours 
Active enzyme, 24 hours, 25°C AE, 24 hours 
Active enzyme, 24 hours, 25°C plus inhibitor AEI, 24 hours 
Undigested protein  
Undigested protein, 24 hours 25°C  
1U (4.4 µL) of enzyme was used in each control, 8.8 µL of inhibitor was added were 
appropriate, all controls were made up to a final volume 38.2 µL with sterile water 
and combined with 2 parts 1x SDS-PAGE buffer. 
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4.3.5 1D SDS-PAGE and Western Blot 
1D SDS-PAGE gels were completed as detailed in Chapter 2, Section 2.3; 
Criterion™ TGX™ Precast Gel (4–20%), were used for all digestion profiles.  
Ten µL of sample was loaded in duplicate.  Markers included 4 µL Bio-Rad 
Precision Protein™ Dual Xtra Standards and Spectra ™ Multicolor High Range 
Protein Ladder (Thermo Scientific, UK).  Gels were double stained as detailed in 
Chapter 2, Section 2.5.  Transfer was completed as detailed in Chapter 2, Section 2.6, 
membranes stained as detailed in Chapter 2, Section 2.7 and Western blot and 
chemiluminescence completed as per Chapter 2, Section 2.8 and 2.9 using the 
antibodies listed in Table 4.2.  Western blot controls included active clostripain 
enzyme and soluble protein extracted and purified from a 3 hour culture of 
M15[pREP4].  M15[pREP4] was cultured and purified as detailed in Chapter 3.  
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Table 4.2: Primary and secondary antibodies used for Western blotting in this study. 
Antibody Species Specificity Source Dilution 
Goat anti-toxin reagent Goat
a
  Neutralisation of C. difficile toxin Techlab
®
, UK 1/25 
C. sordellii anti-toxin Horse
a
  Toxin neutralisation NIBSC 1/25 
C. difficile toxin B Rabbit
a
  N terminal 60 kDa catalytic fragment TcdB from E. coli Abcam, UK 1/500 
C. difficile toxin B Mouse
b
  Full length TcdB Abcam, UK 1/110 
Anti-toxin A Goat
a
 Unknown List Biological Laboratories, Inc. 1/10 
Human sera Human Unknown Clinical samples, this study 1/50 
Αnti-Goat-HRP Rabbit Goat IgG (H+L) Life Technologies, UK 1/10,000 
Αnti-Mouse-HRP Goat Mouse IgG (H+L) Thermo Scientific Pierce, UK 1/10,000 
Αnti-Rabbit-HRP Goat Rabbit IgG (H+L) Thermo Scientific Pierce, UK 1/10,000 
Αnti-Horse-HRP Rabbit Horse IgG (H+L) Abcam, UK 1/10,000 
Anti-Human IgG-HRP Mouse
b
 Human IgG Fc PAN (all subclasses) Stratech, UK 1/4000 
Anti-Human IgA-HRP Mouse
b
 Human IgA heavy chains (all subclasses) Life Technologies, UK 1/2000 
a
 polyclonal, 
b
 monoclonal.  HRP, Horse Radish Peroxidase. H, heavy chain, L, Light chain.  NIBSC, The National Institute for Biological 
Standards and Control. 
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4.3.6 Silver Stain for Mass Spectrometry  
Western blot images captured on the Chemi Doc xrs+ system were aligned and 
common immunoreactive bands identified.  To facilitate mass spectrometric analysis, 
a compatible silver staining method was employed.  Gels were prepared as detailed 
in Section 4.3.5.  For silver staining 250 mL of each solution was prepared just prior 
to use and all incubations were carried out on a Stuart gyro-rocker (Fisher Scientific, 
UK) set at 30 r.p.m. at room temperature.  Following electrophoresis, gels were 
immersed for 30 minutes in fixing solution (10% (v/v) acetic acid, 40% (v/v) 
ethanol) followed by sensitizing solution (30% (v/v) ethanol, 17% (w/v) sodium 
acetate, 10 mL, and 5% (w/v) sodium thiosulfate for 30 minutes.  Gels were washed 
in diH2O for three successive 5 minute washes, incubated in 25 mL of 2.5% (w/v) 
silver nitrate) for 20 minutes, washed twice in diH2O for 1 minute and then 
developed (6.25% (w/v) sodium carbonate, 100 µL, 36% (v/v) formaldehyde) for 5-
10 minutes.  The reaction was stopped with 3.65% (w/v) EDTA and the gel washed 
three times in diH2O for 5 minutes.  Selected bands were subjected to sequencing 
following the method detailed in Chapter 2, Section 2.10.   
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4.4 Results 
4.4.1 The Identification of Potential Protease Cleavage Sites 
in Toxins A and B by in silico Analysis 
The amino acid sequences of toxins A and B of C. difficile strain 630 were obtained 
from the Swiss-Prot/TrEMBL database at the ExPASy Molecular Biology Server, 
and were analysed using PeptideCutter software to identify protease recognition 
sites.  Of the 37 chemicals and proteases listed in the programme, 13 were predicted 
to be unable to digest the toxins.  Those capable of digesting the toxins were 
predicted to generate between 1–1251 fragments.  In order to generate toxin 
digestion patterns which were reproducible and easy to interpret, proteases which 
yielded greater than 50 digestion fragments were discounted, leaving nine possible 
enzymes/chemicals (Table 4.3).  As can be seen from the table the enzyme 
clostripain was predicted to yield the greatest number of digestion fragments from 
both full length and recombinant variants of TcdA and TcdB, and was selected for 
digestion analysis.  
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Table 4.3: in silico digestion of TcdA, toxoid A, rTcdA900-2710, TcdB and rTcdB547-2366.  
Proteases and chemicals predicted to cleave native and recombinant TcdA and TcdB between 1-50 times identified ExPASy PeptideCutter. 
Enzyme / Chemical Specificity TcdA  rTcdA900-2710 TcdB rTcdB547-2366 
Clostripain
a
  and Arg-C proteinase
a
 
Hydrolyzes arginine and lysine bonds 
51 27 50 32 
CNBr
b
 Hydrolyses methionine.  31 18 12 10 
Hydroxylamine
b
 Cleaves asparaginyl-glycine bonds 28 27 17 12 
BNPS-Skatole
b
 
Cleaves tryptophan-containing proteins 
27 21 17 12 
Iodosobenzoic acid
b
 Cleaves tryptophan 27 21 46 30 
NTCB   (20-nitro-5-thiocyanobenzoic acid)
b
 Cleaves cysteine 8 6 10 9 
Caspase1
a
 A number of different cleavage patterns  6 6 2 3 
Proline-endopeptidase [*]
a
 Cleaves proline 5 2 5 4 
Caspase10
a
 Cleavage sites composed of Leu-Gln-Thr-Asp--Gly 0 0 2 0 
Cleavage sites for toxoid A are not reported but are presumed to be the same as those identified for native TcdA. 
a 
enzyme, 
b
 chemical. Leu; leucine, Gln; glutamine, Thr; 
threonine, Asp; asparagine, Gly; glycine. 
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4.4.2 Proteolytic Digestion of Toxin 
On the basis of the in silico analysis the protease clostripain was identified as a 
suitable protease with which to digest both toxins (Tables 4.3).  Activation of 
clostripain was confirmed by the hydrolysis of the substrate BAPNA, resulting in the 
formation of the coloured product p-nitoaniline (Figure 4.3).   
 
Figure 4.3: Activation of clostripain.   
Clostripain (1U) was activated in MOPS buffer containing 10 mM calcium chloride 
and 2.5 mM dithiothreitol for 3 hours at 25±0.2°C.  The hydrolysis of BAPNA, 
resulting in the formation of p-nitoaniline was monitored as an increase in 
absorbance at OD410.  Readings were recorded in duplicate.  Negative control 
included 1U inactive clostripain. 
 
4.4.3 Optimisation of Toxin Digestion  
To generate fragments, toxins were subjected to enzymatic digestion with clostripain 
and a time course analysis conducted (Figures 4.4–4.8).  All digestion gels contained 
the appropriate controls as described in Section 4.3.4; for the sake of clarity, the 
clostripain digestion controls have only been displayed in Figure 4.4.  Due to the 
limited availability of native toxin A and B and toxoid A, stability analysis could 
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only be completed once, digestion analysis was completed in duplicate.  Analysis of 
the clostripain control lanes revealed the presence of multiple bands, which as 
expected were also present in the toxin digestion lanes, making subsequent analysis 
difficult.    
 
4.4.3.1 Time Course Analysis of Toxin A Digestion  
Commercially available native toxin A (List Biological Laboratories, Inc., USA), 
with a reported high purity was found to contain multiple additional bands 
(Figure 4.4, Lane 7), these additional bands are most likely to be carried over from 
the purification process and represent natural toxin breakdown products.  These 
bands were visualised due to the sensitivity of the double staining method employed 
in this research.   The  native toxin A from C. difficile (Figure 4.4) was found to be 
unstable when incubated for 24 hours at 25°C in the absence of clostripain 
(Figure 4.4, Lanes 7, pre-incubation and Lane 8, post incubation), with almost three 
times as many bands detected post-incubation when  analysed  using  Image  Lab™ 
software, v.3.0, with  a  band  detection  sensitivity  of  100.  Following 24 hours 
incubation with clostripain the pixel intensity of the band representing full length 
toxin A (308 kDa) remained unchanged, suggestion that enzyme mediated digestion 
had not occurred.  In an attempt to facilitate clostripain mediated digestion of toxin 
A, the incubation period was increased from 24 hours to 48 hours.  Although a 
greater number of bands were detected following prolonged incubation/digestion 
(indicated by red boxes), unfortunately the pixel intensity of the 308 kDa band 
remained unchanged, suggesting that the additional fragments were either a 
consequence of the inherent instability of the protein or enzyme mediated 
degradation of natural toxin breakdown products.  
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Figure 4.4: Clostripain digestion of TcdA.  
Timed digestion of 5 µg TcdA by 1U activated clostripain, analysed on a 4-20% SDS-PAGE double stained by colloidal Coomassie+silver.  
Controls included, Lane 2, inactive enzyme; Lane 3, active enzyme 3 hours; Lane 4, active enzyme 3 hours+inhibitor; Lane 5, active enzyme 
24 hours, 25°C; Lane 6, active enzyme 24 hours, 25°C+inhibitor; Lane 7, undigested TcdA; Lane 8, undigested TcdA 24 hours, 25°C; 
M,  molecular weight marker in kDa. Digestion times are displayed above gel.  Gels were imaged with the Chemi Doc xrs+ system, under white 
light trans illumination, faint band exposure and analysed using Image Lab™ Software, v.3.0, with a band detection sensitivity of 100.  Pre (lane 
7) and post incubation (lane 8) of TcdA (n=1), timed digestion of TcdA (n=2). Red boxes, digestion bands.  
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Due to the problems encountered in obtaining a high yield of rTcdA900-2710 
(Chapter 3), only a faint band corresponding to the predicted size (205 kDa), was 
observed in the undigested control (Figure 4.5).  Therefore digestion of rTcdA900-2710 
was not pursued further and undigested rTcdA900-2710 was utilised for subsequent 
Western blotting studies. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.5: Purity of rTcdA900-2710.   
Analysis of 5 µg rTcdA900-2710 analysed on a 4-20% SDS-PAGE double stained by 
colloidal Coomassie+silver. M, molecular weight marker in kDa. Imaged with the 
Chemi Doc xrs+ system, under white light trans illumination, faint band exposure 
and analysed using Image Lab™ Software, v.3.0, with a band detection sensitivity of 
100.   
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As with native toxin A, the toxoid A profile was also found to be unstable, with 
multiple bands detected following incubation at 25°C for 24 hours in the absence of 
clostripain (Figure 4.6, Lane 1 and 2).  Analysis of the toxoid A profile was 
complicated by the presence of heavy staining in the high molecular weight region 
(>180 kDa), which is suspected to be due to protein aggregation following the 
toxoiding process.   
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Figure 4.6: Clostripain digestion of toxoid A.   
Timed digestion of 5 µg toxoid A by 1U activated clostripain, analysed on a 4-20% SDS-PAGE double stained by colloidal Coomassie+silver.  
Lane 1, undigested toxoid A; Lane 2, undigested toxoid A incubated for 24 hours, 25°C; M, molecular weight marker in kDa. Digestion times are 
displayed above gel. Gels were imaged with the Chemi Doc xrs+ system, under white light trans illumination, faint band exposure and analysed 
using Image Lab™ Software, v.3.0, with a band detection sensitivity of 100.  Pre (lane 1) and post incubation (lane 2) of toxoid A (n=1), timed 
digestion of toxoid A (n=2). Blue box; stability of toxoid A post 24 hours, 25°C incubation.  
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From the above results, incubation of TcdA and toxoid A in the absence of 
clostripain resulted in degradation of the protein.  However, complete digestion of 
TcdA (and toxoid A) with clostripain was not observed.  Based on the number of 
bands resolved a digestion/incubation time of 48 hours was used for Western blot 
analysis.   
 
4.4.3.2 Time Course Analysis of Toxin B Digestion  
As with native toxin A, the toxin B preparation contained multiple protein bands in 
the pre-incubated, undigested sample (Figure 4.7A, Lane 1).  Comparison of native, 
undigested TcdB pre and post incubation at 25°C for 24 hours using Image Lab™ 
Software, v.3.0 (band detection sensitivity of 100), revealed the same number of 
bands (n=29), suggesting that unlike native toxin A, toxin B was stable under these 
conditions (Figure 4.7).  A similar lack of enzyme independent degradation was also 
observed with rTcdB547-2366.  Both the native and recombinant TcdB were susceptible 
to clostripain induced digestion, with 30 minutes identified as the optimum 
incubation period.  Prolonged digestion (24 hours) resulted in a 50% reduction in the 
total number of bands resolved. 
 
For rTcdB547-2366, the gross digestion profiles at 30 minutes appeared to be similar to 
that of native TcdB, with common bands detected at 100, 70, and 25-37 kDa.  A 
cluster of high molecular weight bands (130-180 kDa) were detected in TcdB 
digestion but were absent from rTcdB547-2366.   
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Figure 4.7: Clostripain digestion of TcdB and rTcdB547-2366.   
Timed digestion of 5 µg A) TcdB and B) rTcdB547-2366 by 1U activated clostripain, analysed on a 4–20% SDS-PAGE gel, double stained by 
colloidal Coomassie+silver.  Lane 1, undigested protein, Lane 2, undigested protein incubated for 24 hours at 25°C; M, molecular weight marker 
in kDa. Digestion times are displayed above gel. Gels were imaged with the Chemi Doc xrs+ system, under white light trans illumination, faint 
band exposure and analysed using Image Lab™ Software, v.3.0, with a band detection sensitivity of 100.  Pre (lane 1) and post incubation 
(lane 2) of TcdB and rTcdB (n=1), timed digestion of TcdB and rTcdB (n=2). Blue boxes; stability of TcdB and rTcdB546-2366 post 24 hours, 
25°C incubation, Red boxes indicate digestion bands. Solid arrows; 270 and 206 kDa TcdB and rTcdB546-2366, respectively, dashed arrows 
clostripain heavy and light chain.   
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The results for the toxin B preparations were in contrast with the results for the toxin 
A preparations, with native and recombinant toxin B stable pre and post incubation 
and an optimum digestion time of 30 minutes.  From the above data set, the 
digestions profiles of the various toxin preparations, revealed that the number of 
observable digested fragments were lower than the number predicted by the 
PeptideCutter software.  Closer inspection of the predicted fragments revealed that 
16 and 17 fragments in TcdA and TcdB would have a molecular mass of <2 kDa, 
thus they may not be resolved on the SDS-PAGE gel.  In addition the method 
employed would be unable to distinguish between multiple bands with the same (or 
similar) molecular weights (Appendix 1). 
 
4.4.3.3 Toxin Digestion – 2D SDS-PAGE 
Whilst a 1D gel is a useful tool with which to determine if the various proteins have 
undergone proteolytic degradation, it lacks the discrimination provided by a 2D gel 
based method, which separates fragments on the basis of both pI and size.  To further 
identify clostripain derived protein spots which would also be present in the 
proteolytic digestion, activated clostripain was incubated at 25°C for 48 hours, 
treated with a protease inhibitor cocktail and then subjected to 2D SDS-PAGE.  As 
can been seen from Figure 4.8, in addition to the heavy and light chains the 
clostripain preparation contained multiple protein spots.   
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Figure 4.8: 2D SDS-PAGE of clostripain control.   
1U of active clostripain was subjected to IEF and resolved on a 4–20% SDS-PAGE 
gel, double stained with colloidal Coomassie+silver.  Molecular weight marker in 
kDa.  Gels were imaged with the Chemi Doc xrs+ system, under white light trans 
illumination, faint band exposure and analysed using Image Lab™ Software, v.3.0. 
Yellow boxes indicate predicted position of the heavy and light chains of clostripain 
(n=2).  
 
As expected, the clostripain-digested toxin A 2D SDS-PAGE profile (Figure 4.9), 
revealed the presence of clostripain derived proteins, particularly the heavy and light 
chains of clostripain (indicated by yellow box).  In addition to this the toxin A profile 
revealed multiple toxin derived proteins which were absent from the clostripain 
control, these protein spots spanned a pH range of 3-11 and a molecular weight of 
2-100 kDa.  This analysis emphasised the discriminatory power of 2D SDS-PAGE 
with multiple proteins of the same molecular weight evident.    
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Figure 4.9: 2D SDS-PAGE of clostripain digested TcdA.   
10 µg of digested TcdA was subjected to IEF and resolved on a 4–20% SDS-PAGE 
gel, double stained with colloidal Coomassie+silver.  Molecular weight marker in 
kDa.  Gels were imaged with the Chemi Doc xrs+ system, under white light trans 
illumination, faint band exposure and analysed using Image Lab™ Software, v.3.0. 
Red and blue boxes, indicate differences and similarities between TcdA and 
toxoid A, respectively.  Yellow boxes indicate heavy and light chains of clostripain.  
Green box indicates predicted position of TcdA, 308 kDa, pH 5.5 (n=1).  
 
The 1D toxin A digestion profiles indicated enzyme mediated digestion had not 
occurred, with a 308 kDa band still visible, it was therefore anticipated that protein 
spots of this molecular weight, at a pH of 5.5, would also be present in the 
2D SDS-PAGE profile.  As can be seen from Figure 4.9 this was not the case, it has 
previously been reported that 2D SDS-PAGE poorly resolves proteins >150 kDa 
(Mukherjee et al., 2002).  This reasoning cannot be applied here as subsequent 
analysis of toxoid A resolved proteins >300 kDa (Figure 4.10).  Although faint spots 
(green box) can be observed at the indicated molecular weight and pH, it is unclear 
whether these represent undigested toxin A or are an artefact of staining.  
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Alternatively the absence of the 308 kDa toxin A protein spot may highlight the 
instability of the toxin.  In order to complete the first dimension of 2D SDS-PAGE, 
IPG strips were rehydrated overnight at room temperature (20°C) with the digested 
samples.  Thus, toxin A was theoretically incubated for ~60 hours (48 hours for 
digestion and ~12 hours for rehydration), whether this prolonged incubation was 
sufficient for complete digestion of toxin A is unclear.   As it was not possible to 
either repeat the 2D SDS-PAGE profile or incubate toxin A for greater than 48 hours, 
the absence and indeed the stability of toxin A cannot be definitively addressed.        
 
In contrast to the toxin A profile, in the toxoid A digested profile, multiple protein 
spots were visible at >250 kDa (green box), demonstrating that proteins >150 kDa 
can be resolved by 2D SDS-PAGE.  If indeed the extended incubation condition has 
resulted in the degradation of toxin A, the presence of toxoid A in the 2D profile 
suggests the toxoiding process may have conferred stability to the protein (Salnikova 
et al., 2008), although it is important to note that from the 1D SDS-PAGE (Figure 
4.6) profile toxoid A was also found to be display instability under the incubation 
conditions employed.   
 
As with toxin A, clostripain derived proteins (yellow boxes) were evident in the 
toxoid A digestion profile (Figure 4.10).  The overall spot patterns for clostripain 
digested toxin A (Figure 4.9) and toxoid A (Figure 4.10) were broadly similar, with 
protein spots ranging from pH 3-11.  A cluster of protein spots at pH 8.5 were absent 
from the toxoid digest but were present in the native digestion (indicated by the red 
box in Figure 4.9).  Whilst at a pH of 7.0 a number of spots which were absent from 
the toxin A digest were present in the toxoid digest (indicated by the red box in 
Figure 4.10).   The differences between the digestion patterns of TcdA and toxoid A 
may be indicative of the toxoiding process, causing structural changes in the toxin 
which masks proteolytic digestion sites and hence susceptibility to enzyme mediated 
digestion.   
 
 124 
 
 
 
 
 
 
 
 
 
 
Figure 4.10: 2D SDS-PAGE of clostripain digested toxoid A.   
10 µg of digested toxoid A was subjected to IEF and resolved on a 4–20% 
SDS-PAGE gel, double stained with colloidal Coomassie+silver.  Molecular weight 
marker in kDa.  Gels were imaged with the Chemi Doc xrs+ system, under white 
light trans illumination, faint band exposure and analysed using Image Lab™ 
Software, v.3.0. Red and blue boxes indicate differences and similarities between 
TcdA and toxoid A, respectively.  Yellow boxes indicate heavy and light chains of 
clostripain. (n=1). 
 
From the toxin digested profiles (Figures 4.9 and 4.10) the visual intensity of 
clostripain heavy and light chains were of lower intensity than that observed in 
clostripain control (Figure 4.8), it is possible that this is due to staining variation, 
wherein the clostripain control contains fewer proteins resulting in a greater 
proportion of Coomassie and silver ions binding to the protein and subsequently 
being detected.  In contrast the toxin digestion profiles were composed of a greater 
number of proteins at a range of concentrations, hence staining variability may occur.   
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Due to the previously mentioned problems associated with rTcdA900-2710 purification 
and subsequent digestion, 2D SDS-PAGE analysis of recombinant toxin A was not 
pursued.
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Comparison of the clostripain digestion profiles of native (Figure 4.11A) and 
recombinant toxin B (Figure 4.11B) profiles revealed them to be remarkably similar, 
with the majority of protein spots being acidic in nature.  The native profile does 
appear to contain regions which are absent from the recombinant profile 
(indicated by red boxes), this is unsurprising given the recombinant protein lacks the 
N-terminus.   
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Figure 4.11: 2D SDS-PAGE of clostripain digested TcdB and rTcdB546-2366.   
A) TcdB and B) rTcdB546-2366. 10 µg of digested protein was subjected to IEF and 
resolved on a 4–20% SDS-PAGE gel, double stained with colloidal 
Coomassie+silver.  Molecular weight marker in kDa.  Gels were imaged with the 
Chemi Doc xrs+ system, under white light trans illumination, faint band exposure 
and analysed using Image Lab™ Software, v.3.0.  Red boxes indicate differences 
between TcdB and rTcdB546-2366. Yellow boxes indicate heavy and light chain of 
clostripain enzyme. (n=1).   
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Due to limited availability of the native and toxoided proteins, the concentration of 
protein resolved by 2D SDS-PAGE was only 10 µg; which is half the manufacturer’s 
recommended concentration (20-50 µg).  Hence, it is possible that by using such a 
low concentration of protein, a complete peptide profile was not obtained.  Due to a 
lack of reagents the repeatability of the 2D SDS-PAGE method could not be verified 
and as such 2D SDS-PAGE was completed only once 
 
In contrast to the 1D SDS-PAGE approach, the 2D approach provided better 
discrimination of the peptides in the sample, due to its ability to resolve proteins on 
the basis of molecular weight and pH.  The 2D approach also further highlighted 
potential stability issues regarding toxin A.  It was not possible to utilise the 
2D SDS-PAGE approach for subsequent analysis, therefore a 1D approach combined 
with Western blotting, which has a greater sensitivity than either colloidal Coomassie 
or silver staining was employed. 
 
4.4.4 Toxin B Immunoblots  
4.4.4.1 Probing With Animal Immune Serum  
The ability of two commercially available antibodies, a mouse monoclonal 
(binding site unknown) and a rabbit polyclonal antibody raised against the 60 kDa 
N-terminal fragment of toxin B, to recognise native and recombinant toxin B was 
assessed.  As can be seen in Figure 4.12A, the mouse monoclonal antibody 
recognised multiple bands in the digested and undigested TcdB samples.  The ability 
of this murine monoclonal antibody to recognise rTcdB547-2366, suggests that the 
epitope to which this antibody binds is located within the translocation and receptor 
binding domain (amino acid residues 547-2366) of toxin B.  The binding of the 
antibody to a fragment of approximately 50 kDa suggests that it might be possible to 
further define the site recognised by this antibody.  
 
From Figure 4.12B, the polyclonal rabbit antibody bound to multiple fragments in 
the undigested sample of the native toxin suggesting that the protein had undergone 
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non-enzymatic degradation, possibly during the purification process.  It was 
somewhat surprising that the bands detected in the digested sample did not 
correspond to the bands detected in the intact sample; possibly due to the destruction 
of epitope binding sites following enzymatic digestion.  
 
Given that the polyclonal antibody is directed against the 60 kDa N-terminal region 
of toxin B, the presence of antibody binding fragments in lanes containing 
rTcdB547-2366, (which is devoid of the catalytic domain) was surprising.  Sequence 
alignment of the 60 kDa N-terminal region and rTcdB547-2366 revealed a 5% identity 
and 10% similarity (calculated using http://www.bioinformatics.org) based on 
sequence data for C. difficile 630.  The polyclonal antisera was produced from a 
recombinant GST-fused 60 kDa protein expressed in E. coli (Abcam, UK, personal 
communication), hence it is possible that the bands observed in the recombinant 
toxin are due to cross-reacting host derived antibodies.  The suppliers (Abcam, UK) 
of the antisera were unable to provide details on the antibody binding site, but did 
specify the fragment used to generate the antibody displayed Rho and Rac 
glycosylation activity (Abcam, UK, personal communication).  Hence, the fragment 
must, at the very least, span from amino acid residues 1–547, in order to encompass 
the amino acid residues and motifs, which are essential for enzymatic activity (Busch 
et al., 1998; Busch and Aktories, 2000; Voth and Ballard, 2005; Jank et al., 2007; 
Jank and Aktories, 2008).   
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A)                                                             B)  
 
 
 
 
 
 
 
 
 
 
 
Figure 4.12: 1D Western blot of clostripain digested TcdB and rTcdB547-2366 
probed with Ms mAb and Rb pAb.   
A) Mouse mAb and B) Rabbit pAb.  30 minute digestion of 5 µg of TcdB and 
rTcdB547-2366 by 1U activated clostripain, analysed on a 4–20% SDS-PAGE gel and 
transferred to nitrocellulose.  Molecular weight marker in kDa. Blue boxes; 207 and 
270 kDa rTcdB547-2366 and TcdB, Red boxes; region of commonality. 
 
In the above experiment the ability of two commercially available antibodies to react 
with native and recombinant toxin B was assessed and there approximate binding 
sites identified.  This approach confirmed the suitability of the recombinant protein 
as a surrogate for immunogenic studies, with the monoclonal antibody reacting with 
undigested rTcdB547-2366.  The presence of multiple immunogenic bands in the intact 
native toxin suggests degradation of toxin B, possibly during the purification process.  
Furthermore to assess the presence of cross-reacting antibodies from the host 
expression system, nickel purified soluble protein from the E. coli expression strain, 
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M15[pREP4], was used as an additional control in the subsequent neutralising and 
human sera immunoblots. 
 
4.4.4.2 Probing with Commercial Serum Containing Toxin 
Neutralising Antibodies  
In an attempt to identify toxin protein fragments which contain toxin neutralising 
antibody binding sites, native and recombinant protein digests were probed with two 
commercially available toxin neutralising polyclonal antibody preparations; sordellii 
antitoxin (NIBSC, UK) and goat antitoxin (Techlab®, UK).  The sordellii antiserum 
was prepared from equine immune serum against C. sordellii (NIBSC, UK) and the 
goat antitoxin was prepared from toxoided culture filtrate of C. difficile VPI10463.   
Although, these preparations have been widely used (primarily in cell culture 
diagnostic assays) (Bartlett et al., 1978; Chang et al., 1978b), the regions of each 
toxin recognised by each serum has yet to be determined.   
 
Somewhat surprisingly a fragment of ~37 kDa in the clostripain enzyme was 
recognised by both sera, given its relative size it is likely to represent the heavy chain 
of the enzyme (Figure 4.13).  Sequence alignment of the heavy chain of clostripain, 
with native and recombinant toxin A and B revealed a low sequence identity of 
<16% based on sequence data for C. difficile 630.  Given that Clostridium spp. are 
ubiquitously found it is possible that the animal(s) used to generate the antisera (goat 
and horse), were previously exposed to C. histolyticum and as such possessed anti-
clostripain antibodies.  Alternatively the toxoided culture filtrate used for the 
generation of both anti-sera may contain additional proteases, from C. difficile and 
C. sordellii which are similar to clostripain.  Fortunately on the basis of size 
comparison this band did not overlap with the common immunogenic fragments seen 
in any of the toxin preparations.   
 
To verify the bands identified in the recombinant preparations were not host (E. coli) 
derived, soluble protein was extracted from the E. coli expression strain, 
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M15[pREP4], used in Chapter 3.   Whilst no cross-reactivity was observed with the 
goat antitoxin, three bands where identified with the sordellii sera suggesting that this 
sera contained cross-reacting E. coli antibodies. 
Probing of the native and recombinant toxin B preparations with the goat and 
sordellii antisera revealed a broadly similar immuno-profile, with both antisera 
recognising the intact proteins.  Of note is the presence of a 270 kDa band 
corresponding to intact toxin B in the digestion lane.  From the digestion profile of 
toxin B (Figure 4.7B) enzyme mediated digestion occurred within 30 minutes, 
however with the more sensitive Western blot approach the presence of a 270 kDa 
band in the digestion lane suggests complete digestion has not occurred.  A cluster of 
bands ranging from 75-270 kDa was detected by both immune sera in the intact and 
digested protein.  Lower molecular weight common immunogenic bands are 
indicated by the red boxes in Figure 4.13. 
 
The immuno-profiles for digested rTcdB547-2366 were remarkably similar, with neither 
antitoxin detecting bands >75 kDa in each digested sample.  A group of bands 
between 30-75 kDa were recognised with both antitoxins, with two particularly 
dominant bands at 40 and 60 kDa suggesting the possible location of 
immunodominant epitopes.  Although it should be noted the in silico analysis did not 
predict fragments of these molecular weights (Appendix 1).   
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Figure 4.13: 1D Western blot of clostripain digested TcdB and rTcdB547-2366 probed with neutralising anti-toxin.   
A) Goat anti-toxin B) Sordellii anti-toxin.  30 minute digestion of 5 µg of protein with 1U activated clostripain, analysed on a 4-20% SDS-PAGE 
gel and transferred to nitrocellulose. Clostripain enzyme control, M15[pREP4] Ni purified soluble control. Red boxes indicate commonly 
recognised fragments.  Yellow boxes indicate predicted heavy chain of clostripain enzyme. 
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In summary both antisera recognised distinct fragments of both native and 
recombinant toxin B preparations. The fact that there were common bands in the 
recombinant and native proteins suggests that they share the same/similar epitopes 
and the recombinant protein can be utilised in the future as a surrogate for native 
toxin B.  The generation of smaller fragments, 30-75 kDa, which were recognised by 
the antisera, gives the potential to map the location of antibody binding sites, some of 
which may be neutralising.  Given that these sera are used as commercial controls   
for the majority of cytotoxicity assays, more work needs to be done to determine the 
basis of their action. 
 
Analysis was complicated by the immunogenicity of the clostripain heavy chain, 
although the similarity of this protein with the toxin preparations was low, it is 
evident that cross-reacting antibodies are present in the goat and sordellii sera.  The 
presence of immunogenic bands in the E. coli extracted proteins with the sordellii 
sera further complicated analysis of the recombinant protein.  Whether these two 
results are an indicator of natural exposure to C. histolyticum and E. coli in the 
animals used to generate the antisera is unclear.   
 
4.4.5 Toxin A Immunoblots  
4.4.5.1 Probing With Animal Immune Serum 
As with toxin B, initial efforts focussed on probing blots with non-neutralising 
animal derived antibodies.  It was not possible to determine how the goat polyclonal 
antibody was produced; the rabbit polyclonal antibody recognises a 60 kDa 
N-terminal fragment of toxin B.  The goat polyclonal antibody recognised a 
multitude of bands in all toxin A preparations, highlighting particularly the impurity 
of the commercially available native and toxoided toxin A preparations.  As this 
antibody was found to bind to the 205 kDa recombinant protein, its binding site may 
well reside within the translocation and C-terminal region.  Although the presence of 
multiple protein bands in the intact recombinant toxin A, confirms the impurity of  
the recombinant protein, the immunogenic bands may well represent truncated or 
degraded toxin. 
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The rabbit pAb, which was raised against the N-terminal catalytic fragment of TcdB 
(Figure 4.14B), was found to cross react with native and toxoid A preparation.  This 
is not surprising, given that it is in this region that TcdA and TcdB display a 64% 
homology (von Eichel-Streiber et al., 1990).  Although it should be noted the 
antibody reacted weakly with TcdA and toxoid A.  A band of ~20 kDa was observed 
in all the preparations, indicating the binding site for at least one of the antibodies in 
this polyclonal preparation is within this region (indicated by the red box).   
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.14: 1D Western blot of clostripain digestion of TcdA and toxoid A an 
intact rTcdA900-2710, probed with Gt pAb and Rb pAb. 
A) Goat pAb and B) Rabbit pAb.  30 minute digestion of 5 µg protein by 1U 
activated clostripain, analysed on a 4–20% SDS-PAGE gel and transferred to 
nitrocellulose. M, Molecular weight marker in kDa.  Blue boxes indicate 205 and 
308 kDa full length rTcdA900-2710 and TcdA respectively. Red box region of 
commonality.    
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4.4.5.2 Probing with Commercial Serum Containing Toxin 
Neutralising Antibodies 
The ability of the two neutralising polyclonal antisera (goat and sordellii) to 
recognise toxin A preparations is displayed in Figures 4.15A and B, respectively.  
Both the goat and sordellii antisera reacted with intact rTcdA900-2710, indicating the 
epitopes (and possible neutralising epitopes) recognised, by at least one of the 
antibodies in these polyclonal sera resides between amino acid residues 900–2710.  
 
The digestion profiles of native TcdA and toxoid A were similar to their respective 
intact toxin profiles suggesting enzymatic digestion had not destroyed common 
epitopes.  Although regions of commonality are present between native and toxoided 
toxin A, multiple immunogenic bands (100-250 kDa) can be observed in the native 
TcdA profile, which are absent in the toxoid profile.  Whether this is a consequence 
of the toxoiding process, wherein common immunogenic epitopes have been 
destroyed, or highlights the instability of native toxin A preparations is unclear.  In 
all three toxin preparations (recombinant, native and toxoided) a band of 60 kDa was 
detected by the goat antisera.   Although a band of ~40 kDa is present in the digested 
native and toxoid lanes, it is unclear whether this is derived from the toxin or the 
clostripain enzyme.   
 
As with the goat antisera, the sordellii antisera recognised intact recombinant, native 
and toxoid A.  In contrast to the goat antitoxin, the sordellii antisera recognised a 
limited number of fragments in the native and toxoided profiles.  It has not been 
possible to decipher the exact methodology used to prepare the sordellii antisera, 
other than it was generated from the culture filtrate of C. sordellii.  The strain of 
C. sordellii used and hence which toxins and the concentration of these toxins in the 
preparation is unknown.  If the predominant toxin in the preparation was the lethal 
toxin, which displays a 75% amino acid sequence similarity with TcdB and 41% 
sequence similarity TcdA (Rupnik and Just, 2006), this would account for the limited 
immunogenicity observed with toxin A.  Although fewer bands were identified with 
the sordellii serum than the goat serum, when the two blots were overlaid, the bands 
correlated with those identified with the goat antitoxin, suggesting that both sera 
recognised a spectrum of similar epitopes.  
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Figure 4.15: Western blot of clostripain digestion of rTcdA900-2710, TcdA and toxoid A.   
A) Goat antitoxin and B) Sordellii antitoxin.  48 hour digestion of 5 µg of TcdA and toxoid A by 1U activated clostripain, analysed by 
SDS-PAGE on a 4-20% gel and transferred onto nitrocellulose.  Blue boxes indicate 205 and 308 kDa full length rTcdA900-2710 and TcdA, 
respectively. Red boxes indicate regions of commonality. 
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In summary both antisera recognised intact recombinant, native and toxoided toxin A 
preparations indicating that the antisera recognise similar spectrum of epitopes.  The 
identification of 60 and 40 kDa fragments, gives the potential to map the location of 
antibody binding sites, some of which may be neutralising.  The differences observed 
in the immunogenicity of native toxin A and B with the sordellii antisera may be 
associated with preparation of the antisera and hence would be related to the 
homology across the large clostridial cytotoxin family.   
 
4.4.6 Human Sera Immune Study 
To characterise the immune response of infected individuals to toxins A and B, blood 
samples were collected from C. difficile infected patients.  Data obtained in 2008 for 
patients admitted to the University Hospital of Wales, Cardiff, revealed that a total of 
1185 individuals were diagnosed as C. difficile infected, based on an 
Enzyme-Linked Immunosorbent Assay (Personal communication, Dr Robin Howe).  
A significant proportion of these patients were in the Internal/General Medicine 
(40%) and Nephrology/Renal Medicine specialities (11%), with a modal age range of 
80-95 years.  On the basis of this historical data, these specialties were deemed 
appropriate for patient recruitment for this study.   
 
The research proposal and study documents (case report form, patient information 
sheet and consent form) can be found in Appendix 2; the study was designed to 
recruit 100 patients from the Medical and/or Renal wards, 80 C. difficile infected and 
20 C. difficile negative, control patients.  Blood samples were to be collected at 
infected diagnosis of C. difficile and 21 days after infected diagnosis for a single 
episode of CDI.  For recurrent/relapse CDI a total of four serum samples were to be 
requested and a single sample for C. difficile negative control patients.  Controls 
were to be ward, aged and gender matched. 
 
This project was subjected to ethical review by the Dyfed Powys Research Ethics 
Committee, the Cardiff and Vale University Health Board and the School of 
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Pharmacy and Pharmaceutical Sciences Ethics Committee and received approval 
in February 2011, with recruitment commencing in August 2011.  
 
Due to the time taken to obtain ethical approval, it was only possible to collect six 
serum samples at a single time point, following diagnosis.  No negative samples were 
collected.  All serum samples were anonymised and unblinding of clinical data 
(Table 4.4) occurred following analysis of all experimental data.  The average age of 
the patients was 67 years (range 48 to 89 years).  Two of the patients reported a 
history of CDI and had experienced multiple episodes of infection.  The severity of 
CDI ranged from mild (3 patients) to moderate (2 patients) and severe (1 patient).  
On average, serum samples were collected 6 days after diagnosis (range 1-15 days).  
 
As part of the current study clinical data from C. difficile infected patients was also 
collected, in other studies similar parameters have been used to assess disease 
severity and outcome (Walk et al., 2012; Butt et al., 2013; Walker et al., 2013).  In 
these aforementioned studies clinical data from >200 cases of CDI were investigated.  
Due to the limited number of samples collected in this study, it was not possible to 
draw any significant conclusions with regards to the clinical data collected.  
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Table 4.4: C. difficile infected patient sera, clinical data.   
Sample Age Gender Date of 
Admission 
to ward 
Date of 
Infected 
Stool 
Date serum 
sample 
obtained 
Severity WBC Serum 
Creatine 
Albumin History of 
C. difficile 
Major co-
morbidities 
CD1 89 Male 01/08/2011 01/08/2011 16/08/2011 Mild 11 93 22 None Rheumatoid 
arthritis 
CD2 43 Female 26/08/2011 31/08/2011 01/09/2011 Mild 12.6 46 24 None Legionella 
pneumonia 
CD3 68 Female 05/10/2011 06/10/2011 Unknown  Moderate 13.3 49 14 5 previous 
infecteds  
None 
documented 
CD4 81 Male 16/09/2011 30/09/2011 07/10/2011 Mild 8.4 181 
(chronic 
elevation) 
15 None Colon 
cancer 
CD5 75 Male 05/10/2011 17/10/2011 20/10/2011 Moderate 6.8 198 
(chronic 
elevation) 
Not 
recorded 
None Aortic valve 
replacement, 
Urostomy 
CD6 48 Female 17/10/2011 16/10/2011 20/10/2011 Severe 16 318 Not 
recorded 
4 previous 
infecteds 
Renal 
transplant 
All sera were anonymised until analysis of experimental data.   
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4.4.7 Probing of Toxin B with C. difficile Infected Immune 
Sera  
To identify antibody specific binding sites within toxin B, intact and clostripain 
digested recombinant and native toxin B were probed with serum from four patients; 
CD1,CD3,CD5 and CD6.  Due to a limited amount of CD2 sera, this sample was 
omitted from all subsequent analysis.  Sera CD4 was found to display a red 
discolouration, indicating leakage of haemoglobin from the red blood cells due to 
haemolysis, possibly due to improper separation and was not used in subsequent 
analysis. 
 
4.4.7.1 Toxin B Specific IgG Response 
Surprisingly the sera of two patients (CD3 and CD6) recognised an immunogenic 
band in the clostripain control, on the basis of size; this is most likely to represent the 
42 kDa heavy chain of the enzyme (Figure 4.16).  Given the limited number of C. 
histolyticum infections in humans (Health Protection Agency, 2003), the presence of 
anti-clostripain antibodies is intriguing.  Given the numerous antigens the human 
immune system is exposed to the presence of cross-reacting epitope(s) which are 
structurally similar to other antigens is feasible.   Particularly as the human sera 
consists of polyclonal antibodies capable of recognising multiple epitopes. 
 
In contrast, a single band was recognised in the E. coli protein control by only one 
serum sample (CD3), suggesting that the majority of the immunogenic bands seen in 
the recombinant profile preparation represent toxin fragments as opposed to 
co-purified host derived proteins from the expression system.   
    
Whilst all of the patient sera tested contained IgG antibodies that recognised intact 
TcdB, only two individuals had antibodies which recognised intact rTcdB547-2366 
(CD3 and CD6), suggesting that the majority of the immune response maybe directed 
towards the N-terminal region of the toxin (Figure 4.16).  It has recently been shown, 
strains of C. difficile display antigenically variable C-terminal domains of TcdB 
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(Lanis et al., 2013).  In this study the recombinant protein was produced from 
C. difficile 630 (ribotype 012), therefore if patient sera CD1 and CD5 were infected 
with, for example C. difficile 027, the antibodies generated against toxin B in these 
individuals may not recognise the recombinant protein.   
 
Sera from CD1 and CD5 displayed a limited ability to recognise digested TcdB; 
unsurprisingly these two sera also displayed the lowest binding intensity (based on 
visual observation of blots) for intact TcdB.  This suggests that the two sera contain a 
low concentration of antitoxin B IgG antibodies.  Indeed, the variability of 
toxin-specific antibodies in clinical sera is well documented (Kelly et al., 1992; 
Kelly, 1996; Kyne et al., 2000, 2001b).   
 
In addition to highlighting the variability in the immune response against the toxin 
preparations, Figure 4.16 also identified fragments at 80, 60, 40 and 25 kDa, which 
were consistently identified in both TcdB and rTcdB547-2366 preparations by multiple 
sera (indicated by red boxes).  Thus, indicating the presence of immunodominant 
regions within the 270 kDa toxin, whether these regions contain neutralising epitopes 
or can be utilised in diagnostic assays for assessing the immune response generated 
against the toxins is yet to be determined. 
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Figure 4.16: IgG specific response of clostripain digested rTcdB547-2366 and TcdB with human sera.   
30 minute digestion of 5 µg of protein by 1U activated clostripain, analysed by SDS-PAGE on a 4–20% gel and transferred to nitrocellulose and 
detected with SuperSignal Femto. Molecular weight marker in kDa.  Blue boxes indicate 207 and 280 kDa full length rTcdB546-2366 and TcdB, 
respectively. Red boxes indicate commonly recognised fragments. 
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4.4.7.2 Toxin B IgA Specific Response 
From visual observations, the two sera which displayed the strongest IgG responses 
were also the only sera to display an IgA toxin B specific response (Figure 4.17).  
For rTcdB547-2366, immunoreactive bands were seen between 25-75 kDa, in addition 
to these bands immunoreactive bands >75kDa were also observed for TcdB 
(Figure 4.17).   
 
 
 
 
 
 
 
 
 
 
Figure 4.17: IgA specific response of clostripain digested rTcdB547-2366 and TcdB 
with human sera.  
30 minute digestion of 5 µg of protein by 1U activated clostripain, analysed by 
SDS-PAGE on a 4–20% gel and transferred to nitrocellulose and detected with 
SuperSignal Femto. Molecular weight marker, kDa.  Blue boxes indicate 207 and 
280 kDa full length rTcdB546-2366 and TcdB, respectively. Red boxes indicate 
commonly recognised fragments. 
 
The human sera recognised multiple immunogenic bands in the toxin B preparations.  
The cluster of bands (37-75 kDa) identified by the human sera resembled the bands 
identified by the goat and sordellii antitoxins (Figure 4.13).  The cross-reactivity with 
clostripain and E. coli derived host protein(s) further complicated the analysis.  
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4.4.8 Probing of Toxin A with C. difficile Infected Immune 
Sera  
As was the case for toxin B, a wide variation in the toxin A protein fragments which 
were recognised by immune serum from different patients was observed.  The ability 
of IgG and IgA antibodies from C. difficile infected patients to recognise toxin A, 
toxoid A and rTcdA900-2710 are shown in Figure 4.18 and 4.19, respectively. 
 
4.4.8.1 Toxin A Specific IgG Response 
All serum samples contained IgG antibodies which were able to recognise intact 
TcdA (Figure 4.9, blue boxes).  For digested TcdA, the immune response was 
predominantly centralised in the high molecular weight region (>37 kDa), with sera 
CD5 and CD6 displaying the weakest IgG response against digested TcdA, both in 
the number and visual intensity of the fragments identified.  All patient sera 
identified a fragment with an apparent molecular weight of 40 kDa.  Regions of 100, 
75 and 60 kDa were also found to be immunogenic at varying intensities 
(Figure 4.9, red boxes).   
 
The overall IgG response to rTcdA900-2710 was found to be consistent across all four 
patient sera, with a cluster of high intensity bands identified between 30-100 kDa 
(particularly for CD5 and CD6).  An IgG specific response to intact toxoid A was 
only evident for sera CD1 and CD3.   This suggests that the ability of patients to 
recognise the toxoid will be variable.  
 
Despite the significant amount of variation between the serum samples, these results 
suggest the presence of common immunogenic regions, amongst all three toxin A 
preparations.  A 40 kDa fragment of toxin A was detected in all of the samples, to a 
varying degree.  Given its close proximity to the predicted molecular weight of the 
heavy chain of clostripain (42 kDa), it cannot be ruled out that this immunogenic 
band is enzyme derived.  Although its presence in the intact undigested toxin A 
preparation does suggest that it represents a toxin derived fragment.  
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Figure 4.18: IgG specific response of clostripain digested TcdA and toxoid A and intact rTcdA900-2710, probed with human sera.   
48 hour digestion of 5 µg of protein by 1U activated clostripain, analysed on a 4–20% SDS-PAGE gel, transferred to nitrocellulose and detected with 
SuperSignal Femto. Red boxes indicate regions of commonality. Blue boxes indicate 205 and 308 kDa full length rTcdA900-2710 and TcdA, respectively.  
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4.4.8.2 Toxin A Specific IgA Response 
Overall, the pattern of the IgA responses (Figure 4.19) were similar to those seen 
with IgG response, although there was a reduction in the number of bands detected in 
the rTcdA900-2710 preparation  
 
Whilst all patient sera contained IgG antibodies which recognised intact TcdA, only 
two serum samples contained IgA antibodies with specificity for the intact toxin.  
Only serum CD3 displayed an IgA response against intact toxoid A.  As with IgG, a 
fragment of 40 kDa was consistently observed in each of the toxin A preparations by 
all of the patient sera.  This corresponds with the 40 kDa fragments detected with the 
goat and sordellii antitoxin (Figure 4.13). 
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Figure 4.19: IgA specific response of clostripain TcdA and toxoid A and intact rTcdA900-2710, probed.   
48 hour digestion of 5 µg of protein by 1U activated clostripain, analysed on a 4–20% SDS-PAGE gel, transferred to nitrocellulose and detected 
with SuperSignal Femto.  Molecular weight marker in kDa. Red boxes regions of commonality. Blue boxes indicate 205 and 308 kDa full length 
rTcdA900-2710 and TcdA respectively.   
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4.4.9 Mass Spectrometry 
Common immunogenic fragments detected by human immune sera, goat and 
sordellii neutralising sera were selected for sequencing.  All bands were manually 
selected from silver stained 1D SDS-PAGE gels.   
 
Table 4.5: Bands selected for mass spectrometry.   
Toxin preparation Molecular weight (kDa) 
Toxin A 40 
60 
25 
rTcdA900-2710 40 
60 
25 
Toxoid A 40 
 60 
Toxin B 60 
25 
rTcdB547-2366 60 
 40 
 
Unfortunately it was not possible to identify the immunogenic bands at a sequence 
level and hence the location of these immunogenic bands could not be determined.   
Protein identification by mass spectrometry is a multistep process with a number of 
limitations.  Although trypsin is the most commonly used protease for generating 
peptides for identification, it may not be the optimal protease for all proteins.  The 
generation of sufficient peptides for unambiguous identification is paramount and it 
may have been beneficial to use a combination of proteases and/or chemicals to 
facilitate peptide generation.   The types of peptides generated may not be reflective 
of those predicted for trypsin, either due to non-specific or missed cleavage.   This 
may have occurred during peptide preparation or as a consequence of clostripain 
mediated digestion.  The choice of matrix utilised for the identification of peptides 
will influence ionization, stability and fragmentation of peptides (Lubec and Afjehi-
Sadat, 2007).  In this study the matrix of choice was α-cyano-4-hydroxycinnamic 
acid (CHCA), which has been shown to be applicable for a range of peptides (Vestal 
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and Campbell, 2005).  However, if the generated peptides are >2.5 kDa (Jensen et 
al., 1997), as may be the case if indeed the trypsin digestion has been unsuccessful, 
then the matrix would need to be optimised.  As the bands were selected from 1D 
SDS-PAGE gels it is also feasible that two or more proteins were simultaneously 
analysed.  In addition to the peptides from the toxins, the presence of the digestion 
enzymes may have complicated analysis.  Although filters were applied to remove 
these known contaminants from the analysis, it is impossible to eliminate all 
contaminants.  Due to the lack of time and resources (both financial and availability 
of toxin samples), it was not possible to optimise all of the aforementioned factors 
and hence it was not possible to attempt sequencing again.    
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4.5 Discussion 
In this chapter we aimed to identify immunogenic fragments of native and 
recombinant toxins A and B and toxoid A, using animal sera and human sera.  
 
4.5.1 Toxin Digestion 
in silico analysis revealed that the proteins could be digested by a number of 
proteases and chemicals generating upwards of 1000 fragments.  With the intended 
techniques, it was not possible to resolve fragments of this number.  Based on its 
high substrate specificity, preferentially cleaving arginine residues (Mitchell, 1977; 
Otto and Schirmeister, 1997) and its prediction to yield 51 fragments, clostripain was 
identified as a suitable enzyme.  The number of peptide fragments seen in this study 
was less than the number predicted by the computer software.  Closer analysis of the 
predicted fragments revealed many of the fragments to be ≤2 kDa, which is below 
the limit of detection of conventional SDS-PAGE.  In addition, some of the 
fragments were of similar molecular weights, and thus could not be distinguished, 
using a 1D SDS-PAGE approach.  Finally the digestion prediction programme does 
not take into consideration the conformational structure of the protein.  Hence, the 
predicted number of fragments is likely to be an overestimation of what can be 
achieved in reality.  
   
Based on the time taken to achieve digestion, 48 hours and 30 minutes, for TcdA and 
TcdB, respectively, it would appear TcdB is more susceptible to clostripain digestion 
than TcdA.  TcdA has been reported to be resistant to pure trypsin, even at high 
concentrations (10 mg/mL), whilst TcdB is susceptible (Torres and Lönnroth, 1988; 
Lyerly et al., 1989).  A recent study has utilised trypsin, chymotrypsin, 
endoproteinases GluC, AspN and LysC separately and in combination to digest both 
toxin A and B, with digestion conditions of 37°C for 2-24 hours, depending on the 
enzyme (Moura et al., 2013a).  Whether the difference in digestion susceptibility is 
associated with the grade of protease utilised or the digestion conditions is unclear.  
If TcdA is resistant to trypsin digestion it may also be resistant to the proteolytic 
action of numerous enzymes.  These observations mirror the natural autoprocessing 
of TcdA and TcdB, whereby TcdA is more resistant to InsP6-induced cleavage than 
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TcdB (Kreimeyer et al., 2011; Pruitt and Lacy, 2012), it is intriguing to speculate 
that an in vivo mechanism which (possibly) prevents premature processing of the 
toxin confers universal resistance to proteolytic degradation.  The expression and 
processing of bacterial toxins is a co-ordinated and controlled approach presumably 
intended to benefit the bacterium.  In the case of C. difficile the role of toxin 
production, to the bacterium, is unclear.  Bacterial toxins may be produced to acquire 
nutrients from the host, thus for C. difficile this would allow the bacterium to 
maintain its vegetative state in an anaerobic environment.  Alternatively, the 
destruction of host cells, aids in the invasiveness and dissemination of the pathogen 
further into the host tissue.  This would appear somewhat contradictory for 
C. difficile as it would result in exposure to aerobic environments resulting in cell 
death or spore formation.  Having said this there are reported cases of extraintestinal 
C. difficile infections, including bacteremia (Libby and Bearman, 2009; Lee et al., 
2010b).  Given that the majority of C. difficile bacteremia are polymicrobial in 
nature, involving the gut flora (Bacteroides spp., E. coli, Enterococci spp.) (Libby 
and Bearman, 2009), it is intriguing to speculate that the C. difficile  toxins are 
expressed to facilitate the translocation and dissemination of other gut microbes, thus 
reducing the competition within the intestinal niche occupied by C. difficile and 
indirectly enhancing the pathogenicity of multiple gut bacteria.  
    
Recently, Marozsan et al., (2012) utilised a proteolysis and Western blot approach to 
epitope map the location of antitoxin A (PA-50) and antitoxin B (PA-41) monoclonal 
antibodies.  The authors used enterokinase and caspase-1 for the digestion of TcdA 
and TcdB, respectively.  As the authors do not provide coomassie or silver stained 
gels, comparison of digestion profiles could not be made with the data presented in 
this thesis.  Interestingly the protease, enterokinase, employed by Marozsan and 
colleagues for the digestion of TcdA, was not predicted to cut the protein when 
analysed using the PeptideCutter software in this thesis.  Thus it may be the case that 
the fragments identified by Marozsan et al., represent natural degradation products 
due to the incubation conditions employed (48 hours at 25°C), as opposed to 
enzymatic digest fragments.  In the case of TcdB, Marozsan et al., (2012) digested 
the toxin for 96 hours at 37°C, this appears to be excessive given the susceptibility of 
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TcdB to proteolytic digestion as compared to TcdA (results presented in this thesis 
and Lyerly et al., (1989) and Taylor et al., (1981).     
The major limitation of employing an enzymatic digestion approach is the potential 
immunogenicity of the protease itself, as observed in this study.  In order to reduce 
this effect it may have been feasible to utilise a Fluorescence Difference Gel 
Electrophoresis (DIGE) approach, whereby the digest enzyme and the toxin sample 
are labelled with unique fluorescent dyes allowing for differentiation following 
imaging.  This approach would also allow for the recombinant and native toxin 
preparations to be run simultaneously allowing for easier comparisons.  In spite of 
the difficulties encountered with the enzymatic digestion approach it does appear to 
be a feasible method for the generation of multiple fragments which can facilitate 
mapping studies.   
 
4.5.2 Immunoreactive Regions of TcdA and TcdB  
It was only possible to make a qualitative assessment on the immunogenic regions of 
TcdA and TcdB in this study, with attempts at sequencing failing to yield identifiable 
peptide bands.  
 
The use of recombinant proteins is primarily intended to facilitate the yield and 
purity of toxin available for investigation (Just and Gerhard, 2004).  The 
immunogenicity of recombinant toxin B, with the monoclonal murine antibody 
suggests it can be employed as a surrogate for the native toxin B.  For toxin A the use 
of PCG-4 (Frey and Wilkins, 1992), a well characterised murine monoclonal 
antibody should have been employed.  This analysis was not undertaken due to the 
problems encountered in obtaining a high yield of recombinant toxin A.   
 
Although the neutralising capability of C. sordellii antitoxin has been established for 
over three decades (Rifkin et al., 1977; Chang et al., 1978a; Chang et al., 1978b; 
Larson et al., 1978; Allo et al., 1979; Popoff, 1987; Martinez and Wilkins, 1988), to 
the best of our knowledge, no study has attempted to map the regions of TcdA and 
TcdB which are recognised by this serum. This is surprising given the documented 
cross-neutralisation of C. difficile and C. sordellii toxins (Allo et al., 1979; Fernie et 
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al., 1983).  The earliest study found to display immunoblot data relating to the cross-
reactivity of the lethal toxin of C. sordellii and the cytotoxin of C. difficile was 
conducted by Popoff (1987).  Although the sera displayed neutralising activity it 
failed to recognise antigen from C. difficile culture supernatant.  This may be due to 
the concentration of antibody used to probe the blot (1/100 compared to 1/25 used in 
this study) or the low concentration of toxin A and B present in the culture 
supernatant.  As the author does not provide culture conditions for C. difficile it was 
not possible to ascertain the effect of the media used on the production of toxins 
(Karlsson et al., 1999; Merrigan et al., 2010; Vohra and Poxton, 2011).  In 1990, von 
Eichel-Streiber et al., used C. sordellii antiserum to isolate recombinant clones 
expressing regions of TcdB.  Three of the clones were located at the N-terminus and 
three at the C-terminus of TcdB, suggesting that multiple epitopes are recognised by 
the sordellii antitoxin and neutralisation may be achieved both by blocking receptor 
binding (C-terminus) and enzymatic activity (N-terminus).  It should be noted that 
von Eichel-Streiber et al. (1990) did not purify the recombinant clones and utilised 
total cell lysates for Western blot analysis, thus non-specific binding of the polyconal 
sera with proteins from the E. coli expression system cannot be excluded, as found in 
this thesis (Figure 4.13). 
 
The relatively reduced reactivity observed against TcdA with the sordellii antitoxin, 
is suspected to be due to the antitoxin being raised against the lethal toxin of 
C. sordellii, which displays a 75% and 41% amino acid sequence similarity with 
TcdB and TcdA, respectively (Rupnik and Just, 2006), although this has not been 
definitively determined.   
 
In contrast to the sordellii antitoxin, which was raised against the culture filtrate from 
C. sordellii, the goat serum used in this study was produced from a toxoided culture 
filtrate of C. difficile.  The results suggest that the toxoiding process does not appear 
to affect immunogenicity, at least when compared to native TcdA.  However, given 
that the antitoxin has been generated from a toxoid preparation, this would be 
expected.  If, however the goat antitoxin (like the sordellii antitoxin) predominantly 
recognises TcdB, it is imperative to assess the effect of toxoiding on the 
immunoreactivity of toxoid B.  Using circular dichroism spectrometry, a recent study 
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has shown conformational changes in a toxoid B preparation compared to the native 
toxin (Wang et al., 2012).  The authors report the toxoid B preparation displayed 
lower IgG neutralising antibody response in a mouse model, with highly neutralising 
epitopes absent in the toxoid preparation, resulting in 70% lethality following 
challenge with TcdB.  This study emphasises the importance of generating a 
neutralising antibody response, which may not be efficiently generated using a 
toxoided vaccine. 
 
The utilisation of recombinantly produced regions frequently raises concerns with 
regards to the level and type of immune response that is likely to be generated, as 
there is no guarantee that the recombinant protein will produce conformational 
epitopes which mirror the native protein.  Due to limited reagents and time it was 
only possible to complete the SDS-PAGE and immunoblot profiles once, and 
although the profiles for the toxin B preparation in this study suggest that similarities 
exist between the native and recombinant proteins, this would need to be repeated for 
confirmation. 
 
The use of recombinant toxins in immunisation and neutralisation studies (Lyerly et 
al., 1990; Kink and Williams, 1998; Ward et al., 1999a; Ward et al., 1999b; Gerhard 
et al., 2005; Permpoonpattana et al., 2011; Tian et al., 2012), further suggests 
recombinant proteins would stimulate the appropriate immune response, whilst 
eliminating problems encountered using a toxoided approach.  A chimeric toxin 
composed of the receptor binding domain of TcdA (amino acid residues 1848-2710) 
and the glucosyltransferase and translocation domain of TcdB (amino acid residues 
1–1851) conferred long-term protection (3 months) in mice against lethal challenge 
with TcdA and TcdB (Wang et al., 2012).  
 
The location of toxin neutralising epitopes in the receptor binding domain of the 
toxins (particularly for TcdA) has been demonstrated by a number of researchers 
(Corthier et al., 1991; Frey and Wilkins, 1992; Kink and Williams, 1998; Babcock et 
al., 2006; Demarest et al., 2010; Hussack et al., 2011; Marozsan et al., 2012).  The 
presence of multiple epitopes in the receptor binding domain, is likely to be a 
reflection of multivalent receptor binding sites which are located within this domain 
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(Ho et al., 2005; Greco et al., 2006).  Further evidence of multiple neutralising 
epitopes within the receptor binding region, has been provided by mapping studies 
using the toxin neutralising murine monoclonal antibody, PCG-4, which recognises 
amino acid residues 2097-2141 and 2355–2398 (Lyerly et al., 1985a; Frey and 
Wilkins, 1992). 
 
The literature suggests that at least one toxin neutralising epitope is located in the 
N-terminal domain of TcdB.  Marozsan et al., (2012) mapped the location of a 
humanised toxin neutralising monoclonal antibody (PA-41) to a 63 kDa region 
within the N-terminal domain of TcdB.  As the recombinant protein produced in this 
thesis lacked this domain, potential immunogenic regions within this domain would 
not be detected.  Although this limitation was somewhat circumvented by the 
incorporation of native toxin B.  
 
CDA1 and CDB1 represent the first human monoclonal antibodies (HuMAbs) 
specific for TcdA and TcdB used in a human clinical trial for the treatment of 
recurrent CDAD (Babcock et al., 2006; Lowy et al., 2010).  The CDB1 antibody in 
this study bound to a region within the C-terminal region of toxin B, in contrast to 
PA-41 which recognised a neutralising epitope at the N-terminus of the toxin 
(Marozsan et al., 2012).  Thus toxin B neutralisation can be achieved by targeting 
both the enzymatic and receptor binding domains, and when attempting to develop a 
vaccine, it may be beneficial to target multiple epitopes across various regions of the 
toxin B molecule. 
 
The variability in the ability of patient sera to recognise individual toxin fragments 
may be a reflection of a number of factors including the severity of infection and the 
strain(s) of the pathogen to which the individual has been exposed.  In this research, 
based on visual intensity of immunoblots, sera CD3 and CD6 displayed the strongest 
toxin specific IgG and IgA response, if this is a reflection of the multiple episodes of 
CDI experienced by these individuals, it provides further support for the importance 
of an anamnestic toxin immune response (Johnson et al., 1992; Warny et al., 1994; 
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Kyne et al., 2000; Loo et al., 2011).  For C. difficile, sIgA has been suggested to be 
important for protection (Wada et al., 1980; Kelly et al., 1992; Warny et al., 1994; 
Johnson et al., 1995; Ward et al., 1999b; Stubbe et al., 2000), thus it was anticipated 
that in recurrent patients (CD3 and CD6) a IgA response would be evident, this was 
demonstrated for toxin B (Figure 4.17) but less evident for toxin A (Figure 4.19), 
with only CD3 recognising intact toxin A.  This difference may be a related to the 
type of epitope (linear or conformational) that is recognised by the sera or the strain 
responsible for infection.    
 
As part of this study it had been our intension to generate immuno-profiles of 
individuals with single and recurrent episodes of infection, with the intention to 
identify differences in the relative quality of the antibody responses of the two 
patient groups as a means of identify key protective targets.  Unfortunately due to the 
time taken in obtaining ethical approval and subsequently in obtaining serum 
samples, it was not possible to undertake these studies.  We were also unable to 
determine the C. difficile ribotypes/toxinotypes of the strains which had infected the 
patients from whom we had obtained sera.  Given that there are antigenic variations 
in toxins between strains (Lanis et al., 2013); it is feasible the antibodies present in 
the patient sera are specific to a particular toxinotype which does not cross-react with 
the toxins used in this study (VPI 10463 and C. difficile 630).       
 
It has recently been shown that the presence of  toxin neutralising sIgA antibodies, 
stimulated by oral  immunisation with A26-39 provided a stronger correlation with 
protection in a hamster model than serum IgG antibody responses (Permpoonpattana 
et al., 2011).  A26-39 (formerly known as 14CDTA) corresponds to amino acid 
residues 2386-2706 of the C-terminal region of TcdA.  This study also showed that 
serum raised against this region of toxin A cross-reacted with the C-terminal region 
of toxin B, B15-24 (amino acid residues 2137-2366).  Analysis of these regions 
showed a 29 and 37% sequence identity and similarity, respectively, with conserved 
regions at sequences YFAPANT, MQ, IGVF, AAT, and YYF.  In light of this 
research the identification of common regions recognised by IgA and IgG 
(particularly for TcdA) would represent valid targets for future therapeutic 
developments.  For example the 40 and 60 kDa fragment in the toxin A preparations, 
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identified in this thesis by human (IgG and IgA) (Figure 4.18 and 4.19) and toxin 
neutralising animal antisera (Figure 4.15) may represent promising candidates.  It is 
feasible that this fragment correlates to the 37 kDa fragment utilised by 
Permpoonpattana et al.,(2011) and would also include one of the PCG-4 epitopes 
(Frey and Wilkins, 1992).  In hindsight probing with the PCG-4 antibody would have 
been beneficial to further assess the immunogenicity of these regions.   The presence 
of common immunogenic regions in toxin A and B could not be determined in this 
thesis, due to the failure of protein identification.      
 
One significant limitation of the current study is that the toxin sequences (both native 
and recombinant) are based on VPI 10463 (TcdB003) and C. difficile 630 (TcdB012), 
respectively.  Whilst the hypervirulent 027 strains, which have been sequenced to 
date, expressed almost identical TcdA (99% similarity and 98% identity) when 
compared to that produced by VPI 10463 and C. difficile 630, a greater degree of 
variation in TcdB sequences between these strains was observed (96% similarity, 
92% identity) (Lanis et al., 2010; Lanis et al., 2012; Lanis et al., 2013).  This 
variation is most prominent in the C-terminal domain (CTD, 88% sequence identity 
between TcdB0271651-2366 and TcdB0031651-2366).  Given that the recombinant protein 
produced in this thesis included this region, the immunogenic fragments recognised 
in this study may not represent all of the immunogenic regions with toxin B 
homologs produced by 027 strains.   
 
In a recent study the immunogenicity of the C-terminal receptor binding domain 
(amino acid residues 1651-2366) of toxin B from two different ribotypes of 
C. difficile (ribotype 027 and 003) was assessed (Lanis et al., 2013).  Although 
thirteen overlapping epitopes were recognised, no shared cross-neutralising epitopes 
were found between the two ribotypes and significantly there was an absence of 
neutralising epitopes in the C-terminus of TcdB027.  Given this recent finding the 
ability of the commercially available neutralising animal sera and indeed the human 
sera to recognise TcdB027, should be under taken.   
  
  
159 
 
4.6 Conclusion 
This chapter aimed to identify the immunogenic fragments of toxin A and toxin B 
recognised by toxin neutralising animal sera and human sera from C. difficile 
infected individuals.  Utilising a proteolysis based approach; native, recombinant and 
toxoided proteins were successfully digested and immunogenicity of the resulting 
fragments identified.  Although toxin A and toxoid A were found to display 
instability under the incubation conditions employed, the proteins were not 
susceptible to clostripain mediated digestion.  This is in contrast with toxin B which 
was both stable and susceptible to enzyme mediated digestion.  Regions of 
commonality were found between the recombinant and native toxin preparations, 
which was particularly evident for toxin B, based on 2D SDS-PAGE profiles.  In 
comparison to native toxin A, the toxoid A immunoblot profiles displayed a reduced 
binding affinity across all antibodies tested. 
 
The two commercially available neutralising animal sera recognised both TcdA and 
TcdB, with the latter toxin showing greater immunogenicity against the sordellii 
antisera, possibly due to the sordellii sera being raised against the lethal toxin of 
C. sordellii which displays a greater homology with the C. difficile toxin B.   
 
The immunoblot profiles obtained in this study with the human sera varied greatly.  
Given the limited number of samples analysed and the inherent variability of the 
immune response to these toxins these preliminary results must be validated to assess 
repeatability and also with the use of additional serum samples.  The presence of a 
40 and 60 kDa immunogenic band in the toxin preparations recognised by both 
neutralising and human sera, warrants further research.   
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CHAPTER FIVE 
THE VARIABILITY OF VEGETATIVE 
CLOSTRIDIUM DIFFICILE 
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5.1 Introduction 
Chapters 3 and 4 have focused on characterising the primary virulence factors 
(TcdA and TcdB) of C. difficile.  This chapter examines the vegetative form of 
C. difficile cells, focusing primarily on morphotype variability and their associated 
surface structures and the contribution they make to the survival of the bacterium in 
the gut. 
 
5.1.1 Colony Variants 
Small colony variants (SCVs) represent a slow growing sub-population of bacteria 
that are one-tenth the size of wild-type bacterial colonies and display unique 
phenotypic and pathogenic traits (Proctor et al., 2006).  Common traits include slow 
growth, auxotrophy, antibiotic resistance and ability to revert to wild-type colony 
(Proctor et al., 2006).  They are not restricted to a particular genera or species and 
have been reported in Lactobacillus acidophilus (Kopeloff, 1934), S. aureus (Bulger, 
1967), B. subtilis (Carlisle and Falkinham, 1989), V. cholerae (Salles et al., 1976) 
and Burkholderia pseudomallei (Chantratita et al., 2007).  It has been suggested that 
SCVs in these bacteria contribute to disease progression by promoting bacterial 
persistence and survival (Proctor et al., 2006).  The presence of variant colonial 
morphotypes in C. difficile has attracted little or no attention, with the presence of 
“dwarf” colonies observed by a number of researchers (Brazier and Borriello, 2000).  
Whether the “dwarf” colonies of C. difficile represent SCVs is yet to be determined.  
 
5.1.2 Bile Salts  
Despite the relationship between C. difficile spores and bile salts (primarily 
taurocholate) being widely recognised, the interaction between these compounds and 
vegetative C. difficile cells is yet to be fully characterised.  Bile is a biological 
detergent, synthesised from cholesterol and produced by the liver, it is composed of 
proteins, ions, pigments and bile acids (Merritt and Donaldson, 2009).  Cholic acid 
and chenodeoxycholic acid represent the primary bile acids (Begley et al., 2005; 
Ridlon et al., 2006), which are conjugated with taurine (to form taurocholate or 
taurochenodeoxycholate) or glycine (to form glycocholate or glycodeoxycholate).  
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These secondary bile salts can be deconjugated into the primary bile salts (cholate 
and chenodeoxycholate) by bile salt hydrolases (BSH) found on the surface of 
bacterial cells (Ridlon et al., 2006).  Intestinal bacteria, such as Clostridium scindens, 
further metabolise the deconjugated primary bile salts, converting cholate into 
deoxycholate and chenodeoxycholate into lithocholate (Begley et al., 2005; Ridlon et 
al., 2006).  Finally, lithocholate can be metabolised by intestinal bacteria to form the 
tertiary bile salt ursodeoxycholate (Merritt and Donaldson, 2009), summarised in 
Figure 5.1. 
 
Figure 5.1: Bile acid metabolism and C. difficile. 
Metabolism of bile salts in the intestine and their positive and negative effects on 
C. difficile.  From Britton and Young, (2012).  
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Understanding the interaction between bile salts (both conjugated and unconjugated 
as well as primary, secondary and tertiary) and bacteria will facilitate an 
understanding of how bacteria, particularly C. difficile, can survive within the human 
gut.  To date, the relationship of C. difficile with bile salts has focussed on the 
germination of spores in response to taurocholate (Wilson et al., 1982; Wilson, 1983; 
Sorg and Sonenshein, 2008; Sorg and Sonenshein, 2009, 2010; Heeg et al., 2012).  
The interaction of C. difficile spores and bile salts occurs along the GI tract, resulting 
in germination (Sorg and Sonenshein, 2008; Wheeldon et al., 2011).  Thus far, 
chenodeoxycholate is the only reported bile component that inhibits the germination 
of C. difficile spores (Sorg and Sonenshein, 2009, 2010) and inhibits the growth of 
vegetative C. difficile cells (Sorg and Sonenshein, 2008) (Figure 5.1), although this 
relationship appears to be strain specific (Heeg et al., 2012). 
 
Enteric bacteria have developed resistance mechanisms (although poorly understood) 
to survive the toxic effects of bile.  These include efflux pumps (acr), Tol genes 
(tolQRA), porin genes (ompF) and regulatory genes (Gunn, 2000; Noriega et al., 
2004).  As C. difficile is a gut pathogen, once spores germinate, the vegetative 
organism is exposed to bile salt concentrations ranging between 0.2-2% (w/v) in the 
intestines (Gunn, 2000).  Thus the organism must possess some mechanism by which 
it tolerates exposure to bile salts.   The mechanism(s) by which this is achieved in 
Clostridium spp. is unknown; analysis of the C. difficile genome has identified the 
presence of a bile acid inducible dehydrogenase gene (CD0065), which converts 
chenodeoxycholic acid into lithocholic acid (Sebaihia et al., 2006).  Orthologs of 
bilEA (CD3215) and bilEB (CD3216), which function as bile exclusion systems in 
Listeria monocytogenes, have also been identified in C. difficile (Sebaihia et al., 
2006).   
 
In Bacteroides fragilis (Gram-negative, enteric, anaerobic, commensal), phase 
variation has been studied in relation to the expression of eight distinct capsular 
polysaccharides (Chatzidaki-Livanis et al., 2009; Chatzidaki-Livanis et al., 2010).  
Phase variation is associated with host-pathogen interactions (immune evasion and 
colonisation) and strain evolution (stress resistant phenotype and protection against 
foreign DNA and phage) (van der Woude, 2011).  C. difficile is also capable of phase 
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variation (Emerson et al., 2009), comparative analysis of three C. difficile genomes 
(630, R202091, CD196) has identified 3 intragenic inversions (Cdi1, Cdi2 and Cdi3) 
(Stabler et al., 2010) and at least four tyrosine recombinases recV (CD1167), 
CD1222, CD1333 and CD1932, and phage-related recombinases (Stabler et al., 
2010).  The surface exposed, CwpV is a 160 kDa phase variable protein which is 
post-translationally cleaved into a 40 kDa cell wall anchoring domain and a 120 kDa 
surface exposed domain.  CwpV is hypothesised to promote aggregation but may 
also be involved in immune evasion.  Intriguingly CwpV mutants display altered 
colony phenotypes, in these mutants the protein is permanently on (Emerson et al., 
2009; Reynolds et al., 2011).  Given that both B. fragilis and C. difficile are intestinal 
bacteria and phase variation in the former allows evasion and survival (Chatzidaki-
Livanis et al., 2010),  phase variation in gene regulation of C. difficile may also be of 
equal importance.   
 
The presence of variant colony morphologies in C. difficile is an aspect of C. difficile 
microbiology which is yet to be fully investigated.  This chapter will address the 
variability of C. difficile at the macroscopic (colony morphotype), microscopic, 
proteomic and immunological level and attempt to draw some conclusions as to the 
contribution of these variants to virulence. 
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5.2 Aims and Objectives 
The aims of this chapter are to characterise the vegetative cell surface of C. difficile, 
with a view to identifying components which contribute to virulence and 
immunogenicity. 
 
The experimental objectives are to: 
1. Assess the frequency and stability of variant C. difficile morphotypes. 
2. Assess the susceptibility of morphotypes to bile salts. 
3. Characterise variant C. difficile via light microscopy and electron microscopy. 
4. Analyse the surface proteome of variant C. difficile using 1D and 2D SDS-PAGE 
5. Identify immunogenic proteins using immune serum from animals and infected 
individuals. 
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5.3 Materials and Methods 
All media was prepared in sterile de-ionised water (diH2O) (inorganics at 25°C, 
15 MΩ-cm, Total Organic Carbon <30 ppb) from an Elga PureLab Option-S 
(Elga, UK).  Unless otherwise stated, all reagents were purchased from 
Fisher Scientific, UK or Sigma-Aldrich, UK. 
 
5.3.1 Bacterial Strains 
Twenty-one C. difficile isolates were kindly donated by Dr. Jon Brazier of the 
Anaerobic Reference Unit, Cardiff.  NCTC strains were purchased freeze-dried from 
the Health Protection Agency (Colindale, UK).  Details of these strains are noted in 
Table 5.1. 
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Table 5.1: C. difficile isolates used in this study. 
Strain Ribotype Patient Sex Patient Age Origin 
DS1759 001 M 87 Maidstone 
DS1747 001 F 82 St James Leeds 
R8652 001 * * NCTC 11209 
DS1750 001 F 88 St James Leeds 
DS1813 027 M 80 Hinchingbrooke 
DS1801 027 F 64 Leicester 
R20291 027 * * Stoke Mandeville 
DS1807 027 F 31 Salford 
R10459 106 * * Dudley 
DS1798 106 M 94 Poole 
DS1787 106 M 83 Leicester 
DS1771 106 M 88 Bristol Southmead 
DS1742 014 M 27 Bristol Frenchay 
DS1748 002 F 83 Leeds 
DS1721 005 M 66 Leicester 
DS1752 012 F 81 Bradford 
DS1723 078 M 71 Leicester 
DS1724 020 M 83 Leicester 
DS1684 010 F 92 Brighton 
DS1665 023 F 92 Bath 
NCTC 11204 001 * * Sheffield 
Unknown  002 * * * 
*Information not available 
 
  
168 
 
5.3.2 Anaerobic Conditions 
All work was carried out using a gloveport Bugbox Plus anaerobic workstation 
(Ruskinn Technology Limited, UK) or an Electrotek AW200SG anaerobic 
workstation (Electrotek, UK).  The anaerobic environment consisted of 
85% N2, 10% CO2, 5% H2 and was maintained by a palladium catalyst and circulated 
by a tangential fan.  Disposable anaerobic indicator strips (Becton Dickinson, UK) 
were replaced daily to confirm a strict anaerobic environment was maintained.  The 
temperature of the work station was set at 37°C and monitored by a temperature 
probe.  
 
5.3.3 Culture Media 
Vegetative C. difficile were routinely cultured on BHI agar and BHI broth prepared 
by following the manufacturer’s instructions.  C. difficile spores were cultured on 
BHI agar supplemented with 0.1% (w/v) sodium taurocholate.  Blood agar plates 
were prepared with Columbia Blood Agar base (Oxoid Ltd., Basingstoke, UK), 
supplemented with 5% (v/v) defibrinated horse blood (Oxoid Ltd., Basingstoke, UK) 
by following the manufacturer’s instructions.  Cycloserine-Cefoxitin-Fructose Agar 
(CCFA) plates were purchased from Oxoid Ltd. (Basingstoke, UK).  Proteose 
Peptone Yeast (PPY) extract media was prepared as follows (per litre of diH2O) 
(proteose peptone, 40 g; yeast extract, 5 g; agar, 20 g).  VL media was composed of 
(per litre of diH2O) tryptone, 10 g; NaCl, 5 g; beef extract, 3 g; yeast extract, 5 g; 
cysteine hydrochloride, 0.4 g, glucose, 2.5 g; agar, 12 g supplemented with 5% (v/v) 
defibrinated horse blood (Beerens et al., 1963).  Media was sterilised for 20 minutes 
at 121°C (Prestige Medical, UK) and reduced at 37°C for 24 hours in an anaerobic 
work station prior to use.  Cultures were incubated at 37°C for 48 hours in an 
anaerobic workstation.   
 
5.3.4 Freezer Cultures 
PROTECT microbial preservation kit (Technical Service Consultants Ltd, UK) was 
used for long-term C. difficile storage.  Multiple colonies from a 48 hour culture 
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were inoculated in the cryopreservative fluid.  The vial was vigorously shaken and 
the liquid removed using a sterile Pasteur pipette and stored at -80°C.  Rescue from 
these stocks was performed onto blood plates (7% (v/v) defibrin horse blood) 
supplemented with Clostridium difficile Moxalactam Norfloxacin (CDMN) selective 
supplement (Oxoid, UK). 
 
5.3.5 Spore Production  
C. difficile and C. perfringens spores were prepared following the method described 
by Perez et al., (2005).  Colonies from a 48 hour culture were inoculated in 25 mL 
pre-reduced BHI broth and incubated for 5-10 days at 37°C under anaerobic 
conditions.  The culture was centrifuged at 5,000 g for 15 minutes at 4°C 
(Heraeus Primo R, Thermo, UK).  The supernatant was discarded and the pellet 
re-suspended in 2.5 mL chilled sterile deionised water (SDW), to which 10 mL 
absolute ethanol was added and the suspension was incubated at room temperature 
for 1 hour.  The spore preparation was centrifuged as above for two centrifugation 
cycles, with SDW washing between cycles.  The pellet was re-suspended in 10 mL 
SDW and heated in a water bath (Fisher Scientific, UK) at 80°C for 10 minutes.  The 
spore suspension was centrifuged and re-suspended in 1 mL SDW, serially diluted 
from 10
-1
 to 10
-5
 in sterile PBS and 10 µL of the resulting dilutions were spotted onto 
BHIT agar in triplicate and incubated anaerobically for 48 hours.  Spore suspensions 
were stored at 4°C. 
 
5.3.6 Bacterial Staining 
All slides were air dried, stained appropriately and examined under oil immersion at 
x1000 magnification with an Olympus DX-50 microscope (UK); images were 
captured on an Olympus DP10 camera (UK). 
 
5.3.6.1 Gram Stain 
A single colony was smeared with sterile diH2O and allowed to air dry; slides were 
immersed in crystal violet for 1 minute followed by Lugals Iodine for 1 minute.  
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Slides were de-stained with 95% ethanol for 30 seconds and counter-stained with 
Safranin (2.5% (w/v)) for 1 minute.  Slides were gently rinsed with diH2O water 
between each stage.  
 
5.3.6.2 Capsule Stain – Crystal Violet  
Singles colonies were air dried onto slides, immersed in double filtered 1% (w/v) 
crystal violet for 6 minutes and washed with 20% (w/v) copper sulfate.   
 
5.3.7 Proportion of Morphotypes 
Spore stocks were prepared as described in 5.3.5, for each culture media spore 
suspensions were serially diluted in sterile, reduced PBS.  From each dilution series 
100 µL was spread evenly across the surface of the agar.  All dilutions were 
completed in triplicate.  Once dry, the plates were inverted and incubated at 37°C 
under anaerobic conditions for 48 hours.    
 
5.3.8 RaPID ANA II System 
Identification of C. difficile was achieved by utilising the RapID ANA II System 
(Remel, Lenexa).  The RapID ANA II panels contain 10 reaction cavities; where 
cavities 3 through to 10 are bifunctional (Table 5.2).  Vegetative cells were produced 
from spore stocks as described in Section 5.3.7.  Spore stock and vegetative cells of 
the control strain C. perfringens 8359 was produced as described in Sections 5.3.5 
and 5.3.7.  Bacterial cells were suspended in 1 mL of RapID inoculation fluid to 
achieve a visual turbidity equal to that of a No. 3 McFarland turbidity standard.  
RapID ANA II panels were inoculated with the test suspension and incubated 
aerobically at 37°C for 5 hours.  Cavities 3 through to 10 were scored; RapID ANA 
II reagent was added to cavities 3 through to 9 and allowed to react for 1 minute; 
RapID Spot Indole reagent was added to cavity 10.  The resulting microcode was 
screened against the Electronic RapID Compendium (ERIC).   
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Table 5.2: Principles and components of the RaPID ANA II reaction panel. 
Cavity 
# 
Test 
Code 
Reactive Ingredient Principle 
Before reagent addition 
1 URE Urea Hydrolysis of urea 
produces basic 
products which raise 
the pH and change the 
indicator 
2 BLTS p-Nitrophenyl-β,D-disaccharide  
 
Enzymic hydrolysis 
of the colourless aryl-
substituted glycoside 
or phosphoester 
releases yellow o- or 
p-nitrophenol 
3 αARA p-Nitrophenyl-α,L-arabinoside, 
4 ONPG o-Nitrophenyl-β,D-galactoside 
5 αGLU p-Nitrophenyl-α,D-glucoside 
6 βGLU p-Nitrophenyl-β,D-glucoside 
7 αGAL p-Nitrophenyl- α,D-galactoside 
8 αFUC p-Nitrophenyl- α,L-fucoside 
9 NAG p-Nitrophenyl-N-acetyl-β,D-
glucosaminide 
10 PO4 p-Nitrophenylphosphate 
After Reagent Addition 
3 LGY Leucyl-glycine-β-naphthylamide  
 
Enzymic hydrolysis 
of the arylamide 
substrate releases free 
β –naphthylamine 
4 GLY Glycine-β-naphthylamide 
5 PRO Proline-β-naphthylamide 
6 PAL Phenylalanine-β-naphthylamide 
7 ARG Arginine-β-naphthylamide 
8 SER Serine-β-naphthylamide 
9 PYR Pyrrolidonyl-β-naphthylamide 
10 IND Tryptophane Utilisation of the 
substrate results in the 
formation of indole 
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5.3.9 Transmission Electron Microscopy (TEM) Negative Stain 
Variant C. difficile colonies were suspended in 1 mL of PBS.  A 5 µL drop of sample 
was placed on a copper grid incubated at room temperature for 5 minutes; excess 
sample was removed by blotting on filter paper. A 5 µL drop of 2% (w/v) 
methylamine tungstate was added; incubated for 5 minutes and blotted on filter 
paper. The grids were dried at room temperature and examined on a transmission 
electron microscope EM 280 (Phillips, Croydon, UK) at x16,000 magnification.  
Images were recorded from five randomly selected fields of vision. 
 
5.3.10 Bile Salt Sensitivity 
Following 48 hour growth, M1 and M2 colonies were isolated and suspended in 
sterile diH20 (Section 5.3.7).  Cultures were standardised to an OD600 of 
approximately 1.0.  The following solutions were prepared, sodium taurocholate 
(0.1% (w/v)), chenodeoxycholate (0. 1% (w/v)) and Triton-X (0.05% (w/v)) and their 
effect on M1 and M2 was assessed spectrophotometrically.  This work is based on 
the study conducted in C. perfringens by Camiade et al., (2010).  Triton-X-100 can 
be utilised to determine the general autolytic system of bacteria, as its interaction 
with lipoteichoic acids form micelles which inhibit autolytic activity in the 
peptidoglycan.  To 900 µL of solution (sodium taurocholate (0.1% (w/v)), 
chenodeoxycholate (0. 1% (w/v)) and Triton-X (0.05% (w/v)), 100 µL of colony 
suspension was added.  The OD600 readings were taken every minute for 30 minutes 
using an Ultraspec pro3100 spectrophotometer (GE Healthcare, UK).  All assays 
were performed from three biological replicates.    
 
5.3.11 Vegetative Cell Surface Protein Extraction  
Unless otherwise stated, all centrifugations were completed in an Eppendorf 5417R 
centrifuge with a F45-30-11 fixed angle rotor (UK). 
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5.3.11.1 Glycine Extraction 
Variant colonies were re-suspended in sterile PBS and extraction was completed as 
per the method of Wright et al., (2005).  Cells were centrifuged at 2,000 g for 
15 minutes at room temperature and washed in PBS twice.  Cells were re-suspended 
in 400 µL of 0.2 M glycine (pH 2.2) containing 200 μL of Complete Mini Protease 
Inhibitor Cocktail (Roche, UK) and incubated for 30 minutes at room temperature.  
The suspension was then centrifuged at 17,000 g for 10 minutes at room temperature.  
The supernatant was neutralised with 2 M Tris-HCl and TCA-precipitated as detailed 
in Chapter 2.0, Section 2.2.1.  The resulting pellet was re-suspended in collection 
buffer (7 M urea, 40 mM Tris-base, 0.5% (v/v) ampholytes, 1% (w/v) ASB-14), the 
protein concentration determined by BCA assay (Chapter 2.0, Section 2.2.2) and 
reduced and alkylated (Chapter 2.0, Section 2.1.3).  Protein samples were aliquoted 
and stored at -20°C until subsequent analysis. 
 
5.3.11.2 CHAPS Extraction 
Extraction was performed as per the protocol of Hansmeier et al., (2006).  Variant 
colonies were re-suspended in 50 mM Tris-HCl (pH 7.2) and centrifuged at 5,000 g, 
4°C for 10 minutes.  The pellet was washed twice with Tris-HCl buffer and 
re-suspended in 400 µL of Tris-HCl buffer containing 2% (w/v) CHAPS and 200 µL 
of Complete Mini Protease Inhibitor Cocktail.  The preparation was placed on ice for 
a minimum of 2 hours, followed by centrifugation at 3,500 g for 30 minutes at 4°C.  
The supernatant was TCA-precipitated and the resulting pellet was re-suspended in 
collection buffer (7 M urea, 40 mM Tris-base, 0.5% (v/v) ampholytes, 
1% (w/v) ASB-14), the protein concentration determined by BCA assay (Chapter 
2.0, Section 2.2.2) and reduced and alkylated (Chapter 2.0, Section 2.4.1).  Protein 
samples were aliquoted and stored at -20°C until subsequent analysis. 
5.3.12 1D SDS-PAGE and Staining 
SDS-PAGE gels were completed as detailed in Section 2.3; Criterion™ TGX™ 
Precast Gel, 4–20% were used.  Unless otherwise stated, 10 µg of total protein was 
loaded.  Markers included 4 µL Bio-Rad Precision Plus Protein™ WesternC 
Standards.  Gels were double stained as detailed in Chapter 2.0, Section 2.5 or 
transferred to nitrocellulose membranes. 
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5.3.13 Western Blot and Chemiluminescence 
Western blot and chemiluminescence was completed as detailed in Chapter 2.0, 
Sections 2.8 and 2.9 using the antibodies listed in Table 5.3. Rabbit anti-CwpVrptI 
was kindly provided by Prof. Neil Fairweather (Imperial College, UK).   
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Table 5.3: Antibodies used in this chapter.   
Antibody Antigen Dilution   Supplier 
Rabbit anti-CwpVrptI 120 kDa repeat sequence 1/5000  Imperial College London, UK 
Human Sera
1 Unknown 1/50  This study 
Goat anti-Rabbit-HRP Rabbit antibodies 1/10000  Thermo Scientific, UK 
Mouse Anti-Human IgG-HRP IgG Fc PAN (all subclasses) 1/4000  Stratech, UK 
Mouse Anti-Human IgA-HRP IgA heavy chain (all subclasses) 1/2000  Life Technologies, UK 
Mouse Anti-Human IgM-HRP Human IgM heavy chain Fc region 1/2000  Life Technologies, UK 
1
 Details of C. difficile positive patient sera are recorded in Chapter 4, Table 4.5. 
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5.3.14 2-Dimensional Sodium Dodecyl Sulfate Polyacrylamide 
Gel Electrophoresis (SDS-PAGE) 
2D SDS-PAGE was completed as outlined in Chapter 2.0, Section 2.4 and stained 
(Chapter 2.0, Section 2.5) 
 
5.3.15 Mass Spectrometry 
The 120 kDa immunoreactive band was selected for sequencing following the 
method in Chapter 2.0, Section 2.10.  The band was excised from colloidal 
Coomassie stained SDS-PAGE gel. 
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5.4 Results 
5.4.1 Clostridium difficile Culture 
A collection of 22 clinical isolates of C. difficile representing a range of PCR 
ribotypes, including 027, 001 and 106, were cultured from spore stocks on a range of 
media (BHI, BA, CCFA, PPY and VL).  All isolates yielded two distinct colony 
types (morphotypes): Morphotype 1 (M1) displayed the characteristic large, ground 
glass, greyish-white irregular colony of C. difficile whilst Morphotype 2 (M2) 
formed a smaller round glossy colony (Figure 5.2).  As depicted in Figure 5.2, the 
M2 colony was often found in close proximity to the M1 colony, making isolation 
and analysis difficult.  While every effort was made to ensure that only M2 variants 
were sampled it may be possible that small quantities of material from the M1 
colonies were also harvested.  
 
 
 
 
 
 
 
 
Figure 5.2: Morphotypes of C. difficile 11204.  
Representative image of C. difficile NCTC 11204 (ribotype 001).  Cultures were 
prepared from spore stocks, incubated anaerobically at 37°C for 48 hours on 5% 
(v/v) Columbia blood agar. (n=3). 
 
Multiple passaging (three times) of the morphotypes onto BHI agar revealed that 
both the M1 and M2 colonies were unstable, producing cultures of mixed 
morphotypes.  Inoculation of a single M1 or M2 colony into BHI broth for 48 hours 
resulted in the generation of mixed colonial morphotypes upon sub-culturing onto 
BHI agar.  These results are consistent with those presented by Lynch and colleagues 
(2013), who were unable to separate C. difficile colonies by size, when incubated for 
M1 
M1 
M2 
M2 
M2 
 
 
 
M2 
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48 hours on Brucella agar supplemented with 10 μg/mL vitamin K, 5 μg/mL haemin, 
5% laked sheep blood. 
 
5.4.2 Proportion of Morphotypes 
As all 22 strains assessed in this study produced variant colonies, to simplify further 
analysis NCTC strain 11204 (ribotype 001) was selected and cultured on the 
following media; BA, CCFA, PPY and VL. As can be seen from Figure 5.3 the 
frequency of the resulting morphotypes varied depending on the culture media with 
M1 accounting for between 70-90% of the colonies depending on the culture media.  
To confirm that the difference in morphotypes was not due to the presence of a 
contaminant the biochemical profile of each variant was confirmed as being that of 
C. difficile using the RapID ANA II System. 
 
Figure 5.3: Effect of media on proportion of M1 and M2 morphotypes.  
Spore stock of C. difficile 11204 was serially diluted in PBS with 100 μL spread onto 
reduced media; cultures were incubated under anaerobic conditions at 37°C for 
48 hours.  Error bars correspond to standard deviation of three replicates.  Statistical 
analysis was conducted with ANOVA, a statistically significant difference, p<0.05, 
was found in all media tested. 
  
0
500
1000
1500
2000
2500
3000
BHI BHIT BA CCFA PPY VL
C
F
U
/m
L
 
Media 
M1 M2
  
179 
 
5.4.3 Light and Electron Microscopy of Morphotypes 
Light microscopic examination of strain NCTC 11204 grown in BHI broth for 
48 hours revealed the presence of multiple Gram positive cells of differing 
morphologies.  Cells can be seen as single individual cells (red arrows) or arranged 
end to end as short (blue arrows) or long chains of cells (yellow brace) (Figure 5.4). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.4: Gram stain of C. difficile 11204 48 hour broth culture.  
Cells were grown in BHI broth for 48 hours, Gram stained and viewed under oil 
immersion at x1000 magnification with an Olympus DX-50 microscope; images 
were captured on an Olympus DP10 camera. Bar 10 µm. Red arrows; single cells, 
Blue arrows; chains comprised of short cells, Yellow brace; Chains comprised of 
longer cells, Black arrow; spores, (from 5 fields of view).   
 
To assess if the variation in cell morphologies was associated with colony 
morphology, microscopic examination of material from a M1 colony revealed it to be 
predominantly comprised of short, encapsulated cells (2.7±0.9 µm in length) (n=5) 
arranged in chains (Figure 5.5A).  In contrast, the M2 colony consisted primarily of 
filamentous rods (13±0.4 µm in length) (n=5) (Figure 5.5B).  Lynch et al., (2013) 
have recently shown a metronidazole resistant clinical isolate of C. difficile to display 
elongated cell morphology.  The length of the bacilli in the wildtype, metronidazole 
susceptible and resistant isolates were 2.8±0.9 µm, 3.6±2.1µm and 4.0±2.1µm, 
Single cells 
Shorter  
chains 
Longer  
chains 
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respectively.  Although the cell length is similar to the cells comprising the M1 
colony, they are shorter than those of the filamentous cells reported here.   
 
 
 
 
 
 
 
 
 
Figure 5.5: Capsule stain of C. difficile 11204.  
A) M1 and B) M2. Cells were Gram stained and viewed under oil immersion at 
x1000 magnification with an Olympus DX-50 microscope; images were captured on 
an Olympus DP10 camera. Bar 10 µm. Red arrows; single cells, Blue arrows; chains 
comprised of short cells, Yellow brace; Chains comprised of longer cells, Black 
arrow; spores (from 5 fields of view).  
 
Both M1 and M2 colonies contained individual cells. Visual examination suggested 
that the filamentous cells lacked the presence of a capsular layer; however when 
viewed using image enhancement tools (brightness and contrast), the presence of a 
thin capsular layer could be observed. 
 
To further characterise the morphology of the variant cell types of C. difficile, 
samples were negatively stained and imaged by transmission electron microscopy.  
The images revealed the presence of both filamentous and short cells, but 
unfortunately, the images were found to be heavily stained making detailed analysis 
difficult (Figure 5.6).  TEM of the M2 colony revealed the presence of all three cell 
types (individual, chain and filamentous).  It was not possible to definitively 
determine if the short chain represented dividing cells or were two cells arranged end 
to end in a chain, as seen in the light microscope image.  Due to problems associated 
with staining, detailed cell images could not be obtained. 
 
 
 
Cell 
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A) B) 
Cell 
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Figure 5.6:  Negatively stained TEM of C. difficile NCTC 11204.   
A) M1 and B) M2. Images were negatively stained with 2% (w/v) methylamine 
tungstate and examined on a transmission electron microscope EM 280. 
Magnification A)16 Kx and B) 3.2 Kx (from 5 fields of view).    
 
The presence of variant colonies and cells of C. difficile raises a number of questions; 
are they seen in vivo and do they display differing properties which contribute to 
virulence and what purpose, if any, do they serve.  The polymorphic nature of 
C. difficile has been reported, with small colony phenotypes (Kirby et al., 2009; 
Reynolds et al., 2011), filamentous cells (Lynch et al., 2013) and cells arranged in 
chains (Martin et al., 2013) occurring as a consequence of genetic manipulation.  To 
the best of our knowledge the data presented above is the first to demonstrate such 
variability in the absence of genetic manipulation.  During the course of submitting 
this thesis, research conducted by Lipovsek et al., (2013) has confirmed the presence 
of multiple cell types of differing lengths within a typical C. difficile colony.     
 
5.4.4 Bile Salt Sensitivity 
Thus far very few studies have reported the interaction between bile salts and the 
vegetative cells of C. difficile.  Triton-X-100 inhibits autolytic activity in the 
Single cell 
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peptidoglycan by forming micelles with lipoteichoic acid (LTA) (Gutmann et al., 
1996; Neuhaus and Baddiley, 2003).  The inhibitory effect of LTA is dependent on 
the net negative charge of the cell surface, which can be reduced by diluting in 
Triton-X-100 (Gutmann et al., 1996).  This method provides an overview of the 
general bacterial autolytic system in the two morphotypes and can be utilised to 
assess lysis induced by other detergents, including bile salts.   A cuvette based 
method was employed to determine if the morphotypes varied in their sensitivity to 
Triton-X-100 and bile salts chenodeoxycholate and taurocholate (Figures 5.7–5.9).  
Using Triton-X-100 as a model to represent bacterial autolysis, the M1 morphotype 
lysed significantly more rapidly than M2, (post hoc Tukey’s test, p<0.05), suggesting 
that there may be a difference in the autolytic system of the two variants 
(Figure 5.7A and B).   
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Figure 5.7: Timed Lysis assay of C. difficile NCTC 11204 (ribotype 001) M1 and 
M2 with water and 0.05% (v/v) Trition-X-100.   
A) Water and B) 0.05% (v/v) Trition-X-100. Autolysis is expressed as percentage 
reduction of initial OD600.  Error bars indicate standard deviations.  Statistical 
analysis was conducted with ANOVA and post hoc Tukey’s test. *, indicates 
statistically significant difference, p<0.05. (n=3). 
* 
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As with  Triton-X-100 the M1 variant was found to be significantly more sensitive to 
the effect of the bile salt, chenodeoxycholate than the M2 variant (p<0.05) 
(Figure 5.8).
 
Figure 5.8: Timed lysis assay of C. difficile NCTC 11204 (ribotype 001) M1 and 
M2 with 0.1% (v/v) chenodeoxycholate.   
Autolysis is expressed as percentage reduction of initial OD600.  Error bars indicate 
standard deviations.  Statistical analysis was conducted with ANOVA and post hoc 
Tukey’s test, *, indicates statistically significant difference, p<0.05. (n=3). 
  
* 
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In contrast no significant difference in lysis was observed between the morphotypes 
in the presence of sodium taurocholate (p>0.05), Figure 5.9, this is more likely to be 
a reflection of the need for a greater number of replicates, as the post hoc Tukey’s 
test only compares the difference between means.  
 
Figure 5.9: Timed lysis assay of C. difficile NCTC 11204 (ribotype 001) M1 and 
M2 with 0.1% (w/v) taurocholate.   
0.1% (w/v) taurocholate.  Autolysis is expressed as percentage reduction of initial 
OD600.  Error bars indicate standard deviations.  Statistical analysis was conducted 
with ANOVA and post hoc Tukey’s test. p>0.05. (n=3).  
 
From the results presented above, the M1 variant is significantly more sensitive to 
lysis in the presence of both Triton-X-100 and chenodeoxycholate than M2.  Given 
that colonial morphology has been associated with virulence in some species of 
bacteria (S. aureus and Neisseria gonorrhoea), it is intriguing to speculate the 
differences observed in lysis susceptibility of M1 and M2 could also be associated 
with virulence in C. difficile.  Further studies are required to determine if this is the 
case and whether the lytic properties of the two morphotypes aid in survival and 
persistence in the GI tract. 
 
5.4.5 Cell Surface Extraction 
To determine if the composition of the cell surface proteins of each morphotype 
differed, proteins from each morphotype was extracted and subjected to SDS-PAGE.  
M1 and M2 colonies were harvested from ~200 agar plates and each morphotype 
pooled to generate sufficient material to support subsequent analysis.  The ability of 
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low pH glycine and CHAPS extraction buffer to extract bacterial proteins was 
compared using 1D SDS-PAGE (Figure 5.10).  Glycine extraction yielded a similar 
banding pattern to that previously reported in the literature, with two major bands 
corresponding in size to the HMW (45 kDa) and LMW (36 kDa) S-layer proteins 
(Wright et al., 2005).    The CHAPS extraction method yielded a greater number of 
protein bands than the glycine extracted method from each morphotype.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.10: Extraction of S-layer proteins from M1 and M2 variants.   
Protein extraction was completed as detailed in 5.3.15, 10 µg total protein was 
analysed on a 4–20% SDS-PAGE gel and stained with colloidal Coomassie. 
M; molecular weight maker in kDa.  HMW SLP, high molecular weight surface layer 
protein and LMW SLP, low molecular weight surface layer protein. 
 
Subsequent analysis of these cell wall extracts using 2DE showed generally similar 
protein profiles (Figure 5.11), with the majority of the protein spots located in the 
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low pH range (3-6).  Overall the M1 profile displayed a greater number of protein 
spots than the M2 profile.  
 
Although the protein concentration was standardised using a BCA assay, staining of 
the gel revealed unequal protein loading (Figures 5.10 and 5.11).  The BCA assay 
detects the presence of three or more amino acids (particularly cysteine/cystine, 
tyrosine and tryptophan) in peptides, resulting in the formation of a coloured 
complex which is proportional to the number of amino acids present in the sample.  
A visual comparison of the number and intensity of the peptides detected by 1D and 
2D SDS-PAGE gels, suggests that contrary to the results obtained with the BCA 
assay, the concentration of M2 in the loaded samples was lower than that of M1.  
The reason for this difference is unclear and could be due to some form of 
interference with the protein sample and the BCA assay.  One possible explanation is 
that the amino acid composition of M1 and M2 may vary, although further studies 
would need to be undertaken to determine if this is the case.  If this is indeed true it 
may have an impact on the immunoreactivity of the two morphotypes. 
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Figure 5.11: 2DE of CHAPS and Glycine extracted M1 and M2 variants.   
A) M1 CHAPS, B) M2 CHAPS, C) M1 Glycine and D) M2 Glycine.  Cell surface proteins were resolved by 2D SDS-PAGE and stained with colloidal 
coomassie.  Gels were imaged with the Chemi Doc xrs+ system, under white light trans illumination, faint band exposure and analysed using Image Lab™ 
Software, v.3.0. (n=2). 
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5.4.6 1D Western Blot Analysis 
Due to the problems mentioned in standardising protein loading, direct comparisons 
between the immunogenicity of M1 and M2 could not be made.   However, given 
that the gross protein composition of M1 and M2 was found to be broadly similar 
coupled with the sensitivity of Western blotting; the presence and absence of 
immunogenic bands may still be assessed.  
 
5.4.6.1 CwpV 
CwpV has been identified as a phase variable cell wall protein, expression of which 
has been shown to affect cellular organisation and hence colony morphology 
(Emerson et al., 2009; Reynolds et al., 2011).  To determine if the M1 and M2 
morphotypes differed with regards to CwpV expression, glycine and CHAPS extracts 
of M1 and M2 were probed with an antibody which recognises CwpVrptI 
(Figure 5.12).  A band of approximately 120 kDa, corresponding in size to CwpV 
was recognised only in the CHAPS extracts obtained from M1 and M2.  This result 
was surprising given that glycine extracted proteins have previously been shown to 
contain a 120 kDa immunogenic band detected by anti-CwpVrpt1 (Emerson et al., 
2009).  The absence of this band in the glycine extract could be due to differences in 
sample preparation (protein extracted from 48 hour plate culture vs. 24 hour broth 
culture) or in the concentration of the sample loaded onto the gel.  To confirm the 
validity of the antibody, a positive control in the form of recombinantly expressed 
CwpV should have been utilised.  In addition to the 120 kDa band, eight other bands 
were detected in the CHAPS extracted M1 and M2 samples.  Comparison of the 
antibody binding profile of the glycine and CHAPS extracts, revealed the presence of 
a 75 kDa band in all samples; in the case of the glycine extracts this could represent 
degraded CwpV.  Given our problems with standardising the level of protein loading 
it is not possible to comment with any confidence on the relative intensity of each 
band in M1 and M2, even though it would appear that a more intense signal was seen 
for M1. 
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Figure 5.12: Western blot analysis of glycine and CHAPS extracted M1 and M2 
proteins probed with anti-CwpVrptI.   
Anti-CwpVrptI (1/5000) probe of glycine and CHAPS extracted protein, resolved on 
a 4–20% SDS-PAGE gel and transferred to nitrocellulose and detected with 
SuperSignal Femto.  Blots were imaged with the Chemi Doc xrs+ system.  5 µL of 
Precision Plus Protein™ Western C marker (M). 
 
5.4.6.2 Human Patient Sera 
A total of six serum samples were collected from C. difficile infected patients who 
had been treated at the University Hospital of Wales.  As discussed in Chapter 4, sera 
CD2 and CD4 were not used for Western blot studies and will not be referred to in 
this chapter.  Additionally sera CD5 displayed a high level of background staining 
which made it impossible to identify immunoreactive bands.   
 
Probing of glycine and CHAPS extracts of M1 and M2 with human sera revealed the 
presence of IgM antibodies which recognised proteins in the CHAPS extracts of both 
morphotypes (Figure 5.13).  A band with an approximate molecular weight of 
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120 kDa was consistently detected in all patient sera (Figure 5.13).  Based on the size 
of the protein band, this band may represent the CwpV protein which was detected 
by anti-CwpVrpt1 (Figure 5.12), although further studies are required to determine if 
these human antibodies are specific for CwpV.   
 
   
 
 
 
 
 
 
 
 
Figure 5.13: Western blot analysis of glycine and CHAPS extracted M1 and M2 
proteins, human sera IgM.   
Total protein was resolved on a 4–20% SDS-PAGE gel and transferred to 
nitrocellulose, probed with human sera (1/50) and detected with SuperSignal Femto.  
Blots were imaged with the Chemi Doc xrs+ system.  5 µL of Precision Plus 
Protein™ Western C marker (M). 
 
A greater number of immunoreactive bands were observed with IgA than IgM 
(Figure 5.14), particularly for CD3 and CD6.  All sera recognised the 120 kDa band, 
previously described by the IgM response.  In contrast to CD1, CD3 and CD6 
recognised multiple bands in the M1 and M2 extracts.  Unlike IgM, the IgA response 
for CD3 and CD6 detected the presence of immunoreactive proteins in the glycine 
extracted profiles.  Given their size the 48 and 36 kDa immunoreactive proteins are 
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likely to represent the HMW and LMW SLP, respectively, although this would need 
to be confirmed by additional studies.  Four common immunoreactive bands were 
identified (120, 100, 48, 36 kDa) (Figure 5.14, red boxes), suggesting patients 
infected with C. difficile may recognise common proteins, which in turn could be 
utilised to support the development of future therapeutics and diagnostics. 
 
 
 
 
 
 
 
 
 
 
Figure 5.14: Western blot analysis of glycine and CHAPS extracted M1 and M2 
proteins, Human sera IgA.   
Total protein was resolved on a 4-20% SDS-PAGE gel and transferred to 
nitrocellulose, probed with human sera (1/50) and detected with SuperSignal Femto.  
Blots were imaged with the Chemi Doc xrs+ system.  5 µL of Precision Plus 
Protein™ Western C marker (M). Red boxes indicate common immunogenic bands. 
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Considerably more protein bands were recognised by patient derived IgG 
(Figure 5.15) than with IgA and IgM, and as before a greater number of 
immunoreactive bands were detected in the CHAPS extracts than the glycine 
extracts.  Consistent with the IgA and IgM response a band of 120 kDa was 
identified in all the immune sera.   In addition to the 120 kDa band, immunoreactive 
bands with apparent molecular weights of 100, 36 and 15 kDa were also detected.   
 
 
 
 
 
 
 
 
 
Figure 5.15: Western blot analysis of glycine and CHAPS extracted M1 and M2 
proteins, Human sera IgG.   
Total protein was resolved on a 4-20% SDS-PAGE gel and transferred to 
nitrocellulose, probed with human sera (1/50) and detected with SuperSignal Femto.  
Blots were imaged with the Chemi Doc xrs+ system.  5 µL of Precision Plus 
Protein™ Western C marker (M). 
 
The CHAPS extraction method identified a greater number of bands than the glycine 
based extraction method.  The problems encountered with regards to protein loading 
made comparisons between immunoreactive profiles of M1 and M2 morphotypes 
difficult.  Consistently an immunoreactive band of 120 kDa was identified with 
anti-CwpVrptI and human sera from C. difficile infected patients, which was 
frequently absent from the M2 profile. 
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5.4.7 Mass Spectrometry 
Due to time constraints and costs associated with mass spectrometry, only the 
120 kDa band was selected for subsequent sequencing.  This protein was found to 
contain one identifiable peptide (LPFIHFFDGFR), the identification of which was 
accepted based on the e-value (0.00033) being p<0.0001.  The protein from which 
this peptide was derived was identified as 
pyruvate-ferredoxin/flavodoxin oxidoreductase (PFO), Accession Q183B6_CLOD6, 
CD2682, with an estimated molecular weight of 129 kDa.  Following a database 
search of TrEMBL, this protein was found to be encoded by nifJ, which is present in 
all C. difficile genomes, sequenced to date.  Figure 5.16 depicts the genetic 
arrangement of nifJ in C. difficile 630. 
 
 
 
Figure 5.16: Diagrammatic representation of genetic arrangement of nifJ.   
Image is representative of C. difficile 630, created using http://www.xbase.ac.uk/.   
 
PFO is an essential enzyme in anaerobic metabolism, reversibly catalysing the 
conversion of pyruvate into acetyl-CoA+CO2+H2 and reduced ferredoxin resulting in 
the production of short chain fatty acids (lactate and acetate butyrate), ethanol and 
butanol (Chabrière et al., 1999; Karlsson et al., 2000; Janoir et al., 2013).  During 
this process the production of CO2 and H2 may contribute to maintaining an 
anaerobic environment (Shimizu et al., 2002).   In other intestinal bacteria PFO is 
associated with an oxidative stress response and bile tolerance.   
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5.5 Discussion 
The presence of variant C. difficile cells and colonies raises many questions.  What 
benefit (if any) do these variations provide to the bacterium, and are such variations 
in bacterial form seen in vivo?  If so, is there an association between variation, 
virulence and persistence, particularly in relation to survival in the gut.  If one 
morphotype is favoured over the other in the context of infection, it would make 
practical sense to ensure that this morphotype is employed when seeking to 
characterise host specific immune responses.     
 
5.5.1 Clostridium difficile Morphotype Characteristics  
The polymorphic nature of C. difficile has been observed by others, with 
spontaneously occurring dwarf colonies (Brazier and Borriello, 2000) and small 
colony phenotypes reported as a consequence of genetic manipulation (Kirby et al., 
2009; de la Riva et al., 2011; Reynolds et al., 2011).  A recent paper by Lipovsek et 
al., (2013) has confirmed a number of observations made in this thesis, in that 
several different cell populations can be seen within an individual C. difficile colony.  
Consistent with the data presented herein, Lipovsek et al. identified two colony 
morphotypes, large irregular colonies and small round colonies, in four strains of 
C. difficile grown on Columbia blood agar plates.  Unfortunately the authors failed to 
provide data on the small colony and therefore direct comparison with the M2 colony 
cannot be made.  This is not surprising given the difficulty encountered during the 
course of this research in producing sufficient M2 material for analysis.  
 
Interestingly the authors reported differences in colony morphology between 2 and 5 
day cultures, with the latter displaying a smoother colony and vegetative cells 
embedded in an extracellular matrix.  The presence of capsular-material in the M1 
and M2 colonies in this thesis and its role/contribution to the formation of an 
extracellular matrix is unclear.  In contrast to the Lipovsek et al., a smooth colony 
with an extracellular capsule layer was observed in 2 day cultures in this thesis, 
which may be due to strain-to-strain variation.  Although it was not possible to 
quantify the thickness of the capsule layers of M1 and M2, visual analysis of the 
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light microscope images suggested the short cells of the M1 colony displayed a 
capsule which extended further from the vegetative cell than the M2 capsule.  The 
M2 capsule surrounding the filamentous cells was found to be closely associated 
with the vegetative cell surface.  Earlier work by Davies and Borriello (1990) had 
described the presence of two types of capsules in C. difficile, a dense layer with or 
without globular masses and a loose-knit, branching layer.  If, the capsules identified 
herein are indeed morphologically distinct then they would represent the first 
documented instance of within-strain capsule variability in C. difficile.  Although this 
would need to be confirmed by further TEM and SEM studies.  Such variability with 
regards to surface proteins and polysaccharide has been reported in B. fragilis 
(Patrick et al., 1995).  B. fragilis is an intestinal, anaerobic, Gram-negative organism, 
capable of producing phase and antigenically distinct capsular structures associated 
with evasion of the host immune response.  van der Woude, (2011) defines phase 
variation as a heritable, yet reversible regulatory event resulting in a clonal 
population with a heterogeneous phenotype, which is akin to the observations 
discussed above for C. difficile.  Historically, phase variation is related to varied 
colony morphology due to altered surface proteins, capsule and cell wall composition 
(van der Woude and Bäumler, 2004), resulting in differences in virulence-associated 
factors (colonisation and antigenic), as such the morphotypes presented in this work 
may be indicative of one or more proteins which is capable of phase variation.  
Capsule variation in C. difficile may also be indicative of this.  The role of phase 
variation in the regulation of the cell wall protein, CwpV (Emerson et al., 2009; 
Reynolds et al., 2011) coupled with the presence of multiple inversions in the 
C. difficile genome (Stabler et al., 2010) suggests that in C. difficile (as in other 
intestinal bacteria) phase variation is important for survival.     
 
The encapsulated chain-like arrangement observed in this study is not unique to 
C. difficile, and has been reported in other Clostridium spp. (Betz, 1970; Kuhner et 
al., 2000).  In other bacterial species, bacterial chains rapidly facilitate the transfer of 
DNA to cells within the chain (Babic et al., 2011) or may serve as a means of 
resisting infection from bacteriophages, indeed the presence of a capsular layer may 
well aid in this as well (Betz, 1970; Abedon, 2012).  In a recent study of the agr 
locus in C. difficile, TEM images of an agr mutant revealed the presence of 
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C. difficile cells arranged in chains, possibly surrounded by an external layer, which 
mirrors the light microscope images obtained in this thesis (Martin et al., 2013).   
 
Using a Triton-X-100-induced autolysis assay an overview of the general bacterial 
autolytic system of the M1 and M2 morphotypes was deduced, revealing that the M1 
morphotype lysed significantly more rapidly than M2, indicating that the two 
morphotypes display differences in their autolytic activity.  In B. subtilis (Margot et 
al., 1998; Margot et al., 1999; Smith et al., 2000), C. perfringens (Camiade et al., 
2010) and Listeria monocytogenes (Carroll et al., 2003), the formation of long chains 
is attributed to mutations which effect the activity of peptidoglycan hydrolases 
(PGHs).  A mutant of C. perfringens deficient in the expression of the PGH, Acp, 
grows as a long chain of cells similar to those seen in C. difficile (Camiade et al., 
2010). While C. difficile, contains a homologue to Acp called Acd (59% amino acid 
similarity), the Acd mutants examined to date revealed no phenotypic differences in 
chain formation or cell separation (Dhalluin et al., 2005; Peltier et al., 2010).  This is 
possibly due to functional compensation by one or more of the 28 putative autolysins 
which have been identified in the C. difficile genome (Wright, 2006).  Autolysins are 
involved in peptidoglycan turnover, cellular division, sporulation/germination and 
antibiotic-induced lysis (Peltier et al., 2010), in the latter case the differences 
observed in autolysis of M1 and M2 may therefore confer the M2 morphotype a 
competitive advantage in vivo upon administration of antibiotics.  Furthermore, in the 
presence of the bile salt, chenodeoxycholate, M1 was more susceptible to lysis than 
the M2 morphotype, suggesting that the M2 morphotype may be better able to 
survive in the GI tract.   
 
It should be noted that the lysis assays were performed under aerobic conditions, thus 
the influence of oxygen related stress cannot be ruled out.  Gram stain images taken 
before and after the bile salt assays did reveal the presence of both spores and 
vegetative cells, with the latter being predominant.  The presence of spores and 
vegetative cells is not surprising as M1 and M2 colonies were isolated following 
incubation for 48 hours.  Although a viability assay was not performed, C. difficile 
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has been shown to tolerate microaerophilic conditions (Jump et al., 2007; Emerson et 
al., 2008) 
 In C. difficile genetic analysis of a metronidazole resistant and susceptible strain 
revealed differences associated with electron transport, including glycerol-3-
phosphate dehydrogenase (glyC) and PFO (nifJ) (Lynch et al., 2013).  In addition to 
affecting the efficiency of metronidazole entry into the cell and subsequent 
activation, disruptions in electron transport are associated with small colony variants 
(Lynch et al., 2013).  Although Lynch and colleagues did not observe small colonies 
in their research, it is intriguing to speculate that the similarities observed between 
their research and that presented in this thesis may indeed be associated with SCVs.  
The absence of small colonies in the work conducted by Lynch et al., maybe due to 
difference in the strain or media employed (Brucella agar supplemented with 10 
µg/mL vitamin K, 5 µg/mL haemin, 5% laked sheep blood+8 µg/mL metronidazole).  
In this thesis the sensitivity of M1 and M2 to metronidazole was not assessed but 
should be investigated in subsequent studies.  It is unclear whether our observations 
are reflective of an adaptive response to culturing in the laboratory or represent an 
unreported survival mechanism of C. difficile.  Given the number of factors 
(including potential virulence factors) affected, a global regulation mechanism may 
be required. 
 
5.5.2 Clostridium difficile Morphotype Proteomics and 
Immunoreactive Proteins 
In support of published data (Wright et al., 2005), glycine extraction revealed the 
presence of proteins which corresponded in molecular weight to the HMW and 
LMW SLP.   The results presented here indicate that a CHAPS based method is 
capable of extracting a greater number of cell surface proteins than low pH glycine 
and as such may give a more complete profile of the surfaceome of C. difficile.  
Although sequencing of the CHAPS extracted bands would aid in identifying how 
many of these proteins are recognised SLPs.  Furthermore, glycine is recognised as a 
co-germinant for C. difficile spores (Sorg and Sonenshein, 2008; Wheeldon et al., 
2011), however its interaction with vegetative cells is unreported.  Based on the 
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number of proteins extracted and analysed by 1D SDS-PAGE, the CHAPS based 
method outperformed the glycine extraction method. 
 
To determine if the morphotypes expressed proteins recognised during the course of 
human infection, we probed glycine and CHAPS extracted proteins with sera from 
C. difficile infected patients.  Due to the problems encountered in standardising 
protein loading, which may well be attributed to differences in amino acid 
composition, direct comparison between M1 and M2 extracted proteins could not be 
made.      However, it was noted that the 120 kDa immunogenic band was frequently 
absent from the M2 extract but present in the M1 extract.  Previously, authors have 
identified immunodominant proteins of C. difficile by using a mixture of anti-human 
IgA, IgM, and IgG HRP conjugated antibodies (Wright et al., 2008).  In this study, 
we probed cell surface extracts of C. difficile with antibody conjugates which 
recognised each subclass individually.  Based on the number of the immunoreactive 
bands detected, IgG displayed the strongest response, followed by IgA and IgM.   
The immunogenic profiles obtained in this thesis are similar to those obtained in the 
published literature (Wright et al., 2008).  Unfortunately, due to the limited 
availability of M1 and M2 protein extracts and human patient sera we were unable to 
perform any further analysis using 2DE Western blots.  This would have allowed 
better resolution and identification of common immunogenic proteins.  If the M1 and 
M2 morphotypes do truly display differences in immunogenicity, this will not only 
have an impact on the pathogens ability to evade the host immune system but also on 
the development of therapeutics based on cell surface structures.      
 
Although a number of common proteins were identified following Western blot 
analysis, due to time restraints and limited financial resources, a single band was 
selected for sequencing and identified as pyruvate-flavodoxin oxidoreductase (PFO), 
which is encoded by nifJ.  The nifJ gene is associated with oxidative response and 
has been identified in other intestinal bacteria, including Klebsiella pneumoniae, 
B. fragilis and Enterococcus faecalis (Schmitz et al., 2001; Begley et al., 2005), to 
play a role in bile tolerance.  In the latter organism, nifJ was one of 45 genes up 
regulated following bile salt treatment (Flahaut et al., 1996a; Flahaut et al., 1996b; 
Begley et al., 2005).  Whether the low (sub-lethal) concentration of bile salts that 
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would naturally be present in the most commonly used C. difficile culture media, 
BHI, results in an adaptive response against stresses, is unclear.  Currently, it is only 
possible to speculate if this is occurring in C. difficile.  Given that intestinal 
pathogens are exposed to the same environmental stresses, it would be conceivable 
that they have adapted similar survival mechanisms.  
 
PFO is an essential metabolic enzyme in anaerobic bacteria, in addition to catalysing 
the conversion of pyruvate into acetyl-CoA+CO2+H2 to produce short chain fatty 
acids (lactate and acetate butyrate), ethanol and butanol, it may also aid in 
maintaining an anaerobic environment (Chabrière et al., 1999; Karlsson et al., 2000; 
Janoir et al., 2013).  It is intriguing to speculate the role(s) of nifJ in Clostridium 
spp., does it confer an advantage in growth and survival by maintaining an anaerobic 
environment in host tissue (Shimizu et al., 2002), is it involved in bile tolerance 
(Flahaut et al., 1996a; Flahaut et al., 1996b) or as observed in Vibrio does it in some 
way contribute to virulence by enhancing capsule production and adherence (Pace et 
al., 1997).  Further studies would be required to investigate the relationship between 
bile salts and morphotypes in C. difficile.  Furthermore PFO has recently been shown 
to be the target for the antibiotic, amixicile, which has displayed clinical efficacy 
against CDI in a mouse model (Warren et al., 2012).  PFO has also been shown to be 
immunogenic in C. perfringens (Kulkarni et al., 2007) and Entamoeba histolytica 
(Thammapalerd et al., 1996) and as such may represent a valid therapeutic target.   
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5.6 Conclusion 
This chapter aimed to characterise the differences in variant C. difficile colonies.  All 
strains analysed were found to display colonial variance.  Two colonies, M1 and M2 
were characterised further by microscopy, lysis assay, proteomics and 
immunoproteome studies.   
 
Colonies of C. difficile display differences in autolytic and bile salt sensitivity, with 
M1 being more susceptible to lysis in the presence of chenodeoxycholate.  The 
identification of a protein (pyruvate-flavodoxin oxidoreductase) associated with 
oxidative and/or bile salt-related stress warrants further investigation.  Given the 
proteins immunogenicity it may be exploited for therapeutic purposes.  The presence 
of varying cell types within the colonies and the presence of a capsule should also be 
investigated further. 
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CHAPTER SIX 
GENERAL DISCUSSION 
  
203 
 
6.1 General Comments 
It can be argued that C. difficile research has long been neglected, and it is only in the 
last thirteen years (following a number of major outbreaks) that steps have been 
taken to decipher the complex nature of this organism and its disease causing ability.  
Broadly speaking we can categorise C. difficile research into three aspects; the 
vegetative cells, toxins and spores.  This thesis has sought to investigate the 
vegetative cells and toxins A and B of C. difficile, focusing on their variability with 
regards to immunogenicity and possibly virulence.    
 
6.2 Variability of Vegetative Clostridium difficile 
The vegetative form of the bacteria is associated with toxin production resulting in 
active disease in the gut.  The strain-to-strain variation in growth rate, sporulation, 
toxin production and surface layer proteins in C. difficile is well documented.  Thus, 
it is not surprising that we too have observed differences, intriguingly the aspect of 
colonial variation adds another dimension to the variability of this organism.  In this 
thesis we have characterised in detail the variant morphotypes (M1 and M2) 
produced by a single clinical isolate of C. difficile.  The production of variant 
morphotypes by twenty-two other clinical isolates indicates that colonial variation is 
universally present in C. difficile isolates.  
  
Examination of the variant colonies revealed morphological differences at a cell 
structure level, which may impact on adherence, cell lysis, immunogenicity and 
virulence.  Given the relative difference in autolysis and bile salt-induced lysis, it is 
tempting to speculate that one morphotype maybe better equipped to survive in the 
hostile environment of the gut.  At this stage it is only possible to speculate on the 
implication(s) of the morphotypes in the context of virulence and pathogenesis.   
 
The presence of a capsular layer in the two morphotypes may well pose a challenge 
for therapeutics targeting the cell wall, although its presence in vivo would need to be 
confirmed.  In the intestinal bacteria, Bacteroides fragilis, a phase variable capsule 
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aids in colonization and host immune evasion (Chatzidaki-Livanis et al., 2010), the 
presence of CwpV in C. difficile demonstrates that this intestinal pathogen is also 
capable of producing a phase and antigenically variable protein.  Based on the visual 
differences observed in the capsule surrounding the short and long cells of 
C. difficile, it is intriguing to speculate that the capsules are morphologically distinct 
and as such may well be expressed in a phase variable manner.  This thesis has 
highlighted that there is much to be explored with regards to the vegetative form of 
C. difficile, particularly the interaction of vegetative C. difficile with bile salts, given 
that C. difficile is a gut pathogen.  Thus far all research has focused on the interaction 
of C. difficile spores and bile salts; given that once the spore germinates it is the 
vegetative cell which will be exposed to the detergent activity of bile, the organism’s 
ability to survive such conditions must be understood.   
 
Western blotting of vegetative cell extracts of both morphotypes revealed the 
presence of a common immunogenic band which was recognised by antibodies from 
animal and human sera.  This band was subsequently identified as 
pyruvate-flavodoxin oxidoreductase (PFO), a protein involved in anaerobic 
metabolism and associated with an oxidative response in other intestinal pathogens 
(Flahaut et al., 1996a; Flahaut et al., 1996b; Schmitz et al., 2001; Begley et al., 
2005).  In C. perfringens, PFO is an immunogenic, lytic enzyme released during 
germination (Ando, 1979), immunization with truncated PFO protected chickens 
from experimental challenge with virulent C. perfringens (Kulkarni et al., 2007).  
Although the C. difficile PFO does not contain a discernible signal sequence it has 
been identified in the secretome of three C. difficile isolates (Boetzkes et al., 2012).  
Given that this protein has also been shown to mediate immunity to invasive 
amoebiasis from E. histolytica (Thammapalerd et al., 1996), it is intriguing to 
speculate that these findings may also be mirrored in C. difficile.  The 
immunoreactivity of C. difficile PFO has been demonstrated in this study, whether 
this confers to a protective host immune response would need to be investigated.  
Recently, amixicile, a novel PFO inhibitor, has been shown to display clinical 
efficacy against CDI in a mouse model (Warren et al., 2012), indicating PFO may 
well be a promising therapeutic target for antibiotics and immunotherapies.  A better 
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understanding of the form of vegetative C. difficile encountered in the gut would aid 
in the development of new therapeutics and diagnostics. 
 
6.3 Recombinant Expression of Toxin A and B 
A high yield E. coli based recombinant protein expression system, producing the 
non-toxic fragments of the C-terminal and translocation domains of toxins A and B 
was developed.  This was undertaken to support the characterisation of immune 
responses directed against the toxins.  Despite the use of identical expression systems 
(M15[pREP4] and pQE-30) the yield and purity attained for rTcdA900-2710 and 
rTcdB546-2366 was significantly different.  Expression of rTcdB546-2366 yielded 
8-12 mg/L of pure protein in contrast to the 0.8–1.0 mg/L for rTcdA900-2710.  
Difficulties encountered in the expression of non-codon optimised and codon 
optimised regions of TcdA have been reported by others (Phelps et al., 1991; Craggs, 
1999; Letourneur et al., 2003; Ackermann et al., 2004b), suggesting that codon 
optimisation alone is not sufficient to generate a high yield recombinant expression 
system for TcdA.  Whether the problems encountered with expression are due to the 
toxic effects of rTcdA900-2710 is unclear.  Although the optimisation of expression 
strain, media and culture conditions, enabled the production of soluble rTcdA900-2710, 
the yield achieved did not mirror that of rTcdB546-2366.  Thus we can only conclude 
that, although convenient, an E. coli based recombinant expression system may not 
be suitable for the expression of TcdA.  In contrast, expression of TcdA with the 
B. megatarium system appears to eliminate the problems encountered with E. coli 
expression (Burger et al., 2003; Yang et al., 2008; Pruitt et al., 2012; Wang et al., 
2012). Analysis of gene sequences using bioinformatic software although valuable 
may not reflect experimental outcomes.  Indeed a ‘one-rule-fits-all’ method cannot 
be applied for all proteins expressed in E. coli. 
 
6.4 Immunogenicity of Toxin A and B 
Analysis of the recombinantly expressed toxin B indicated that it is structurally 
similar to its native counterpart.  Comparison between native and recombinant toxin 
A was complicated by the low yield and purity obtained for the latter protein.  Whilst 
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toxin A was found to be more resistant to enzymatic digestion than toxin B, toxin B 
demonstrated greater stability following 24 hour incubation at 25°C.  Whether these 
observations have any relevance to the in vivo mechanism of cellular intoxication is 
unclear.  During cellular intoxication the toxins undergo a number of conformational 
changes in response to environmental signals; the ability of TcdA to resist proteolytic 
digestion may prevent premature proteolysis, whilst the stability of TcdB is reflective 
of its temporal activity.  Toxin A is reported to cause initial damage to the epithelial 
cells (Krivan et al., 1986; Tucker and Wilkins, 1991), facilitating the subsequent 
uptake and cytotoxic activity of toxin B (Lyerly et al., 1985b; Bongaerts and Lyerly, 
1994).  Digestion of the toxins may have been enhanced if exposed to in vivo 
conditions, such as InsP6 or low pH, resulting the conformational changes to the 
protein and the subsequent  exposure of enzymatic digestion sites (Qa'Dan et al., 
2000; Barth et al., 2001; Lanis et al., 2010). 
 
The similarities in the 1D and 2D SDS-PAGE and immunogenicity profiles of the 
recombinant and native proteins obtained indicates that recombinant proteins can be 
used as surrogates for the development of therapeutics.  Although to obtain a true 
picture, analysis of the complete recombinant toxins would be required.  The 
immunogenic validity of recombinant proteins and there use as surrogates has been 
demonstrated in a range of expression systems (Heinrichs et al., 2012).      
 
Using animal derived toxin neutralising sera and sera from C. difficile infected 
patients’ common immunogenic regions within TcdA and TcdB (40 and 60 kDa) 
were identified.  Attempts to identify these regions by mass spectrometry were 
unsuccessful.  The resistance of toxin A to trypsin digestion (Taylor et al., 1981; 
Lyerly et al., 1989) may account for the failure to generate meaningful mass 
spectrometry results.  The major limiting factor in peptide identification is protein 
digestion (van Montfort et al., 2002; Wu et al., 2003; Fischer and Poetsch, 2006), the 
use of a combination of proteases may have yielded positive results.  During the 
course of this experiment it became apparent that although a proteomic based 
approach is valuable there are limitations at every stage of the technique, from 
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peptide preparation (staining, digestion, contamination) to sequence analysis.  In 
hindsight it would have been beneficial to analyse the peptides generated from 
trypsin digestion of the toxins prior to gel analysis.  This approach would have 
allowed us to ascertain if the toxin was susceptible to trypsin digestion and if so 
assess the peptides which could be successfully identified.  This study successfully 
identified the major immuno-responsive regions within the 308 kDa (toxin A) and 
270 kDa (toxin B) C. difficile toxins, with common regions residing within 40 and 
60 kDa fragments which may indeed contain toxin neutralising epitopes and are thus 
worthy of further study. 
 
6.5 Conclusion 
The various experiments conducted and observations made during the course of this 
thesis, highlight the need for a multivalent therapeutic approach to treating CDI, 
which includes both toxins A and B as well as non-toxic proteins (possibly PFO).  
Although there is a renewed interest in C. difficile research following the 
‘hypervirulent’ outbreaks in 2000, it is evident that some fundamental questions still 
remain unanswered.  
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6.6 Future Work 
Variability of vegetative C. difficile: This work highlights the variability of 
vegetative C. difficile cells, opening many avenues of research.  Thus far it has not 
been possible to stably produce variant colonies and thus samples may contain a 
small proportion of the other variant.  The identification of the trigger for variant 
colony formation will provide an understanding of the mechanism(s) behind its 
existence and whether it is replicated in vivo.  The use of multiple strains is also 
essential to assess the validity of the results presented herein.  To date, transcriptional 
analysis studies have focussed on the stress response in relation to pH, oxidative 
shock, sub-inhibitory concentrations of antibiotics and heat (Emerson et al., 2008; 
Jain et al., 2011; Ternan et al., 2012), it is surprising that no study has assessed the 
stress response associated with exposure to bile salts.  Based on the differences in the 
autolytic activity of the two morphotypes, it is possible the cell wall chemistry and 
cell surface composition differs, which may in turn alter the net cell surface charge 
(Bendinger et al., 1993) and thus effect adherence, as reported in Group A 
Streptococcus (GAS) (Kristian et al., 2005).  Although time did not permit us to 
pursue the differences in adherence properties of the two morphotypes, it is 
intriguing to speculate that one variant maybe more adherent than the other.  
Furthermore the differences observed in cell physiology maybe indicative of a 
difference in the growth phase of the cell which may have an impact on toxin 
production.  The use of the newly developed Cdifftox agar plate assay (CDPA), to 
assess the presence/absence of toxin production in the two colonies may provide an 
insight into this (Darkoh et al., 2011), alternatively the use of single-colony 
whole-genome sequencing would provide a wealth of data as to any differences 
which exist at a genomic level between the two morphotypes, the use of such 
techniques has recently been demonstrated with C. difficile (Köser et al., 2013).  
Potential therapeutic targets include PFO and capsule; in the latter case biochemical 
analysis to assess its composition (carbohydrate or protein capsule) and level of 
expression should also be conducted.  The role of PFO and its impact on other 
virulence factors can be investigated though mutational analysis using the ClosTron 
system.  The presence of variant cell types within colonies of C. difficile is 
intriguing, and could be further investigated by Fluorescence-Activated Cell Sorting 
(FACS), which would allow the heterogeneous population of cells to be physically 
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sorted and subsequently analysed.  The presence of multiple cell types of C. difficile, 
suggests like other bacteria (B. subtilis) (Lopez et al., 2009), the cells of C. difficile 
may display differences in gene expression, which subsequently effects cell 
morphology and potentially virulence.  Recently studies have utilised bacterial 
cytological profiling to identify the mechanism of action of antibacterial compounds 
(Nonejuie et al., 2013).  Using this approach E. coli was treated with a range of 
antibiotics at 5x the minimum inhibitory concentration.  Post exposure differences in 
cellular morphology were observed depending on the cellular target of the antibiotic.  
The presence of single individual cells and long filamentous cells within single 
colonies cultured under the same conditions suggests the components in the media 
may be targeting different pathways, resulting in distinct morphological profiles.  If 
this is indeed true, then bacterial cytological profiling by exposing the cells to 
varying concentrations of the media components, including bile salts could be 
utilised.      
  
Recombinant expression system: A number of factors could have been assessed to 
enhance expression of TcdA.  Due to the project originally being approved for 
containment level 2 work, we were restricted in the host strains we could utilise.  All 
expression strains assessed were under the control of the T5 promoter whilst 
published reports utilised expression systems with a T7 promoter, such as BL21.  It 
would also have been beneficial to assess the use of alternative vectors such as 
pQE80L which confers higher repression levels.  In terms of the culture conditions, a 
number of factors could have been further investigated (non-metabolisable sugars, 
chaperones and dissolved oxygen content).  The main limitation of this work is the 
lack of comparison between codon optimised and non-codon optimised proteins.  
Without this the true effect of codon optimisation on expression yields cannot be 
determined. 
 
Identifying immunodominant regions of toxin A and toxin B:  Sequencing of the 
immunogenic regions identified by the human sera will enable immunogenic 
mapping of the toxins and allow for comparisons between toxin A and B, and the 
native, recombinant and toxoid preparations, which will underpin the development of 
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therapeutic targets.  In order to achieve this, a greater concentration of digested 
protein must be employed to allow analysis by 2D SDS-PAGE and facilitate 
sequencing.  This would provide clearer resolution of the fragments and reduce the 
chance of co-purifying multiple protein fragments.  Once immunogenic regions have 
been located, further improvements in resolution can be made by utilising a narrower 
pI and molecular weight range.  The use of peptide gels which allow resolution of 
peptides between 1–40 kDa could be utilised.  Finally the use of multiple strains 
should also be investigated, with recent studies demonstrating the antigenic 
variability of toxin B in the current hypervirulent 027 strain (Lanis et al., 2013).  
Furthermore, it has recently been reported that the toxoiding process alters the 
conformational structure of toxoid B and hence the presentation of key neutralising 
epitopes (Wang et al., 2012), the immunogenicity of native and toxoided toxin B 
should also be a investigated.  
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Appendix 1: Predicted peptide sequences obtained from TcdA and rTcdA900-2710 
in silico digestion with clostripain.  
Of the 51 fragments identified by ExPASy PeptideCutter, 16 had a predicted 
molecular weight of <2 kDa and would be difficult to visualise on a SDS-PAGE gel 
and are therefore not displayed. Bold indicates regions in native and recombinant 
protein.  
Resulting Peptide Sequence TcdA 
Peptide 
Mass (kDa) 
MSLISKEELIKLAYSIR 2 
ENEYKTILTNLDEYNKLTTNNNENKYLQLKKLNESIDVFMNKYKTSSR 6 
ALSNLKKDILKEVILIKNSNTSPVEKNLHFVWIGGEVSDIALEYIKQWADIN
AEYNIKLWYDSEAFLVNTLKKAIVESSTTEALQLLEEEIQNPQFDNMKFYK
KR 
12 
 
FINYYKSQINKPTVPTIDDIIKSHLVSEYNR 4 
ANSLFTEQELLNIYSQELLNR 2 
LLALKNFGGVYLDVDMLPGIHSDLFKTISR 3 
WEMIKLEAIMKYKKYINNYTSENFDKLDQQLKDNFKLIIESKSEKSEIFSKL
ENLNVSDLEIKIAFALGSVINQALISKQGSYLTNLVIEQVKNR 
11 
 
YQFLNQHLNPAIESDNNFTDTTKIFHDSLFNSATAENSMFLTKIAPYLQVGF
MPEAR 7 
STISLSGPGAYASAYYDFINLQENTIEKTLKASDLIEFKFPENNLSQLTEQEI
NSLWSFDQASAKYQFEKYVR 
8 
 
DYTGGSLSEDNGVDFNKNTALDKNYLLNNKIPSNNVEEAGSKNYVHYIIQ
LQGDDISYEATCNLFSKNPKNSIIIQR 
9 
 
NMNESAKSYFLSDDGESILELNKYR 3 
LKNKEKVKVTFIGHGKDEFNTSEFAR 3 
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LSVDSLSNEISSFLDTIKLDISPKNVEVNLLGCNMFSYDFNVEETYPGKLLLS
IMDKITSTLPDVNKNSITIGANQYEVR 
9 
 
KELLAHSGKWINKEEAIMSDLSSKEYIFFDSIDNKLKAKSKNIPGLASISEDI
KTLLLDASVSPDTKFILNNLKLNIESSIGDYIYYEKLEPVKNIIHNSIDDLIDE
FNLLENVSDELYELKKLNNLDEKYLISFEDISKNNSTYSVR 
 
 
17 
 
 
Resulting Peptide Sequence TcdA continued 
Peptide 
Mass (kDa) 
FINKSNGESVYVETEKEIFSKYSEHITKEISTIKNSIITDVNGNLLDNIQL
DHTSQVNTLNAAFFIQSLIDYSSNKDVLNDLSTSVKVQLYAQLFSTGLN
TIYDSIQLVNLISNAVNDTINVLPTITEGIPIVSTILDGINLGAAIKELLDE
HDPLLKKELEAKVGVLAINMSLSIAATVASIVGIGAEVTIFLLPIAGISA
GIPSLVNNELILHDKATSVVNYFNHLSESKKYGPLKTEDDKILVPIDDL
VISEIDFNNNSIKLGTCNILAMEGGSGHTVTGNIDHFFSSPSISSHIPSLSI
YSAIGIETENLDFSKKIMMLPNAPSR 
36 
 
 
 
 
 
VFWWETGAVPGLR 2 
FYAFFDYAITTLKPVYEDTNIKIKLDKDTR 4 
NFIMPTITTNEIR 2 
NKLSYSFDGAGGTYSLLLSSYPISTNINLSKDDLWIFNIDNEVR 5 
EISIENGTIKKGKLIKDVLSKIDINKNKLIIGNQTIDFSGDIDNKDR 5 
YIFLTCELDDKISLIIEINLVAKSYSLLLSGDKNYLISNLSNIIEKINTLGL
DSKNIAYNYTDESNNKYFGAISKTSQKSIIHYKKDSKNILEFYNDSTLEF
NSKDFIAEDINVFMKDDINTITGKYYVDNNTDKSIDFSISLVSKNQVKVN
GLYLNESVYSSYLDFVKNSDGHHNTSNFMNLFLDNISFWKLFGFENINF
VIDKYFTLVGKTNLGYVEFICDNNKNIDIYFGEWKTSSSKSTIFSGNGR 
29 
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NVVVEPIYNPDTGEDISTSLDFSYEPLYGIDR 4 
YINKVLIAPDLYTSLININTNYYSNEYYPEIIVLNPNTFHKKVNINLDSSS
FEYKWSTEGSDFILVR 
8 
 
YLEESNKKILQKIR 2 
IKGILSNTQSFNKMSIDFKDIKKLSLGYIMSNFKSFNSENELDR 5 
DHLGFKIIDNKTYYYDEDSKLVKGLININNSLFYFDPIEFNLVTGWQTI
NGKKYYFDINTGAALISYKIINGKHFYFNNDGVMQLGVFKGPDGFEYF
APANTQNNNIEGQAIVYQSKFLTLNGKKYYFDNDSKAVTGWR 
16 
 
 
IINNEKYYFNPNNAIAAVGLQVIDNNKYYFNPDTAIISKGWQTVNGSR 5 
YYFDTDTAIAFNGYKTIDGKHFYFDSDCVVKIGVFSTSNGFEYFAPANT
YNNNIEGQAIVYQSKFLTLNGKKYYFDNNSKAVTGWQTIDSKKYYFNT
NTAEAATGWQTIDGKKYYFNTNTAEAATGWQTIDGKKYYFNTNTAIA
STGYTIINGKHFYFNTDGIMQIGVFKGPNGFEYFAPANTDANNIEGQAI
LYQNEFLTLNGKKYYFGSDSKAVTGWR 
25 
 
 
Resulting Peptide Sequence TcdA continued 
Peptide 
Mass (kDa) 
IINNKKYYFNPNNAIAAIHLCTINNDKYYFSYDGILQNGYITIER 5 
NNFYFDANNESKMVTGVFKGPNGFEYFAPANTHNNNIEGQAIVYQNK
FLTLNGKKYYFDNDSKAVTGWQTIDGKKYYFNLNTAEAATGWQTID
GKKYYFNLNTAEAATGWQTIDGKKYYFNTNTFIASTGYTSINGKHFYF
NTDGIMQIGVFKGPNGFEYFAPANTHNNNIEGQAILYQNKFLTLNGKK
YYFGSDSKAVTGLR 
23 
 
 
 
TIDGKKYYFNTNTAVAVTGWQTINGKKYYFNTNTSIASTGYTIISGKHF
YFNTDGIMQIGVFKGPDGFEYFAPANTDANNIEGQAIR 
10 
 
FLYLHDNIYYFGNNSKAATGWVTIDGNR 3 
  
280 
 
YYFEPNTAMGANGYKTIDNKNFYFR 3 
NGLPQIGVFKGSNGFEYFAPANTDANNIEGQAIR 4 
FLHLLGKIYYFGNNSKAVTGWQTINGKVYYFMPDTAMAAAGGLFEID
GVIYFFGVDGVKAPGIYG 
7 
 
 
 
 
 
 
 
 
 
 
 
 
 
Appendix 1: Resulting peptide sequences for TcdB and rTcdB546-2366 in silico 
digestion with clostripain.  
Of the 51 fragments identified by ExPASy PeptideCutter, 17 are predicted to have a 
molecular weights of <2 kDa and are not displayed. Bold indicates regions in native 
and recombinant protein.  
Resulting Peptide Sequence TcdB 
Peptide Mass 
(kDa) 
MSLVNR 1 
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KQLEKMANVR 1 
TQEDEYVAILDALEEYHNMSENTVVEKYLKLKDINSLTDIYIDTY
KKSGR 
6 
NKALKKFKEYLVTEVLELKNNNLTPVEKNLHFVWIGGQINDTAIN
YINQWKDVNSDYNVNVFYDSNAFLINTLKKTVVESAINDTLESFR 
10 
MEIIYDKQKNFINYYKAQR 2 
EENPELIIDDIVKTYLSNEYSKEIDELNTYIEESLNKITQNSGNDVR 5 
NFEEFKNGESFNLYEQELVER 3 
ISALKEIGGMYLDVDMLPGIQPDLFESIEKPSSVTVDFWEMTKLEA
IMKYKEYIPEYTSEHFDMLDEEVQSSFESVLASKSDKSEIFSSLGD
MEASPLEVKIAFNSKGIINQGLISVKDSYCSNLIVKQIENR 
15 
YKILNNSLNPAISEDNDFNTTTNTFIDSIMAEANADNGR 
 
4 
VGFFPDVKTTINLSGPEAYAAAYQDLLMFKEGSMNIHLIEADLR 5 
NFEISKTNISQSTEQEMASLWSFDDAR 3 
NYFEGSLGEDDNLDFSQNIVVDKEYLLEKISSLAR 4 
GYIHYIVQLQGDKISYEAACNLFAKTPYDSVLFQKNIEDSEIAY
YYNPGDGEIQEIDKYKIPSIISDR 
8 
PKIKLTFIGHGKDEFNTDIFAGFDVDSLSTEIEAAIDLAKEDISP
KSIEINLLGCNMFSYSINVEETYPGKLLLKVKDKISELMPSISQ
DSIIVSANQYEVR 
11 
ELLDHSGEWINKEESIIKDISSKEYISFNPKENKITVKSKNLPEL
STLLQEIR 
6 
NNSNSSDIELEEKVMLTECEINVISNIDTQIVEER 4 
IEEAKNLTSDSINYIKDEFKLIESISDALCDLKQQNELEDSHFISF
EDISETDEGFSIR 
7 
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Resulting Peptide Sequence TcdB continued 
Peptide Mass 
(kDa) 
FINKETGESIFVETEKTIFSEYANHITEEISKIKGTIFDTVNGKLV
KKVNLDTTHEVNTLNAAFFIQSLIEYNSSKESLSNLSVAMKVQ
VYAQLFSTGLNTITDAAKVVELVSTALDETIDLLPTLSEGLPIIA
TIIDGVSLGAAIKELSETSDPLLR 
17 
QEIEAKIGIMAVNLTTATTAIITSSLGIASGFSILLVPLAGISAGIP
SLVNNELVLR 
6 
DKATKVVDYFKHVSLVETEGVFTLLDDKIMMPQDDLVISEIDF
NNNSIVLGKCEIWR 
7 
MEGGSGHTVTDDIDHFFSAPSITYR 3 
EPHLSIYDVLEVQKEELDLSKDLMVLPNAPNR 4 
VFAWETGWTPGLR 2 
YFAFIADALITTLKPR 2 
SFIVPIITTEYIR 2 
EKLSYSFYGSGGTYALSLSQYNMGINIELSESDVWIIDVDNVVR 5 
DVTIESDKIKKGDLIEGILSTLSIEENKIILNSHEINFSGEVNGSN
GFVSLTFSILEGINAIIEVDLLSKSYKLLISGELKILMLNSNHIQQ
KIDYIGFNSELQKNIPYSFVDSEGKENGFINGSTKEGLFVSELPD
VVLISKVYMDDSKPSFGYYSNNLKDVKVITKDNVNILTGYYLK
DDIKISLSLTLQDEKTIKLNSVHLDESGVAEILKFMNR 
24 
KGNTNTSDSLMSFLESMNIKSIFVNFLQSNIKFILDANFIISGTTS
IGQFEFICDENDNIQPYFIKFNTLETNYTLYVGNR 
9 
QNMIVEPNYDLDDSGDISSTVINFSQKYLYGIDSCVNKVVISPNI
YTDEINITPVYETNNTYPEVIVLDANYINEKINVNINDLSIR 
10 
 
YVWSNDGNDFILMSTSEENKVSQVKIR 3 
FVNVFKDKTLANKLSFNFSDKQDVPVSEIILSFTPSYYEDGLIG
YDLGLVSLYNEKFYINNFGMMVSGLIYINDSLYYFKPPVNNLIT
20 
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GFVTVGDDKYYFNPINGGAASIGETIIDDKNYYFNQSGVLQTG
VFSTEDGFKYFAPANTLDENLEGEAIDFTGKLIIDENIYYFDDN
YR 
GAVEWKELDGEMHYFSPETGKAFKGLNQIGDYKYYFNSDGV
MQKGFVSINDNKHYFDDSGVMKVGYTEIDGKHFYFAENGEM
QIGVFNTEDGFKYFAHHNEDLGNEEGEEISYSGILNFNNKIYYF
DDSFTAVVGWKDLEDGSKYYFDEDTAEAYIGLSLINDGQYYF
NDDGIMQVGFVTINDKVFYFSDSGIIESGVQNIDDNYFYIDDNG
IVQIGVFDTSDGYKYFAPANTVNDNIYGQAVEYSGLVR 
28 
VGEDVYYFGETYTIETGWIYDMENESDKYYFNPETKKACKGI
NLIDDIKYYFDEKGIMR 
7 
Resulting Peptide Sequence TcdB continued 
Peptide Mass 
(kDa) 
TGLISFENNNYYFNENGEMQFGYINIEDKMFYFGEDGVMQIG
VFNTPDGFKYFAHQNTLDENFEGESINYTGWLDLDEKR 
9 
YYFTDEYIAATGSVIIDGEEYYFDPDTAQLVISE 4 
 
 
 
